[
  {
    "text":"Cytokinetics to Participate in Upcoming Investor Conferences. SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in virtual fireside chats at the Piper Sandler 32 nd Annual Healthcare Conference taking place December 1-3, 2020, and the 3 rd Annual Evercore ISI HealthCONx Conference on Thursday, December 3, 2020 at 3:05 PM ET.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis. - Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -. - Statistically Significant Reduction of 62% and 70% in Combined Unique Active Magnetic Resonance Imaging Lesions in 45mg and 30mg Patient Cohorts, As Compared to Placebo -. - Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -. - Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -. - Conference Call and Webcast to be Held on August 3, 2020 at 8:30am ET -. NEW YORK , Aug. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the company's selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS).\u00a0The study achieved all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the study met\u00a0its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active (CUA) magnetic resonance imaging (MRI) lesions up to week 24 in patients receiving 45mg of IMU-838 once daily,\u00a0by 62% (p=0.0002), as compared to placebo.\u00a0The study also met its\u00a0key secondary endpoint,\u00a0showing a statistically significant\u00a0reduction in\u00a0the cumulative number of CUA MRI lesions for the 30mg once daily dose,\u00a0by 70% (p<0.0001),\u00a0as compared to placebo.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ\u00ae (tasimelteon) in the Treatment of Smith-Magenis Syndrome. WASHINGTON , Aug. 3, 2020 /PRNewswire/ --\u00a0Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review Vanda's applications for Smith-Magenis Syndrome (SMS). The applications include a Supplemental New Drug Application (sNDA) for HETLIOZ \u00ae capsules and a New Drug Application (NDA) for the liquid formulation of HETLIOZ \u00ae for the treatment of adults and children, respectively, with Smith-Magenis Syndrome (SMS). The FDA has set December 1, 2020 as the target date for its decision under the Prescription Drug User Fee Act (PDUFA-VI).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial. - I-SPY COVID will evaluate the impact of cenicriviroc, Otezla\u00ae, and Firazyr\u00ae on inflammatory response in COVID-19 patients. - Additional candidates from COVID R&D member companies entering platform trials in coming weeks. SAN FRANCISCO , Aug. 3, 2020 /PRNewswire/ --\u00a0Today, members of the COVID R&D Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The I-SPY COVID Trial will evaluate the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist, Otezla \u00ae (apremilast), a PDE4 inhibitor, and Firazyr \u00ae (icatibant injection), a bradykinin B2 receptor antagonist in severely ill, hospitalized COVID-19 patients who require high-flow oxygen.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Lannett Announces Launch Of FDA Approved Levothyroxine Tablets. PHILADELPHIA , Aug. 3, 2020 /PRNewswire/ --\u00a0Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and distribution agreement.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"IRLAB's IRL752 is proposed pirepemat as a unique INN by WHO. STOCKHOLM , Aug. 3, 2020 /PRNewswire/ -- IRLAB announced today that the World Health Organization (WHO) has proposed the name pirepemat as the International Nonproprietary Name (INN) for the company's drug candidate IRL752, which is in development for decreasing the risk of falling in patients with Parkinson's disease. Given the drug candidate's unique mode of action, WHO concluded that IRL752 should not be incorporated into any existing INN stem in the classification system. IRL752 therefore has the potential to becoming a first-in-class treatment. The INN will identify the active pharmaceutical substance of IRL752 during its lifetime among healthcare professionals, scientists as well as patients worldwide.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Innovent Announces First Patient Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody in China. SUZHOU, China , Aug. 2, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (\"Innovent\" or \"the Company\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced that the first patient has been successfully dosed in a Phase 1 clinical trial (CIBI322A101) of the potentially first-in-class recombinant anti-CD47/PD-L1 bispecific antibody (IBI322) in China .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID). - More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities; urgent need for therapeutic strategies to prevent COVID-19 in this vulnerable population. - First-of-its-kind study will enroll up to 2,400 residents and staff at long-term care facilities; will utilize customized mobile research units to conduct the study on-site. INDIANAPOLIS , Aug. 3, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the initiation of BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the U.S. (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities). LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera, is a neutralizing antibody against SARS-CoV-2, the virus that causes COVID-19. The rapid spread of SARS-CoV-2 among residents of long-term care facilities combined with the higher mortality rate for the elderly creates the urgent need for therapies to prevent COVID-19 in this vulnerable population.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"COVID-19 Research Race Shows Importance of Speed, Precision & Efficiency in Genomic Sequencing in Fighting both New and Established Diseases. ANN ARBOR, Mich. , Aug. 3, 2020 /PRNewswire/ --\u00a0Swift Biosciences, a leader in Next-Generation Sequencing Technology lays the groundwork for emerging research into common and rare disease as well as novel infectious disease. The Company's Accel-Amplicon\u00ae and Swift Normalase\u00ae Amplicon Panels (SNAP) use a patented single tube workflow, to create ready to sequence libraries for research in Cancer, Antibiotic Resistance, Cystic Fibrosis, Anthrax, Ebola and the Novel SARS CoV-2 (COVID-19). The Swift benefit is effective and efficient; the ability to work with very small and precious samples of DNA and shortened laboratory time. This advantage helps researchers move quickly and effectively on their path to develop potential therapies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Accumen Releases First FDA EUA COVID-19 Saliva Testing Kits. COVID-19 Saliva Testing Kits and Testing Implementation Support Available. PHOENIX , Aug. 3, 2020 /PRNewswire-PRWeb/ --\u00a0Accumen Inc. is helping healthcare get better, faster. Today the company announced a new partnership with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 saliva testing kits nationally.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx\u00ae Phase 1/2a Clinical Trial in ALS. AstroRx\u00ae demonstrated to be safe and well tolerated in the higher treatment dose. Clinically meaningful decline in disease progression following AstroRx\u00ae treatment consistent in Cohorts A and B. Company notifies of strategic development update. NESS ZIONA, Israel , Aug. 3, 2020 /PRNewswire/ -- Kadimastem Ltd. (TASE: KDST), a clinical-stage biotechnology company developing cell therapies for the treatment of severe debilitating diseases, announced today that its lead product, AstroRx\u00ae, showed a positive efficacy signal and a good safety profile in Cohort B of the Company's Phase 1/2a clinical trial in ALS.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"New Clinical Trial Reports Reduction in COVID-19 Hospitalization Days by 28%. Immunomodulatory Treatment of SARS-CoV-2. CHENNAI, India , Aug. 3, 2020 /PRNewswire/ -- Vopec Pharmaceuticals Pvt Ltd ( https://www.vopecpharma.com/ ) today announces it has completed one of India's first COVID-19 clinical trials on an herbal, Siddha formulation, Amrta Karuna.\u00a0The clinical trial registered with the Indian Council for Medical Research.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik\u00ae. RedHill acquired Movantik \u00ae for opioid induced constipation from AstraZeneca in April 2020; Movantik \u00ae generated $96 million in 2019 -- RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik \u00ae with a new royalty-bearing agreement, under which RedHill will maintain sole and exclusive responsibility for the commercialization of Movantik \u00ae in the U.S. -- The companies also entered a subscription agreement under which Daiichi Sankyo received equity of RedHill as a partial consideration in relation to Movantik \u00ae",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"New Publication in Nature Cancer Demonstrates Signatera's Ability to Evaluate Tumor Response to Immunotherapy. Prospective phase II study shows personalized ctDNA analysis may be used as a biomarker of efficacy across a broad range of tumor types. SAN CARLOS, Calif. , Aug. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a manuscript in Nature Cancer 1 that validates the ability of its Signatera\u2122 personalized circulating tumor DNA (ctDNA) technology to evaluate tumor response to immunotherapy in 25 different types of solid cancer. The full study can be found here.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Lipocine Announces Publication of LPCN 1144 Liver Fat Study (\"LFS\") Results. SALT LAKE CITY , Aug. 3, 2020 /PRNewswire/ --\u00a0Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer reviewed publication of LPCN 144 Liver Fat Study (\"LFS\") results, \"LPCN 1144 Resolves Non-Alcoholic Fatty Liver Disease In Hypogonadal Males\" in Hepatology Communications . Drs. Somaya Albhaisi and Arun Sanyal , from Virginia Commonwealth University , and Dr. Michael Charlton , from the University of Chicago , coauthored the publication. LPCN 1144 is an oral prodrug of bioidentical testosterone (\"testosterone undecanoate\" or \"TU\"). The publication can be accessed via:",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Karius Launches Multicenter Study to Evaluate the Diagnostic Value of the Karius Test for Pneumonia in Immunocompromised Patients. REDWOOD CITY, Calif. , Aug. 3,\u00a02020 /PRNewswire/ -- Karius, the world leader in liquid biopsy for infectious diseases, announced today active enrollment in a multicenter, prospective study that will evaluate the diagnostic value of the Karius \u00ae Test for pneumonia in immunocompromised adult patients including those with hematological cancers. The Karius Test is a non-invasive blood test based on next-generation sequencing of microbial cell-free DNA that can rapidly detect over 1,000 bacteria, DNA viruses, fungi, and parasites.\u00a0The test is currently being used by over 100 hospitals nationwide.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Incysus Therapeutics to Present at LifeSci Partners Summer Symposium. NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (\u201cIncysus\u201d), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (\u03b3\u03b4) T cell immunotherapy for the treatment of cancers, today announced that the Company will present at the 2020 LifeSci Partners Virtual Summer Symposium on Wednesday, August 5th. William Ho, President, Chief Executive Officer, and co-founder of Incysus Therapeutics, will present a company update.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps (NETs) For Patients With Severe COVID-19. - Novel Chromatinase\u2122 platform could rapidly and systemically removes NETs associated with exacerbation of COVID-19. - Investigational biologic aims to treat hyperinflammation and thrombosis in COVID-19 patients, including those with Acute Respiratory Distress Syndrome (ARDS). - Neutrolis awarded competitive grant from the National Institutes of Health (NIH). - Recent study published in The Lancet EBioMedicine found NETs in COVID-19 patients. CAMBRIDGE, Mass. , Aug. 3, 2020 /PRNewswire/ -- Neutrolis , a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Clene Nanomedicine Announces First Patients Enrolled in HEALEY ALS Platform Trial. SALT LAKE CITY , Aug. 3, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, is very pleased that the Sean M Healey & AMG Center for ALS at Mass General announced the first patients have been enrolled into the HEALEY ALS Platform Trial being conducted at sites of the Northeast ALS (NEALS) consortium.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Stupid Strong Announces Research Grant To City of Hope To Support Gastric Cancer Research. $125,000 grant seeks to further advance less invasive, more accurate testing for early disease detection and identification of peritoneal metastasis in gastric cancer. DALLAS , Aug. 3, 2020 /PRNewswire/ -- Stupid Strong Charitable Foundation, a non-profit organization that raises awareness and funds for gastric cancer, is awarding its second seed research grant of $125,000 to fund a Phase II study to validate the micro-RNA biomarkers discovered for the early and non-invasive detection of patients with gastric cancer, as well as the discovery of biomarkers for identifying peritoneal carcinomatosis.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Applied BioMath, LLC Announces Collaboration with Verseau Therapeutics for System Pharmacology Modeling in Oncology. CONCORD, Mass. , Aug. 3, 2020 /PRNewswire/ --\u00a0Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their collaboration with Verseau Therapeutics for the development and delivery of a systems pharmacology model that will be used for efficacious dose prediction for the treatment of cancer.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"BioSkryb Launches Researcher Early Access Program for Genomic Amplification Technology. DURHAM, N.C. , Aug. 3, 2020 /PRNewswire/ --\u00a0BioSkryb, Inc. (\"BioSkryb\"), a developer of genomic amplification technologies that deliver higher coverage and fidelity for gene sequencing, today announced that it has launched an Early Access Program (EAP) for researchers to test its proprietary genomic amplification technology (Primary Template-directed Amplification or PTA). Enrollment in the program secures dedicated workflow support to ensure their participants receive the highest quality results possible to enable their next discovery.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Actuate Therapeutics Announces Initiation Of Phase 2 Clinical Study In Pancreatic Cancer. Enrollment Initiated in First Line Treatment of Patients with Advance Disease. CHICAGO and FORT WORTH, Texas , Aug. 3, 2020 /PRNewswire-PRWeb/ --\u00a0Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as a new arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate's proprietary small molecule glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor which is being developed for adults and children with advanced refractory cancers.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"AskBio CSO Jude Samulski Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine. RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Jude Samulski, PhD, AskBio\u2019s President and Chief Scientific Officer, has been named to PharmaVOICE magazine\u2019s annual list of the 100 most inspiring and entrepreneurial leaders in the life sciences industry.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration. Collaboration intended to support Phase 3 development and commercialization of PH94B for anxiety-related disorders in key Asian markets. SOUTH SAN FRANCISCO, Calif. and SHANGHAI , Aug. 4, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced receipt of a $5 million non-dilutive upfront license payment from EverInsight Therapeutics Inc., the Company's strategic partner focusing on development and commercialization of PH94B for treatment of anxiety-related disorders in multiple key markets in Asia .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation. - Recurrent irregular heartbeat--also known as atrial fibrillation--impacts more than 16 million people globally. - Trial supports Abbott's focus on being the best partner for electrophysiologists treating people living with atrial fibrillation. ABBOTT PARK, Ill., Aug. 4, 2020 /PRNewswire/ -- Abbott (NYSE: ABT)\u00a0today announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat. The study will evaluate the performance of the investigational TactiFlex\u2122 Ablation Catheter, Sensor Enabled\u2122 (SE) for people whose atrial fibrillation (AFib) symptoms are unable to be managed by medication.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD. ROCKVILLE, Md. , Aug. 4, 2020 /PRNewswire/",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Adagio Medical, Inc., reports pre-clinical effectiveness combining their existing ultra-low temperature cryoablation catheter with Pulsed Field Ablation (PFA) in a single Pulsed Field Cryoablation (PFCA) catheter. LAGUNA HILLS, Calif. , Aug. 3, 2020 /PRNewswire/ --\u00a0Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AFib) and ventricular tachycardia (VT), and developer of the i ntelligent C ontinuous L esion A blation S ystem (iCLAS\u2122), today announced successful pre-clinical results demonstrating their existing cryoablation catheter is also capable of ablating the tissue through pulsed field ablation (PFA) delivered via the existing array of electrodes.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Partner Therapeutics Announces $35 Million Contract with U.S. Department of Defense for Advanced Development and Emergency Use of Leukine\u00ae (rhuGM-CSF) for COVID-19 Acute Hypoxemic Respiratory Failure (AHRF). Funding will support two randomized, multi-center clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization (EUA) filing. ",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"PreveCeutical Prepares for Clinical Trials for its Sol-Gel COVID-19 Program. VANCOUVER,\u00a0BC, Aug. 4, 2020 /PRNewswire/ - PreveCeutical\u00a0Medical Inc. (the \"Company\" or \"PreveCeutical\") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that\u00a0it is preparing for clinical trials for its Sol-Gel COVID-19 program. ( News Release dated May 4, 2020 ).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101. LAS VEGAS , Aug. 4, 2020 /PRNewswire/ --\u00a0JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a\u00a0internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its current and future clinical trials, Indications for a New Drug, clinical and research studies planned to be conducted in the future.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Evolution Research Group Announces Appointment of William Martin to Chief Scientific Officer. NEW PROVIDENCE, N.J. , Aug. 4, 2020 /PRNewswire/ --\u00a0Evolution Research Group (\"ERG\"), a leading independent clinical research site company with a focus on improving the quality and delivery of complex, specialized trials across 15 geographically diverse clinical trial sites in the United States , announces the appointment of William Martin , Ph.D. to the position of Chief Scientific Officer.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Janssen Announces Health Canada Approval of DARZALEX\u00ae* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma. TORONTO , Aug. 4, 2020 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved DARZALEX \u00ae SC (daratumumab), a new subcutaneous formulation of daratumumab. 1 DARZALEX \u00ae SC is approved in four regimens across five indications in patients with multiple myeloma, most notably newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX \u00ae SC can be administered over approximately three to five minutes, significantly less time than intravenous (IV) DARZALEX \u00ae , which is administered over hours. 2 DARZALEX \u00ae SC is the only subcutaneous CD38-directed antibody approved in the treatment of multiple myeloma.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Oncolytics Biotech\u00ae Reports 2020 Second Quarter Financial Results and Operational Highlights. Expanded clinical studies to amass clinical proof that pelareorep significantly boosts the effectiveness of high-profile checkpoint inhibitors in breast cancer, multiple myeloma and other cancers. Reported a clinical biomarker to identify cancer patients most likely to respond to pelareorep. Demonstrated clinically that pelareorep reverses the immunosuppressive microenvironments of tumors. Management hosting a conference call and webcast today at 4:30 pm ET. SAN DIEGO and CALGARY, Alberta , Aug. 4, 2020 /PRNewswire/ -- Oncolytics Biotech \u00ae Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended June 30, 2020 . All dollar amounts are expressed in Canadian currency unless otherwise noted.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Oncolytics Biotech\u00ae Reports 2020 Second Quarter Financial Results and Operational Highlights. Expanded clinical studies to amass clinical proof that pelareorep significantly boosts the effectiveness of high-profile checkpoint inhibitors in breast cancer, multiple myeloma and other cancers. Reported a clinical biomarker to identify cancer patients most likely to respond to pelareorep. Demonstrated clinically that pelareorep reverses the immunosuppressive microenvironments of tumors. Management hosting a conference call and webcast today at 4:30 pm ET. SAN DIEGO and CALGARY, Alberta , Aug. 4, 2020 /CNW/ -- Oncolytics Biotech \u00ae Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended June 30, 2020 . All dollar amounts are expressed in Canadian currency unless otherwise noted.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Methodist University Hospital Is First In The World To Participate In Groundbreaking EEG Study For Inpatients That Improves Brain Monitoring During the COVID-19 Crisis. First-of-its-kind technology from Zeto, Inc. allows for more convenience, efficiency and less exposure during EEG tests. MEMPHIS, Tenn. , Aug. 4, 2020 /PRNewswire/ -- Methodist Le Bonheur Healthcare (MLH) is the first hospital system globally to participate in a landmark study using a first-of-its-kind EEG device.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CytoDyn Receives Positive DSMC Recommendation for Leronlimab Phase 3 COVID-19 Trial with No Safety Concerns. VANCOUVER, Washington, Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (\u201cCytoDyn\u201d or the \u201cCompany\"), a late-stage biotechnology company, announced today an independent Data Safety Monitoring Committee (\u201cDSMC\u201d) completed its first safety review of the ongoing Phase 3 clinical trial (CD12) in patients with severe and critical COVID-19 and reported it saw no cause to modify the study. The DSMC reviewed compiled safety data from 149 subjects enrolled in the CD12 trial. The DSMC did not raise any concerns regarding safety and recommended that the trial continue.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Research Centers of America Begins Recruiting Healthy Workers for COVID-19 Vaccine Clinical Trial. HOLLYWOOD, Fla. , Aug. 4, 2020 /PRNewswire/ -- Research Centers of America (RCA), Broward County's largest independent research site, is currently conducting COVID-19 vaccine trials, implemented under Operation Warp Speed (OWS). RCA is recruiting volunteers to participate in these clinical trials, working with the Federal Government and many major Pharmaceutical Companies, which developed a vaccine to potentially prevent COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Nanospectra Biosciences Announces Four Additional Prestigious Trial Sites for Pivotal AuroLase Study. Extension Study for Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue. HOUSTON , Aug. 4, 2020 /PRNewswire/ -- Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the addition of four clinical trial sites to its ongoing AuroLase\u00ae\u00a0pivotal study. The extension study is designed to determine the efficacy of using MRI/ultrasound fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser ablation. Three of the four sites are open for patient screening and study accrual now while the fourth site is fully approved and will be ready to initiate study accrual by this fall.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Mount Sinai Researchers Discover Treatment Option for Rare Genetic Disorder. Personalized Genetic Sequencing Uncovers Previously Unknown Mutation. NEW YORK , Aug. 4, 2020 /PRNewswire-PRWeb/ --\u00a0Researchers from the Icahn School of Medicine used a novel genetic sequencing technology to identify the genetic cause of\u2014and a treatment for\u2014a previously unknown severe auto inflam-matory syndrome affecting an 18-year-old girl since infancy.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Two Studies Presented at AACR Meeting Deepen Understanding Of Cancer Mechanisms. Researchers Use Menarini's Liquid Biopsy Technology to Find Genetic Alterations in Cancer Cells that May Improve Prognosis and Treatment. BOLOGNA, Italy and HUNTINGDON VALLEY, Pa. , Aug. 4, 2020 /PRNewswire/ -- Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced two new studies describing genetic changes in circulating cancer cells that may improve cancer prognosis and help guide treatment. These studies were presented as posters at the June 22-24 virtual annual meeting II of the American Association for Cancer Research (AACR). Menarini's CELLSEARCH \u00ae and DEPArray TM NxT technologies were used to capture and isolate the circulating tumor cells for analysis. In one study ,\u00a0Massimo Cristofanilli, M.D., F.A.C.P., Associate Director of Translational Research at the Robert H. Lurie Cancer Center of Northwestern University , and colleagues collected blood samples from 239 patients with stage III/IV breast cancer, then isolated and selected more than 200 individual tumor cells from patients with HER2+ cells*. The scientists then sequenced the genetic codes of each of those cells.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"NeuTigers and Rajant Begin Validation Testing for CovidDeep: AI-Powered Solution to Screen for SARS-CoV-2/COVID-19 by Analyzing Smart Devices' Built-In Sensor Data. Strategic Partnership to Address More Challenges Across Diverse Industry Verticals Through Artificial Intelligence and Internet of Things (IoT) Applications. PRINCETON, N.J. , Aug. 4, 2020 /PRNewswire/ -- NeuTigers , a leading-edge startup that is revolutionizing the next generation of energy/latency-efficient artificial intelligence (AI), has teamed up with Rajant Corporation, to bring new solutions to the world. As a first step, both companies are addressing the global public health crisis through CovidDeep, an AI-powered monitoring and screening solution to detect the different phases of SARS-CoV-2/COVID-19, currently in validation after a promising clinical trial.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma. STOCKHOLM , Aug. 4, 2020 /PRNewswire/ --\u00a0Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that the first patient has been enrolled in the phase 2 PORT study. The study, which is expected to be fully recruited in December 2020 , is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma, RRMM. Up to 25 RRMM patients who have received at least two previous lines of therapy will be enrolled.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \u201cCompany\u201d or \u201cMarinus\u201d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to two new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 10,000 shares of its common stock as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"New \u2018Negative Pressure Scavenger Kit\u2019 Helps Hospitals Manage Infectious Particles When Treating Patients with COVID-19, Supports Non-Profits Supporting COVID-19 Front-Line Clinicians. FELIX-1 negative pressure scavenger kit creates localized negative pressure area around the patient\u2019s face\n\n\nAll profits from kit sales will be donated to support frontline clinicians and their families through non-profit COVID-19 relief funds. Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the release of a low-cost, easy to use kit to help clinicians create a zone of relative negative pressure at the patient's face which may mitigate the risk of transmission of potentially infectious particles while treating COVID-19 patients. All profits from the kits will be distributed to non-profit organizations supporting front-line clinicians fighting the COVID-19 pandemic.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273). New U.S. government award up to $1.525 billion for 100 million doses\n\n\nOption granted to U.S. government to purchase up to an additional 400 million doses. Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government\u2019s goal of securing early access to safe and effective COVID-19 vaccines for the American people.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Quanterix Announces Closing of Public Offering Including Exercise in Full of Underwriters\u2019 Option to Purchase Additional Shares. Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 3,048,774 shares of its common stock at a public offering price of $32.00 per share, including 397,666 shares sold pursuant to the full exercise of the underwriters\u2019 option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $97.6 million.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock. Seres Therapeutics, Inc. (Nasdaq:MCRB) (\u201cSeres\u201d), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today announced that it is commencing an underwritten registered public offering of 8,000,000 shares of its common stock. As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock on the same terms and conditions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the proposed offering. All of the shares in the proposed offering are to be sold by Seres.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Jamieson Wellness Inc. Reports Second Quarter 2020 Financial Results. Increases Fiscal 2020 Guidance and Declares Increased Quarterly Dividend. Jamieson Wellness Inc. (\u201cJamieson Wellness\u201d or the \u201cCompany\u201d) (TSX: JWEL) today reported financial results for its second quarter ended June 30, 2020. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS measures. See \u201cNon-IFRS Financial Measures\u201d below.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft\u00ae Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns. - StrataGraft\u00ae Skin Tissue, If Approved, Could Reduce or Eliminate the Need for Autografting of Healthy Skin to Treat Burn Wounds -. STAINES-UPON-THAMES, United Kingdom , Aug. 10, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Stratatech Biologics License Application (BLA) for StrataGraft \u00ae , an investigational regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns. The FDA granted the application priority review and assigned a Prescription Drug User Fee Act (PDUFA) target date of\u00a0February 2, 2021.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020. ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 18, 2020 at 8:30 am EDT to report financial results for the second quarter ended June 30, 2020 and provide business updates.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Protalix BioTherapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update. Announced positive top-line data in its Phase III BRIDGE study of PRX-102 for the Treatment of Fabry disease. Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for PRX-102 for the treatment of Fabry disease. Conference call and live webcast scheduled for Monday, August 10, 2020 at 8:30 am ET. CARMIEL, Israel , Aug. 10, 2020 /PRNewswire/ --\u00a0Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx \u00ae plant cell-based protein expression system, today reported financial results for the second quarter ended June\u00a030, 2020, and provided a business update on recent corporate and clinical developments.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference. NEW YORK , Aug. 10, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern , MD, MHSc, President and Chief Medical Officer, will present a corporate overview during the 40 th Annual Canaccord Genuity Growth Conference, to be held virtually August 11-13, 2020 . Company management will also be available for 1on1 meetings with institutional investors via video conference on the day of the presentation. To request a meeting, please contact your representative at Canaccord Genuity.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Precision Pathology Services and bioAffinity Technologies Announce Initiation of CLIA Validation for Non-Invasive Early Lung Cancer Test. Precision Completes Development of CyPath\u00ae Lung and Starts CLIA Validation of Cancer Assay for Sale as a Laboratory Developed Test (LDT). bioAffinity Technologies , a privately held biotech company advancing cutting-edge cancer diagnostics, and Precision Pathology Services , a CAP/CLIA-certified anatomic and clinical pathology laboratory, announced initiation of CLIA validation for CyPath\u00ae Lung, a non-invasive flow cytometric test for early-stage lung cancer. Precision Pathology has licensed bioAffinity\u2019s intellectual property for development of CyPath\u00ae Lung as a laboratory developed test (LDT).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"FDA Approves Gadavist\u00ae (gadobutrol) Imaging Bulk Package. The first and only gadolinium-based contrast agent with an FDA-approved Imaging Bulk Package presentation for multi-patient dosing with a device (e.g. transfer spike) cleared for use with Gadavist IBP in a room designated for radiological procedures with IV contrast. The FDA announced the approval of the Gadavist \u00ae (gadobutrol) Imaging Bulk Package. The Gadavist \u00ae (gadobutrol) Imaging Bulk Package will be available in two presentation sizes, 30 mL and 65 mL , and allows for weight-based dosing with a 24-hour stand time for multi-patient dosing.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"COVID Health Project (CHP) Partners with the University of Texas and Lyon College to Provide COVID-19 Testing and Help Schools Resume Campus Life. COVID Health Project (CHP) announced today its partnership with the University of Texas at Austin and Lyon College. CHP will provide turnkey COVID-19 testing solutions to help both schools resume day-to-day operations this Fall.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Wound Dressings Market 2015-2030 with COVID-19's Impact - ResearchAndMarkets.com. The \"Wound Dressings (Wound Care Management) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"HB NEXT and Passpoint Security Announce COVID-19 Safety Partnership. New integrated technology pairs mobile app with thermal screening kiosks to prevent infection spread. HB NEXT, the leading company in workplace safety, is proud to announce a new partnership with Passpoint Security, to help businesses and schools re-open safely amid the COVID-19 pandemic. Passpoint Security is a top IT and security firm, providing expert knowledge on creating a seamless experience for solution users. Both companies are headquartered in the metro Atlanta area.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"CytRx\u2019s Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign. Exposes Dissident as a \u201cFrivolous Litigant\u201d with a Highly-Questionable Background and Documented History of Poor Judgement\n\n\nHighlights Dissident\u2019s Efforts to Smear CytRx and Misrepresent his Qualifications, Including by Withholding Information from Stockholders Regarding his Past Legal Issues \n\n\nSounds the Alarm to Alert Stockholders to Vote on the BLUE Proxy Card. CytRx Corporation (OTCQB: CYTR), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has mailed a letter to stockholders in connection with the Company\u2019s Annual Meeting of Stockholders that is scheduled for September 3, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX\u00ae RFID Device for DEFINITY\u00ae. Lantheus Holdings, Inc. (the \u201cCompany\u201d) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for VIALMIX \u00ae RFID for DEFINITY \u00ae .",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Inteliquet Appoints Jean Roberson as Chief Financial Officer. Strategic Financial Leader with Experience Raising Equity, Increasing Sales, and Accelerating Operations. Inteliquet , a leading provider of intelligent technology, insights, and services for optimizing clinical trials and research, announced today that it has hired Jean Roberson, CPA, as Chief Financial Officer (CFO). In her new role, she will report directly to Inteliquet\u2019s President and Chief Operating Officer, Marie E. Lamont.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Exactech Appoints New Chief Financial Officer. Seasoned Financial and Operations Executive Kerem Bolukbasi Joins Company. Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, today announced the naming of Kerem Bolukbasi as its new Chief Financial Officer (CFO). Bolukbasi joins Exactech from TPG Capital where he served as an Operations Executive and was responsible for providing interim executive leadership and operational support to management teams and boards of directors for the firm\u2019s portfolio companies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Quidel\u2019s Lyra\u00ae Direct SARS-CoV-2 Assay Receives Health Canada Authorization. Quidel Corporation (NASDAQ: QDEL) (\u201cQuidel\u201d) , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Health Canada authorization to market and sell the Lyra\u00ae Direct SARS-CoV-2 Assay in Canada. (IO315563, COVID-19 Medical Device Authorization for Importation or Sale; 07/20/2020)",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Omega Therapeutics Strengthens Leadership Team with Appointment of Roger Sawhney, M.D. as Chief Financial Officer. Omega Therapeutics\u2122, a company pioneering a new category of genomic medicine through epigenomic programming, today announced the appointment of Dr. Roger Sawhney as Chief Financial Officer. Dr. Sawhney brings 25 years of financial and strategic expertise to Omega, with vast experience ranging from global investments in healthcare sectors to business and strategy development in the biopharma industry.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Schr\u00f6dinger Announces Pricing of Public Offering. Schr\u00f6dinger, Inc. (the \u201cCompany\u201d) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $66.00 per share. The offering consists of 4,500,000 shares being sold by the Company and 500,000 shares being sold by a selling stockholder, resulting in aggregate gross proceeds of $297.0 million to the Company and $33.0 million to the selling stockholder. The offering is expected to close on or about August 17, 2020, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Ask Tabs Wellness Opens State-of-the-Art Mobile COVID-19 Testing Unit in Miami With the Goal in Mind to Open up Wellness Centers All Across the U.S. for Overall Healthcare. A new mobile wellness center launched by Celebrity Doctor George Tabi is helping Florida residents get healthy and get back to work. Ask Tabs Mobile Wellness Center is the latest healthcare venture of Dr. Tabi's company, Ask Tabs Wellness .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sema4 Named to the 2020 CB Insights Digital Health 150, a List of the Most Innovative Digital Health Startups. Sema4 recognized for its cutting-edge precision medicine solutions that enable providers and patients to dramatically improve health outcomes. Sema4 , a patient-centered health intelligence company, has been recognized by CB Insights in its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Analysis on Impact of COVID-19: Adult Diaper Market 2020-2024 | Growing Awareness and Adoption Among Developing Regions to Boost the Market Growth | Technavio. Technavio has been monitoring the adult diaper market and it is poised to grow by $ 3.01 bn during 2020-2024, progressing at a CAGR of over 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Endoscopy Fluid Management Systems Market, 2020-2030: Implications of the COVID-19 Pandemic - ResearchAndMarkets.com. The \"Endoscopy Fluid Management Systems (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Transaction Data Systems Releases Pharmacy eCare Planning Solution. Leader in pharmacy solutions and services deploys eCare platform to further the role of pharmacists as healthcare providers. Transaction Data Systems (TDS), the leader in pharmacy software solutions for the independent pharmacy market, announced the release of eCare, a pharmacy-specific care planning solution within its central TDS Clinical 360 platform.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"E25Bio Receives a Pair of Grant Awards to Expand Coronavirus and Arbovirus Testing. E25Bio, rapid diagnostic innovators, announces award funding of $4.14M from the Bill & Melinda Gates Foundation and $1.68M from the NIH\u2019s Small Business Innovation Research (SBIR) program. The pair of funding awards comes months after the startup announces funding from Khosla Ventures to develop and commercialize a rapid, inexpensive diagnostic for the COVID-19 pandemic.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Swittons Introduces Smart IoT Devices for Pharmaceutical Lab Digital Transformation Initiatives. Swittons , a P360 company, today announced a new line of Internet of Things (IoT) enabled smart devices built specifically for pharmaceutical labs. The fully customizable devices align with strategic Lab of the Future (LoTF) initiatives and help automate various laboratory workflows between people and existing digital lab equipment, systems and solutions. Built on an agile technology platform, Swittons devices are easy to deploy within pharmaceutical laboratories of all types.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"PIC Therapeutics Appoints Dr. Katherine Bowdish as Chief Executive Officer. PIC Therapeutics (\u201cPIC\u201d), a biotechnology company focused on transforming the treatment of cancer though the selective modulation of oncogene translation, today announced the appointment of Katherine Bowdish, Ph.D., as its President and Chief Executive Officer. Dr. Bowdish will also join the Board of Directors of PIC.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"PPG Foundation Awards More Than $200,000 in Scholarships to Empower Next Generation of Innovators. PPG (NYSE: PPG) today announced that the PPG Foundation is providing more than $200,000 in undergraduate college scholarships through the NATIONAL MERIT\u00ae Scholarship Corporation (NMSC). The PPG Foundation has awarded more than 3,000 scholarships to U.S. students since establishing the PPG Foundation Scholarship Program in 1956.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade. Scientific Research Conducted in Collaboration with the Jedd Wolchok Lab at Memorial Sloan Kettering Cancer Center\n\n\nData Demonstrate that AHR Blockade Reverses Tumor Immunosuppression \n\n\nResults Support the Clinical Investigation of IK-175 Alone and in Combination with Anti-PD-1 Therapy. Ikena Oncology, a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced the publication in Nature Communications of a preclinical collaboration with the Jedd Wolchok and Taha Merghoub team at Memorial Sloan Kettering Cancer Center (MSK). The manuscript, titled, \u201cBlockade of the AHR restricts a Treg-Macrophage suppressive axis induced by L-Kynurenine,\u201d (Campesato, et al ) describes the preclinical activity of aryl hydrocarbon receptor (AHR) blockade, alone and in combination with anti-PD-1 immunotherapy. It further supports the potential of IK-175, Ikena\u2019s internally developed, orally administered, selective AHR antagonist currently in Phase 1 clinical development.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Dexcom Appoints Karen Dahut to Board of Directors. DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Helix Receives FDA Emergency Use Authorization for the Helix\u24c7 COVID-19 NGS Test, One of the First Sequencing-Based COVID-19 Tests. The high throughput test will be available in the Fall with next-day turnaround time and will enable Helix to scale its capacity to 100,000 tests per day. SAN MATEO, Calif. , Aug. 10, 2020 /PRNewswire/ --\u00a0Helix, the leading population genomics company, announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Helix \u24c7 COVID-19 NGS Test. The test is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens (nasopharyngeal swabs, oropharyngeal (throat) swab, mid-turbinate nasal swabs, and anterior nasal swabs) from individuals suspected of COVID-19 by their healthcare provider.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer. RNA-based investigation builds on prior bladder cancer research. GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric\u2019s advanced RNA-based molecular profiling platform to elucidate potential signatures of disease progression and drug response to standard of care therapy, including the role of genomic alterations in the fibroblast growth factor receptor (FGFR). Financial terms were not disclosed.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Pipeline Review on Post Menopausal Osteoporosis - H1 2020 - ResearchAndMarkets.com. The \"Post Menopausal Osteoporosis - Pipeline Review, H1 2020\" drug pipelines has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results. Expects to Complete Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss by Early Q4 2020; Study Readout Anticipated in Q2 2021\n\n\nRecently Announced Clinical Data Show FX-322 Delivery to the Cochlea and Preliminary Evidence of a Durable Clinical Benefit; Plans New Studies in Additional Patient Populations \n\n\nRaised $42.3 Million Private Placement, Providing Company Runway into 2023. Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body\u2019s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the second quarter ended June 30, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Battelle Supporting EPA in Testing Pandemic Virus Surface Disinfectants. Research to prioritize disinfection of high touch surfaces such as subway seat fabric and escalator handrail belts. Battelle researchers are working three new Environmental Protection Agency (EPA) projects to determine how long the virus that causes COVID-19 lives on a variety of surfaces and what available disinfecting products are effective.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"BioVentrix Announces Appointment of Accredited Public Company Director Raymond W. Cohen to its Board of Directors. BioVentrix, Inc. , a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company\u2019s board of directors.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"WaveFront Dynamics Names Jeff Kolberg as New Chief Commercial Officer. WaveFront Dynamics Inc . (WaveDyn\u2122), an early stage ophthalmic medical device company, today announced that Jeff Kolberg has been appointed as the company\u2019s Chief Commercial Officer (CCO). Mr. Kolberg joins the leadership team with extensive industry experience to lead WaveDyn\u2019s corporate strategy and future commercialization of its products, including overseeing marketing, sales and service teams. The company is focusing efforts on its dynamic wavefront measurement device and advanced treatment solutions, which will help restore vision and quality of life for patients with highly aberrated eyes.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Innomar Strategies Achieves ISO 9001:2015 Certification for its Clinics and Nursing Services. Innomar is the first and only specialty clinic in Canada to receive this certification, recognizing the highest level of quality control and management in all clinics and home care nursing across Canada. Innomar Strategies (Innomar), Canada's leading specialty pharmaceuticals service provider and a part of AmerisourceBergen, announced today it is the first and only service provider in Canada to have all of its clinics and home care nursing services achieve certification by Intertek under the ISO 9001:2015 standard from the International Organization for Standardization (ISO), effective January 30, 2020. This accomplishment reflects Innomar\u2019s ongoing commitment and investment in quality management systems to advance efficiency, increase customer satisfaction and enhance patient safety.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Jasper Therapeutics Strengthens Management Team with Appointment of Biopharma Industry Executive Kevin N. Heller, M.D., as Executive Vice President, Research and Development. Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the appointment of Kevin N. Heller, M.D., as Executive Vice President, Research & Development. In this newly created role, Dr. Heller will lead the Company\u2019s clinical and research functions and oversee clinical development, clinical strategy and operations, medical affairs and early research and development activities.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"2020 Insights into the Endoscopy Visualization Systems and Components Industry - Market Analysis and Forecast Model - ResearchAndMarkets.com. The \"Endoscopy Visualization Systems and Components (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020. LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure. The virtual Congress runs from Saturday, Aug. 29 through Tuesday, Sept. 1.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"New Study Proves Asclepius Meditec's Hydrogen Oxygen Generator Helps Improve COVID-19 Disease Severity and Dyspnea. SHANGHAI , Aug. 10, 2020 /PRNewswire/ -- An innovative, environmentally friendly treatment with no side effects has been made available to COVID-19 patients, involving the electrolysis of H 2 O to produce a mixture of hydrogen and oxygen for human inhalation. The results of the research as a treatment for COVID-19 were published in the June 2020 edition of the Journal of Thoracic Disease (JTD). In a multicentered, open-label clinical trial described in the article entitled \"Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial\", inhalation of the hydrogen/oxygen mixture prevented the further progression of the disease and, most notably, alleviated the shortness of breath experienced by COVID-19 patients.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Tau Inhibitor - Pipeline Insight, 2020 - ResearchAndMarkets.com. The \"Tau Inhibitor - Pipeline Insight, 2020\" drug pipelines has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Impact of COVID-19 on the Sleep Apnea Diagnostic Sytems Market 2020-2030 - ResearchAndMarkets.com. The \"Sleep Apnea Diagnostic Systems (Anesthesia and Respiratory Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"The Los Angeles County Development Authority Partners with Ready to Offer COVID-19 Testing to Seniors Living at South Bay Gardens. The agency is bringing in on-demand healthcare service, Ready, to provide testing for elderly residents, reducing the risk of exposure to COVID-19 associated with leaving the home. On-demand healthcare service Ready is offering at-home COVID-19 testing and general healthcare options for the residents of the Los Angeles County Development Authority\u2019s (LACDA) senior public housing development, South Bay Gardens. Over 100 residents will have access to Ready\u2019s in-home testing service within the site as a result of the partnership.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"NorthBay Healthcare Selects The Rothman Index for Clinical Surveillance. Health system to focus on enhanced quality initiatives with predictive analytics. As a part of its continued effort to improve patient outcomes and further its mission of compassionate patient care, NorthBay Healthcare has selected the Rothman Index (RI) patient surveillance platform to support clinicians across the Solano County-based hospital system in California. NorthBay Healthcare provides sophisticated healthcare services at two hospitals \u2014 NorthBay Medical Center in Fairfield and NorthBay VacaValley Hospital in Vacaville, housing 204 beds for patient care.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"What 141 HIV/AIDS Patient Groups Thought of 9 Pharma Companies in 2019 | Survey Findings Report 2020 - ResearchAndMarkets.com. The \"The Corporate Reputation of Pharma in 2019 - The Patient Perspective - HIV/AIDS Edition - The Views of 141 HIV/AIDS Groups\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Acromegaly Industry and Competitive Landscape (2020 to 2024) - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com. The \"Global Acromegaly Market and Competitive Landscape - 2020\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Experity Announces Record Urgent Care Patient Volumes in July Amid Pandemic. Urgent cares emerge as key resource for COVID-19 testing as pandemic continues. Experity , the leading provider of clinical and practice management software in the urgent care space, today published a report showing more patient visits in July than any other month this year, according to its client base of more than 5,700 clinics. Additionally, on Monday, July 6 urgent care clinics recorded over 105,000 patient visits, marking the highest single-day visit volume number of 2020. Experity is partnering with Urgent Care Association (UCA) and its database of 2,105 listings to provide data resources for the Department of Health, the National Governors Association and other stakeholders in public health that can use it to aide decision-making or offer resources in response to the COVID-19 pandemic.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"AstraZeneca Ships FLUMIST\u00ae QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season. Production increased in anticipation of higher demand due to COVID-19; Over 25% more US doses of the only nasal-spray vaccine to be available as soon as early August. AstraZeneca today announced the first shipment of FLUMIST \u00ae QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2020-2021 influenza season. FLUMIST QUADRIVALENT, the only nasal-spray flu vaccine, is indicated for those ages 2 through 49. It may not prevent influenza in everyone who gets vaccinated.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Seattle Genetics Announces TUKYSA\u00ae (tucatinib) Approved Within Months for All Countries Participating in FDA\u2019s Project Orbis Initiative. - Australia Joins U.S., Switzerland, Canada and Singapore in Approval of TUKYSA for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer -. Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Australian regulatory authorities have approved TUKYSA \u00ae (tucatinib) in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. Australia joins U.S., Switzerland, Canada and Singapore that approved TUKYSA under Project Orbis, an initiative of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology drugs among participating international regulatory agencies.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Deep Blue Medical Advances Announces FDA Clearance and U.S. Clinical Launch of the T-Line Hernia Mesh. DURHAM, N.C. , Aug. 11, 2020 /PRNewswire/ --\u00a0Deep Blue Medical Advances today announced it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) for its T-Lin \u00ae Hernia Mesh with integrated suture-like extensions. T-Line Hernia Mesh provides superior anchoring strength and eliminates a key point of failure for conventional mesh fixation - the mesh, suture, tissue interface that often leads to mesh migration, contraction and eventual failure.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Hoag Offers Clinical Trial for Pancreatic Cancer Patients. Hoag has been exclusively selected as the only hospital in Orange County, and the only non-academic institution, to offer this promising phase 2 immunotherapy clinical trial for solid tumors. NEWPORT BEACH, Calif. , Aug. 5, 2020 /PRNewswire/ -- Hoag Memorial Hospital Presbyterian has been selected to conduct a Phase 2 clinical trial that researchers hope will demonstrate preliminary efficacy on pancreatic cancer.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Barclays Launches Systematic Study of ESG-Focussed US Equity Funds. ESG-focussed mutual funds are attracting large inflows, but fundamental challenges remain in defining what constitutes an ESG-labelled equity fund. In a systematic study of US equity funds , Barclays\u2019 Quantitative Portfolio Strategy (\u201cQPS\u201d) team finds that ESG-labelled funds do not necessarily provide more ESG exposure than conventional funds.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results. Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT. TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (\"Galmed\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol \u2122 , an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and six months ended June 30, 2020 . The Company will host a conference call and webcast at 08:30 ET today.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Quantitative Scientific Solutions Named to Inc. 5000. Northern Virginia-based Technology Company Named One of the Fastest-Growing Private Companies in America. Quantitative Scientific Solutions (\u201cQS-2\u201d), a leading provider of scientific and technical consulting and data analytics services, announced today that it has made Inc. magazine\u2019s annual Inc. 5000 list, the most prestigious ranking of the nation\u2019s fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy\u2019s most dynamic segment\u2014its independent small businesses.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Varicella Vaccine Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com. The \"Varicella Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Enteral Feeding Devices Market (2020 to 2025) - High Growth Opportunities in Emerging Countries - ResearchAndMarkets.com. The \"Enteral Feeding Devices Market By Type (Feeding Pump, Feeding Tube, Giving Set, Syringes), Age Group (Adult, Pediatric), Application (Oncology, Diabetes, Hypermetabolism), End User (Hospital, Home Care), COVID-19 Impact - Global Forecast To 2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure. - INXN-4001 delivered via retrograde coronary sinus infusion was well-tolerated in patients with chronic heart failure -. - Preliminary data suggest an overall improvement in patient reported outcomes in 50% of patients six months after treatment -. GERMANTOWN, Md. , Aug. 6, 2020 /PRNewswire/ --\u00a0Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627 ), a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure. The INXN-4001 investigational therapy uses a non-viral plasmid designed to constitutively express human SDF-1\u03b1, VEGF165, and S100A1 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling, respectively. INXN-4001 is designed to target the underlying molecular mechanisms of pathological myocardial remodelling and is delivered to the ventricle via retrograde coronary sinus infusion (RCSI).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Titan Medical Reports Second Quarter 2020 Financial Results. Titan Medical Inc. (\u201cTitan\u201d or the \u201cCompany\u201d) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of single-port robotic surgical technologies, announces financial results for the three and six months ended June 30, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Impact of COVID-19 on the Peak Flow Meters Industry, 2020-2030 - ResearchAndMarkets.com. The \"Peak Flow Meters (Anesthesia and Respiratory Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock. Seres Therapeutics, Inc. (Nasdaq: MCRB) (\u201cSeres\u201d), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, at a public offering price of $21.50 per share, before underwriting discounts and commissions. Seres also granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, together with the gross proceeds from a registered offering of 959,002 shares of common stock to Soci\u00e9t\u00e9 des Produits Nestl\u00e9 S.A., before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $245.7 million, excluding any exercise of the underwriters\u2019 option to purchase additional shares. All of the shares in the offering are to be sold by Seres.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference. Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Mycobacterium Tuberculosis Tests: Global Market Analysis and Forecast Model 2015-2030 (with COVID-19 Impact Estimates) - ResearchAndMarkets.com. The \"Mycobacterium Tuberculosis Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"FDA Accepts Application for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indications. \u2013 If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs \u2013\n\n\n\u2013 Filing acceptance is based on the well-established efficacy and safety profile of Xolair in allergic asthma and chronic idiopathic urticaria \u2013. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) accepted the company\u2019s supplemental Biologics License Application (sBLA ) for a new self-administration option for Xolair \u00ae (omalizumab) across all approved U.S. indications. If approved, Xolair prefilled syringe would become available for either self-administration by select patients or administration by their caregivers. A decision on approval is anticipated by Q1 2021. In the U.S., Xolair is currently approved for administration by a healthcare provider in a healthcare setting, and is the only approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of patients with moderate to severe persistent allergic asthma and chronic idiopathic urticaria (CIU).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia. BLADE-CONQUER trial reached half of the 120-subject enrollment goal\n\n\nCompany expects to complete enrollment in 3Q-2020 and provide topline results in 4Q-2020. Blade Therapeutics today announced that the Phase 2 clinical study of the company\u2019s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients. Started in May 2020, BLADE-CONQUER (ClinicalTrials.gov NCT04334460 ) is a double-blind, placebo-controlled clinical trial assessing the efficacy and safety of BLD-2660 on lung function and recovery time in hospitalized patients with pneumonia due to confirmed SARS-CoV-2 infection. BLD-2660 is dosed orally twice a day. The trial permits concomitant use of approved therapeutics including Remdesivir.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"FSHD Society is funding the expansion of the FSHD Clinical Trial Research Network. The patient advocacy organization's support adds four new sites in the U.S. to enable well-powered outcome studies for facioscapulohumeral muscular dystrophy clinical trials. LEXINGTON, Mass. , Aug. 11, 2020 /PRNewswire-PRWeb/ -- The FSHD Society announced today that it has awarded $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on funding of $300,000 a year in 2021 and 2022. The network is a consortium of academic research centers in the United States and Europe with expertise in FSHD clinical research or in neuromuscular clinical trials. Jeffrey Statland , MD, University of Kansas Medical Center , and Rabi Tawil , MD, University of Rochester Medical Center, serve as co-directors of the network. The FSHD CTRN helps close gaps in trial readiness and also provides a network of sites with a centralized streamlined regulatory process, specific, common expertise in FSHD, and an engaged patient population ready to conduct efficient, high quality clinical trials.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Madison Core Laboratories Initiates New Innovation Effort to Better Serve Clients. . Madison Core Laboratories (\u201cMCL\u201d) announced today the launch of a company-wide initiative to become the most innovative diagnostic testing company in the region and provide unsurpassed testing services to better serve clients.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Bone Grafts and Substitutes Market to 2030 - Analysis and Forecast Model - ResearchAndMarkets.com. The \"Bone Grafts and Substitutes (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC): IND.239. The Canadian Cancer Trials Group (CCTG) today announced the commencement of a phase 2 study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 (PLK4) in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer (TNBC). \u201cImmunotherapy in combination with chemotherapy has shown promise in this disease; however, non-chemotherapy combinations which avoid those toxicities and may have activity in the chemorefractory setting are of particular interest,\u201d says Study Co-Chairs Dr. David Cescon, medical oncologist at Princess Margaret Cancer Centre (PMCC), and Dr. Andrew G. Robinson of the Department of Oncology, Queen\u2019s University.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Interior Design Services Market 2020-2025: Impact of COVID-19, Changes in Consumer Behavior, Government Regulations, Technological Disruptions - ResearchAndMarkets.com. The \"Interior Design Services Market - Growth, Trends and Forecasts (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"COVID-19 Impacts: Anesthesia Devices Market will Decelerate at a CAGR of over 7% through 2020-2024 | Advances In Anesthesia Technology to Boost Growth | Technavio. Technavio has been monitoring the anesthesia devices market and it is poised to grow by USD 1.61 bn during 2020-2024. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development. Caprion-HistoGeneX, a specialized CRO providing immunology, proteomics, histopathology and genomics services, and Viroclinics-DDL, a provider of preclinical and clinical trial services for vaccine, antiviral, and diagnostic development, are pleased to announce a new partnership that will offer global, integrated services to support discovery and development of vaccines and antiviral therapies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Impact of COVID-19 on the Global Diabetes Assays Industry 2020-2030 Featuring Siemens Healthineers, Abbott Labs, Roche, Danaher and Tosoh - ResearchAndMarkets.com. The \"Diabetes Assays (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes. BURLINGTON, ON and TORONTO , Aug. 5, 2020 /CNW/ - Positive top-line results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, were announced by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY). EMPEROR-Reduced met its primary endpoint, demonstrating superiority with empagliflozin (10 mg) compared to placebo in reducing the risk for the composite of cardiovascular death or hospitalization due to heart failure, when added to standard of care. Overall, the safety profile was similar to the known safety profile of empagliflozin.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Sterilization Equipment Market by Product & Services, Services, Consumables & Accessories and End-user - Global Forecast to 2025 - ResearchAndMarkets.com. The \"Sterilization Equipment Market by Product & Services (Instruments (Dry Heat), Services (Ethylene Oxide, E-Beam, Steam), Consumables & Accessories (Pouches, Lubricants)), End User (Hospitals & Clinics, Pharmaceutical Companies) - Global Forecast to 2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"European Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation. Strengthened Intellectual Property Portfolio Enables Acceleration of Business Development Activities. TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ --\u00a0Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted. The patent will be set to expire in October 7, 2034 , subject to patent term adjustment or extension.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Emmes Announces its Role in Phase 1 COVID-19 Vaccine Trial. Three Employees Co-Author Preliminary Report for the New England Journal of Medicine. ROCKVILLE, Md. , Aug. 12, 2020 /PRNewswire/ --\u00a0Emmes today announced that it provided the data and statistical analysis support for the Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273. Three Emmes employees were co-authors on the Preliminary Report about the clinical trial, \"An mRNA Vaccine against SARS-CoV-2,\" published in the New England Journal of Medicine on July 14 .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"DarioHealth Announces Poster Presentation at the Virtual Association of Diabetes Care and Education Specialists 2020 Annual Conference. Observational study results demonstrate improved blood pressure and glycemic control for patients suffering from hypertensive blood pressure and diabetes who used the Dario platform. NEW YORK , Aug. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that an emerging science industry poster has been accepted for presentation at the virtual Association of Diabetes Care and Education Specialists (ADCES) 2020 Annual Conference, which is being held today, August 13 , through August 16 , 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Bioceres Crop Solutions Subsidiary Rizobacter Argentina S.A. Completes $17.0 Million Offering of Series IV Corporate Bonds. Bioceres Crop Solutions Corp. (\u201cBioceres\u201d or the \u201cCompany\u201d) (NYSE American: BIOX) , a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today that its subsidiary Rizobacter Argentina S.A. (\u201cRizobacter\u201d) has completed a $17.0 million public offering of Series IV corporate bonds under its global program of corporate bonds in the Argentine market. The bonds mature in August 2023 and pay an annual nominal interest rate of 0.0%.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"RES Makes Inc. 5000 Ten Years in a Row. Sustainable Growth in a Robust Industry\nFocus on Long-term Stewardship. Resource Environmental Solutions, LLC joined an elite group of companies by making the Inc. 5000 list of the fastest-growing private companies in America for the tenth year in a row. RES, a pioneer in ecological restoration and the industry\u2019s largest provider, ranked 2,646 in this year\u2019s rollup, with a three-year growth rate of 153%.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Certara Announces First Enrollee in International Registry to Assess Preventative Therapies in Healthcare Workers Exposed to COVID-19. Real-World Data on 10,000 Healthcare Workers to Inform COVID-19 Prevention Policies. Certara \u00ae , the global leader in biosimulation, has launched an international registry of healthcare workers to collect information on risk factors for developing COVID-19 and the use of preventative therapies. The International Registry of Healthcare Workers Exposed to COVID-19 (UNITY Global) will enable prevention policies to be informed by real-world data collected from 10,000 healthcare workers in low- and middle- income countries. UNITY Global was funded by a grant from the COVID-19 Therapeutics Accelerator.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Remote Patient Monitoring Systems Market 2020-2025: Analysis by Type of Device, Application, End User and Geography - ResearchAndMarkets.com. The \"Remote Patient Monitoring Systems Market - Growth, Trends, and Forecast (2020 - 2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Vascular Grafts - Global Market Analysis and Forecast Model (2015-2030) with COVID-19's Impact - ResearchAndMarkets.com. The \"Vascular Grafts (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights on the Global Anti-block Additives Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio. Technavio has been monitoring the anti-block additives market and it is poised to grow by USD 371.91 million during 2020-2024, progressing at a CAGR of 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters\u2019 Option to Purchase Additional Ordinary Shares. -- Total offering size of $963.5 million --. Horizon Therapeutics plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 13,570,000 of its ordinary shares at a price to the public of $71.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,770,000 additional ordinary shares. The net proceeds to the Company from this offering are expected to be approximately $919.3 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company. Following the closing of the offering, there were 220,346,699 ordinary shares of the Company outstanding as of August 11, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Hyperfine Research Receives 510(k) Clearance from US FDA for Market-Ready Swoop\u2122 Portable MRI System. Novel technology defines new product category for accessible, cost-effective point-of-care magnetic resonance imaging. Hyperfine Research, Inc. has received 510(k) clearance from the US FDA for its category-defining portable MRI technology, the Swoop\u2122 Portable MR imaging device. Hyperfine\u2019s Swoop\u2122 system is a point-of-care MR imaging device that wheels directly to the patient\u2019s bedside, plugs into a standard electrical wall outlet and is controlled through a wireless tablet, making MR imaging accessible, immediate and seamless.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Merchavia invest in Aura Smart Air, a company that deals with purification and air quality management using artificial intelligence technology. In a joint trial of Aura Smart Air and Sheba Medical Center, preliminary results showed that Aura's solution succeeded in eliminating COVID-19 by 99.9%. A total of $3 Million will be invested at a $10 Million valuation. RAMAT GAN , Israel , Aug. 5, 2020 /PRNewswire/ -- Merchavia Holdings and Investments Ltd. (TASE: MRHL) has signed a Memorandum of Understanding (MoU) for its first investment in the Aura Smart Air, a company that deals with purification and air quality management using artificial intelligence technology. According to the MoU, Merchavia will invest $250,000 and will receive preference shares, which constitute approximately 1.93% of Aura Air's issued and fully diluted capital\u00a0for its investment. Merchavia's investment will be made at a $10 Million valuation and is a part of an $3 Million financing round.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Genomics Market Outlook 2020-2025; Dominated by Illumina, Thermo Fisher Scientific, Agilent Technologies, Luminex Corporation and Myriad Genetics - ResearchAndMarkets.com. The \"Genomics Market - Growth, Trends, and Forecasts (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"4D Molecular Therapeutics Receives FDA Fast Track Designation for 4D-310 Gene Therapy for Treatment of Fabry Disease. 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to 4D-310 for Fabry disease, a debilitating lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (AGA) enzyme activity. 4D-310 is a gene medicine engineered with a proprietary optimized AAV capsid discovered by 4DMT through its proprietary Therapeutic Vector Evolution platform.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"WCG Leaders Honored Among PharmaVOICE 100 Most Inspiring People. Don Deieso and Dawn Flitcraft Recognized for Pioneering Efforts to Advance Patient-Centric Clinical Trials. PRINCETON, N.J. , Aug. 5, 2020 /PRNewswire/ -- WCG , the world's leading provider of solutions that measurably improve the quality and efficiency of clinical trials, is pleased to announce that two company leaders have been featured in PharmaVOICE magazine's annual July/August issue showcasing the 100 most inspiring individuals in the global life sciences industry. Donald A. Deieso , PhD, WCG's Executive Chairman and Chief Executive Officer (CEO), and Dawn Flitcraft , President of WCG's Ethical Review Division, were recognized for the transformational work they are doing to drive a new era of clinical trials that enables collaboration across the research community, improves the patient experience and accelerates drug development.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CSG and Clean Republic Form Strategic Alliance to Offer Market-Leading Pathogen Protection Products and Services. Cleaning Services Global (CSG) , a leading provider of products and services related to pathogen protection and \u201cback-to-work\u201d solutions, and Clean Republic , a leading maker of innovative hospital-grade disinfectants and sanitizers, have formed a strategic alliance which will bring together the companies\u2019 products, services and expertise in pathogen mitigation in support of the continuing battle against the Coronavirus pandemic.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Seoul Viosys to Develop a Cancer Diagnosis Technology for Companion Animals with Violeds Technology. Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor solution provider, announced that it has developed an advanced concept technology for early diagnosis of cancer in companion animals with its ultraviolet LED Violeds technology through clinical testing conducted by scientists at the University of Ulsan, based in South Korea.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Annuloplasty Rings Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Increasing Prevalence of Heart Valve Diseases to Boost the Market Growth | Technavio. Technavio has been monitoring the annuloplasty rings market and it is poised to grow by USD 28.65 million during 2020-2024, progressing at a CAGR of over 3% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Catalent Gene Therapy Facility Receives FDA Approval as an Additional Manufacturing Site for AveXis' Gene Therapy. Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it was approved by the U.S. Food and Drug Administration (FDA) to produce commercial drug substance intermediate for AveXis' spinal muscular atrophy (SMA) gene therapy at its manufacturing facility located in Harmans, Maryland. SOMERSET, N.J. , Aug. 6, 2020 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it was approved by the U.S. Food and Drug Administration (FDA) to produce commercial drug substance intermediate for AveXis' spinal muscular atrophy (SMA) gene therapy at its manufacturing facility located in Harmans, Maryland .",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Adicet Bio Receives $10 Million Product Development Milestone From Regeneron. MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the terms of its strategic collaboration with Regeneron. ADI-002 is the first of Adicet Bio's allogeneic off-the-shelf \u03b3\u03b4 T cell product candidates to specifically target solid tumors. ADI-002 is being developed and engineered by Adicet to express a GPC3-targeting chimeric antigen receptor and IL-15.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Hypomorphic Genetic Variants Associated With Childhood Chronic Loose Stools. VERO BEACH, Fla. , Aug. 6, 2020 /PRNewswire/ -- QOL Medical, LLC today announced that PLoS ONE has published the results from a study of hypomorphic SI (sucrase-isomaltase) genetic variants known to cause Congenital Sucrase-Isomaltase Deficiency (CSID). The results show children with a hypomorphic SI variant had more serious gastrointestinal symptoms than those without.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Two-photon Laser Scanning Confocal Microscope Market to 2024 - Increase in Applications in Life Science Research is Driving the Industry - ResearchAndMarkets.com. The \"Global Two-photon Laser Scanning Confocal Microscope Market 2020-2024\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"PTCE Launches \u2018Faces of Pharmacy\u2019 Recognition Campaign. Inaugural yearlong campaign will highlight four pharmacy professionals a month for their hard work and dedication to the pharmacy profession. PT CE, a leader in continuing education for retail, health system, oncology, managed care, and specialty pharmacists, is launching a yearlong recognition program called \u2018 Faces of Pharmacy\u2019 to honor pharmacy professionals. Each month, PT CE will select four pharmacy professionals to feature on its website and social media platforms in recognition of their unwavering commitment to delivering exceptional care to patients.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Anixa and OntoChem Announce Identification of Additional Covid-19 Compounds. SAN JOSE, Calif. , Aug.\u00a013, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have identified additional candidates through their in silico screening study. In addition to four compounds that target an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15) and one additional core compound that targets the main protease (M pro ) of the virus, Anixa and OntoChem have identified 26 additional compounds targeting M pro .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"QIAGEN to Continue Successful Growth Strategy Focused on Execution and Greater Value Creation After Voluntary Public Takeover Offer Falls Short. Tender offer acceptance of 47% did not reach minimum threshold of 66.67% \n\n\n\n\nQIAGEN Supervisory Board and Managing Board respect the views of shareholders\n\n\n\n\nFocus on execution with strong outlook for 2020 and 2021, QIAGEN to continue strategy of creating value through Sample to Insight portfolio for growing molecular testing needs\n\n\n\n\nQIAGEN to move forward with full acquisition of NeuMoDx, adding versatile integrated molecular testing platforms to portfolio and gaining access to U.S. and other markets\n\n\n\n\nOngoing commitment to support global response to coronavirus pandemic. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Phathom Pharmaceuticals Reports Second Quarter 2020 Results. FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.\u00a0(Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Reify Health Raises $30 Million to Integrate Clinical Trials Into the Global Healthcare System. Company\u2019s StudyTeam platform harmonizes biopharma and research site workflows, introducing a new paradigm for clinical research that brings therapies to patients sooner. Reify Health , provider of leading cloud-based solutions that connect and empower the clinical trial ecosystem, today announced a $30 million Series B funding round led by Battery Ventures. Reify developed its platform, StudyTeam, to upgrade the systems that healthcare staff at clinical research sites depend on to run trials. By bringing them onto a shared platform with biopharma sponsors, Reify has helped the industry dramatically accelerate clinical trial enrollment and reduce workloads for stakeholders across the ecosystem.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"MagVenture receives FDA clearance for OCD. ALPHARETTA, GA , Aug. 11, 2020 /PRNewswire/ -- FDA has cleared MagVenture TMS Therapy \u00ae for adjunct treatment of Obsessive-Compulsive Disorder (OCD). This marks the second indication in the US for the Danish medical device company MagVenture who is already FDA cleared for the treatment of major depressive disorder.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Dietary cholesterol and phytosterols contribute directly to heart disease. Genetic variability in cholesterol and phytosterol absorption affects cardiovascular disease risk. REYKJAVIK, Iceland , Aug. 6, 2020 /CNW/ --\u00a0Scientists at deCODE genetics , a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system , University of Iceland , the Copenhagen University Biobank and the Danish Blood Donor Study , recently published a study in European Heart Journal , with new findings that point to harmful effects of dietary cholesterol and phytosterols.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"THREAD Accelerates Expansion to Advance Global Decentralized Clinical Trials. Innovative Technology and Service Provider Receives Additional $50 Million Capital Commitment from Water Street and JLL Partners. DURHAM, N.C. , Aug. 13, 2020 /PRNewswire/ -- THREAD , an innovative technology and service provider that enables decentralized clinical research, announced today that it's accelerating the company's expansion after receiving an additional capital commitment of up to $50 million from strategic health care investors, Water Street Healthcare Partners and JLL Partners. The company's latest capital infusion builds on a year of significant growth and investments in its platform and services to advance decentralized research approaches for large-scale, Phase Ib - IV global clinical trials.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"The Corporate Reputation of Pharma in Canada, 2019-2020: The Views of 53 Canadian Patient Groups - ResearchAndMarkets.com. The \"The Corporate Reputation of Pharma in 2019 - The Patient Perspective - Canadian Edition - The Views of 53 Canadian Patient Groups\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"AI in Drug Discovery Market by Component, Technology, Application, End User, and Geography - Global Opportunity Analysis and Industry Forecast to 2026 - ResearchAndMarkets.com. The \"AI in Drug Discovery Market by Component, Technology, by Application, by End User, by Geography - Global Opportunity Analysis and Industry Forecast up to 2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sherlock Biosciences Announces Research Collaboration with Dartmouth-Hitchcock Health to Launch Study of CRISPR-based Test for SARS-CoV-2. Dartmouth-Hitchcock Health Researchers Evaluating Sherlock\u2122 CRISPR SARS-CoV-2 Kit to Test Real-world Samples from Member Hospitals; Results Expected in Coming Weeks. Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced a research collaboration with Dartmouth-Hitchcock Health (D-HH) to launch a clinical study of the Sherlock\u2122 CRISPR SARS-CoV-2 kit for the detection of the novel coronavirus that causes COVID-19. The kit, for which Sherlock Biosciences recently received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA), will be used to test clinical samples from patients from D-HH member hospitals.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Entera Bio Announces Management Changes. BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Roger Garceau as Interim Chief Executive Officer, effective immediately. Dr. Garceau will succeed Chief Executive Officer and Board Member Adam Gridley, who has resigned from the company to pursue a new opportunity. Dr. Garceau will continue to serve as a Director of Entera Bio.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products. TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (\u201cRedHill\u201d or the \u201cCompany\u201d), a specialty biopharmaceutical company, today announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. (SIX: COPN) (\u201cCosmo\u201d) for an exclusive licensing and manufacturing agreement for multiple products. The transaction is expected to close in the coming weeks.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic Test. SILVER SPRING, Md. , Aug. 7, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies \u2014 NGS and liquid biopsy \u2014 in one diagnostic test in order to guide treatment decisions.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"BioUtah Statement on Launch of Altitude Lab, Largest Life Sciences Incubator in Utah. Recursion and University of Utah found incubator to propel new generation of life sciences in the region. BioUtah President and CEO, Kelvyn Cullimore, issued the following statement following the announcement of the opening of Altitude Lab.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"HARMAN Launches AccuAlertMe \u2013 An Enterprise Platform to Enable Workplace Safety for Employees and Visitors. As an industry-first feature, the solution will provide real-time alerts to users on risks of exposure at places of business. HARMAN , a wholly-owned subsidiary of Samsung Electronics Co. Ltd., focused on connected technologies for automotive, consumer and enterprise markets, today announced the launch of AccuAlertMe, a unique solution to help companies, employees and visitors navigate the risks of COVID-19 while re-opening facilities of business.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"KAHR Medical to Present at Oppenheimer's Private Life Sciences Company Call Series. JERUSALEM , Aug. 13, 2020 /PRNewswire/ -- KAHR Medical today announced the company's participation in Oppenheimer's Private Life Sciences Company Call Series taking place virtually August 17-19, 2020 .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"CytoDyn Announces Clinically Significant Top-line Results from its Phase 2 Trial in Mild-to-Moderate COVID-19 Patients. Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing. BALTIMORE , Aug. 5, 2020 /PRNewswire/ -- Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care tissue-based RAS testing in the United Kingdom (UK).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease. Data Anticipated Q4 2020. CRANBURY, N.J. , Aug. 5, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced completion of enrollment of its Phase 2 study with PL9643 for the treatment of dry eye disease (DED).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Vizient Announces Community Contracting Program to Help Certified Diverse Suppliers Connect with Hospitals. Vizient, Inc. , the nation\u2019s largest health care performance improvement company, today announced an opportunity for minority-, women- and veteran-owned businesses to enroll in its Community Contracting Program, a new initiative designed to connect Vizient member hospitals with local, diverse suppliers and service providers. When launched to its member hospitals, Community Contracting will streamline identification and contracting with certified diverse, local businesses, which will help support economic development in their communities.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020. ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m. Eastern Time.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"FDA Approves New Opioid for Intravenous Use in Hospitals, Other Controlled Clinical Settings. SILVER SPRING, Md. , Aug. 7, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular Degeneration. -- First patient dosed in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene --\n\n\n-- A second Phase II trial evaluating GT005 in a broader population with geographic atrophy is also planned for 2020 --. Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of its Phase II programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Dry AMD is a leading cause of permanent vision loss in people over the age of 50. GT005 is a one-time AAV-based gene therapy that is delivered under the retina. The goal of the Phase II clinical trial programme is to determine if GT005 has the potential to slow the progression of GA.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update. Preparations ongoing for December 30, 2020 FUROSCIX\u00ae PDUFA date. scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights. - Phase 2b Trial Design for BLU-5937 in Refractory Chronic Cough to be Announced in Q3 2020 -. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (\u201cBELLUS Health\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Random Walk Imaging Launches dVIEWR MRI Image Analysis and Workflow Software Platform during ISMRM Conference. Completes License and Development Agreement with NONPI Medical. Random Walk Imaging AB (RWI), a company developing novel software solutions for diffusion magnetic resonance imaging (MRI), today announced the launch of its first commercial software product for clinical researchers and radiologists. The dVIEWR Powered by MICE Toolkit\u2122 is the result of a collaboration with NONPI Medical AB, with whom RWI has entered into an exclusive license and development agreement to market dVIEWR worldwide. RWI is hosting a booth at the first virtual International Society for Magnetic Resonance in Medicine Conference & Exhibition , 8-14 August, 2020 with a demonstration of dVIEWR available at www.dviewr.com .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Providence Therapeutics Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B). TORONTO , Aug. 5, 2020 /CNW/ - Providence Therapeutics Holdings Inc., Canada's leading mRNA vaccine company, today announced compelling preclinical data in their development of a novel mRNA vaccine for COVID-19. Based on what we expected to find for patients who have been infected with the virus and have recovered, we're seeing materially higher neutralizing antibody responses. The results demonstrate strong antibody responses against the spike (S) protein that were highly effective at neutralizing the virus in multiple assays. These responses were accompanied by T cell responses, indicating possible long-lasting immunity. The release of this data puts Providence Therapeutics on track for human vaccine clinical trials in Canada later this year.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Constellation Accepting Applications for 2020 Energy to Educate Grant Program. Grant program has provided nearly $4M to date for STEM education and research programs reaching 200,000 students nationwide. With the coronavirus pandemic causing significant disruptions to the education system, the challenge is greater than ever to provide innovation and resources to support the development of the next generation of STEM and energy leaders. Constellation , an Exelon company, is responding by adapting its annual STEM funding awards to the virtual learning environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMune\u2122 Administration. Animal Data has Potential Implications for Ongoing COVID-19 Prevention Study. Company Continues Quest to Dominate Intellectual Property Regarding COVID-19 Associated Pathologies. OCEANSIDE, Calif. , Aug. 5, 2020 /PRNewswire/ --\u00a0Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today filing of a patent on new data demonstrating memory-protective effects of QuadraMune\u2122 in an animal model of inflammation associated memory loss.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"MOMENTUM 2.0, The V Foundation Wine Celebration, Raises Over $3.6 Million. Virtual Benefit Gala Auction for Cancer Research Held on August 8, 2020. MOMENTUM 2.0, The V Foundation Wine Celebration, held virtually on August 8, 2020, raised over $3.6 million to support the V Foundation\u2019s fight to achieve Victory Over Cancer \u00ae .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Imricor Announces Sales Collaboration with Optoacoustics. Imricor Medical Systems, Inc. ( Company or Imricor ) (ASX:IMR) , the global leader in MRI-guided cardiac ablation products, is pleased to announce a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high performance optical communication solutions for magnetic resonance (MR) applications.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"SRI International Awarded Contract Worth Up to $100M from National Institute of Allergy and Infectious Diseases for Radiation/Nuclear Medical Countermeasures. Grant extends SRI's long history of collaborations with the National Institutes of Health. MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ --\u00a0SRI International has been awarded a contract of up to $100 million from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to support the research and development of radiation/nuclear medical countermeasures (MCMs). Under the contract, SRI Biosciences, a division of SRI International, will provide facilities, expertise, and capabilities to advance the development of MCMs for the mitigation or treatment of acute radiation syndromes as well as the treatment of delayed effects from acute radiation exposure (ARS/DEARE) and internal radionuclide contamination. SRI researchers will also support NIAID's ongoing biodosimetry efforts.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Avellino Hits the 1-Million Genetic Test Milestone. On track for over 10,000 gene-based diagnostic tests performed a day. Avellino announced today that the company has performed over 1-million genetic and molecular diagnostic tests. This milestone includes over 821,000 universal tests for TGFBI corneal dystrophy, over 180,000 AvellinoSARS-CoV-2/COVID-19 (AvellinoCoV2) tests since March 2020, and the November 2019 launch of the AvaGen genetic tests for determining risk of keratoconus and the presence of corneal dystrophies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Acne Vulgaris Pipeline Overview and Outlook 2020: Drugs, Companies, Clinical Trials, R&D Updates and More - ResearchAndMarkets.com. The \"Acne Vulgaris Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Pioneering Endosurgery New Mission Statement at Lumendi. Change Emphasizes Lumendi\u2019s Vision to Transform the GI Landscape from Surgical to Endolumenal. Connecticut-based medical device innovator Lumendi, LLC ( www.lumendi.com ) has announced a change in the company\u2019s Mission & Vision statements to better communicate the intended path of its innovative DiLumen TM Endolumenal Interventional Platform (EIP) to transform the GI landscape from surgical intervention to endolumenal. The new statement, Pioneering Endosurgery, will also be used as its tagline in print, web and social media communications.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Understanding 'Chemo Brain' in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk. BRONX, N.Y. , Aug. 11, 2020 /PRNewswire/ --\u00a0Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers at Albert Einstein College of Medicine , Children's Hospital at Montefiore (CHAM), and Rutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop protective interventions that can prevent permanent harm.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"County-level COVID-19 Projections Improve Following New Masking, Distancing Requirements. PHILADELPHIA , Aug. 5, 2020 /PRNewswire/ --\u00a0New COVID-19 projections released today by PolicyLab at Children's Hospital of Philadelphia (CHOP) show clear evidence that mitigation efforts recommended by the White House Coronavirus Task Force are working to reduce risk of continued widespread transmission in states that have adopted them. Conversely, the model's four-week forecasts have worsened for states that have not enacted masking mandates or adopted strong social distancing practices, such as Oklahoma , Missouri , Tennessee and Georgia .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL. OSLO, Norway , Aug. 6, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO)\u00a0today announces that, following a planned interim analysis of the PARADIGME Phase 2b pivotal trial of Betalutin \u00ae in patients with relapsed/refractory follicular lymphoma (FL), the Independent Review Committee (IRC) has recommended Nordic Nanovector to focus on one dosage arm (15 MBq/kg Betalutin \u00ae after a pre-dose of 40 mg lilotomab; \"40/15\") to completion.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Osteogenesis Imperfecta Treatment Market to Surpass US$ 780.4 Million by 2027, Says Coherent Market Insights (CMI). According to Coherent Market Insights, the global osteogenesis imperfecta treatment market is estimated to be valued at US$ 684.2 million in 2020 and is expected to exhibit a CAGR of 1.90% during the forecast period (2020-2027).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress. Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) technology, today reported financial results for the quarter and six months ended June 30, 2020 and provided an update on corporate progress.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Health Canada Approves OPDIVO\u00ae (nivolumab) plus YERVOY\u00ae (ipilimumab) Combined with Limited Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. ",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"World Cancer Immunotherapy Market Outlook to 2023 - Global Market Forecast to Reach $115 Billion by 2023 - ResearchAndMarkets.com. The \"Global Cancer Immunotherapy Market Analysis & Forecast to 2023\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Pagdin Health Announces Health Canada Approval to Conduct Osteoarthritis Research Using Your Own Stem Cells. KELOWNA, BC , Aug. 6, 2020 /CNW/ - Pagdin Health is excited to announce that Health Canada has approved the \"first of its kind\" stem cell research project for osteoarthritis. This project has the potential to revolutionize the way we approach osteoarthritis, because the options for treatment are currently quite limited: pain medications, cortisone injections, or major joint replacement surgeries.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Lipocine Announces Second Quarter 2020 Financial and Operational Results. SALT LAKE CITY , Aug. 6, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Seasoned Life Sciences Executive Brian Yoor Joins Portal Innovations as Chairman. Former Abbott CFO will provide strategic and operational leadership. Portal Innovations, LLC, a national life sciences, medtech and bioinformatics start-up incubator today announced that Brian Yoor is joining the Company as Chairman and Senior Operations Advisor. Partnering closely with founder and CEO, John Flavin he will leverage his deep experience leading diverse and multi-functional teams to help Portal build a world class team and life sciences venture development platform.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Systemic Mastocytosis Pipeline 2020 - Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.com. The \"Systemic Mastocytosis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy. -- Additionally, European Commission Grants Investigational Medicine EPM-01 Orphan Designation for the Potential Treatment of Becker Muscular Dystrophy --. Epirium Bio Inc., a clinical-stage biopharmaceutical company pursuing novel and clinically significant therapeutic approaches for neuromuscular, neurodegenerative and mitochondrial disorders, today announced enrollment of the first participants in its Phase 1 clinical trial of EPM-01 in Becker muscular dystrophy. EPM-01 is a novel, oral, synthetic compound that has demonstrated compelling proof-of-concept in multiple preclinical and clinical studies of mitochondrial dysfunction. The Phase 1 study will be conducted by investigators at three leading academic centers in the United States, including University of California, Davis, and Washington University School of Medicine, St. Louis.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Laryngoscope Blades & Handles Market Outlook 2020-2030 (COVID-19 Impact) - ResearchAndMarkets.com. The \"Laryngoscope Blades and Handles (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506. First in-human clinical trials will evaluate the safety and pharmacokinetics of a first-in-class \u03b19\u03b110 nicotinic acetylcholine receptor antagonist. SEATTLE , Aug. 12, 2020 /PR Newswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today the Clinical Trial Application (CTA) approval in the Netherlands for initiation of a first in-human clinical trial of KCP506. KCP506 is a first-in-class \u03b19\u03b110\u00a0nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Unprecedented 2-Year, Real-World Post-Marketing Surveillance Study For REMfresh\u00ae, The First And Only Drug-Free, Nonprescription Sleep Product That Mimics The Body's Own 7-Hour Mesa Wave, Now Peer-Reviewed And Accepted For Poster Presentation At Upcoming Sleep 2020, The World's Premier Sleep Conference. ONE-THIRD OF U.S. ADULTS DO NOT MEET THE RECOMMENDED AMOUNT OF DAILY SLEEP OF AT LEAST 7 HOURS. ",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study. STOCKHOLM , Aug. 7, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the first patient has been enrolled in the Immunoglobulin Light Chain (AL) amyloidosis (OP-201) study. This open-label, phase 1/2 study of melflufen and dexamethasone for patients with AL amyloidosis, following at least one prior line of therapy, is the first study to explore the effect of melflufen outside of multiple myeloma.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"The Charlotte R. Schmidlapp Fund, Fifth Third Bank, Trustee, Gives $1.6 Million Endowment to Support Career Development of Minority Women in Medicine and Biomedical Research. The Charlotte R. Schmidlapp Fund, Fifth Third Bank , Trustee, has gifted Cincinnati Children\u2019s Hospital Medical Center with $1.66 million to permanently endow the Charlotte R. Schmidlapp Science, Technology, Engineering and Mathematics (STEM) Scholars program. The program enhances access and support for young, underrepresented minority women interested in pursuing careers in medicine and biomedical research.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Haemonetics Clinical Study Results On A New, Personalized Approach To Plasma Collection To Be Presented At 2020 AABB Annual Meeting. ",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Landmark Cell Publication Reveals Novel Spatial Biology Discoveries Enabled by the CODEX\u00ae Platform. New peer-reviewed paper outlines novel organizing principles and spatial interactions between \u201cneighborhoods\u201d of cells in the tumor microenvironment of colorectal cancer. Akoya Biosciences, Inc., The Spatial Biology Company\u2122, today announced the application of the CODEX\u00ae platform to a recent Cell publication titled \u201c Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front .\u201d The paper was published online in early August (Sch\u00fcrch et al * from the laboratory of Professor Garry Nolan, Ph.D., Stanford University).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"PCT LTD Provides Update of Authorized Distributors and Supplemental Registrants. Distributors in 17 States and Puerto Rico. PCT LTD (OTC Pink: PCTL) continues to gain market share by increasing their network of distributors and US EPA supplemental registrants. Through strategic expansion of this network, PCTL is actively expanding their footprint and serving more geographical regions and markets.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Baxter Obtains U.S. FDA Emergency Use Authorizations for HF20 Set and ST Set Used in CRRT During Covid-19 Pandemic. Provides additional options to help meet increased demand for continuous renal replacement therapy (CRRT) products resulting from COVID-19 pandemic\n\n\nMost recent example of Baxter\u2019s efforts to increase supply of dialysis products used in an acute care environment. Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) for the company\u2019s HF20 Set and ST Set used in continuous renal replacement therapy (CRRT). Under its EUA, the HF20 Set is authorized to deliver CRRT to treat patients of low weight (8-20 kg) and low blood volume who cannot tolerate a larger extracorporeal circuit volume in an acute care environment during the COVID-19 pandemic. The ST Set is authorized for use under its EUA to provide CRRT to treat patients in an acute care environment during the COVID-19 pandemic. Both the HF20 Set and ST Set can be used with the Prismaflex or PrisMax control units (monitors).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Surgical Stapling Devices Markets, 2015-2030 - ResearchAndMarkets.com. The \"Surgical Stapling Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"NS Pharma's VILTEPSO\u2122 (viltolarsen) injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy. Patients taking VILTEPSO showed an increase in dystrophin expression to an average of 5.9% of normal after 20-24 weeks of treatment. Overall, in a pivotal study of VILTEPSO 100% of patients showed an increase in dystrophin levels after treatment and 88% of patients showed dystrophin levels of 3% of normal or greater. ",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Next-Generation Breast Cancer Diagnostic and Screening Market (2020 to 2030) - Analysis and Forecast - ResearchAndMarkets.com. The \"Global Next-Generation Breast Cancer Diagnostic and Screening Market: Focus on Products, Technologies, Cancer Sub-Type, End Users, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Novocure Announces Expansion of Its Executive Leadership Team. Wilco Groenhuysen appointed to an expanded Chief Operating Officer role\n\n\nAshley Cordova promoted to Chief Financial Officer\n\n\nFrank Leonard promoted to Chief Development Officer. Novocure (NASDAQ:NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify executive leadership in preparation for an anticipated period of significant innovation and growth and to recognize the proven senior management experience of key Novocure leaders.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Knee Reconstruction - Global Market Analysis and Forecast Model 2015-2030 (COVID-19 Impact) Featuring DePuy Synthes, Smith & Nephew, Stryker, Zimmer Biomet, MicroPort Scientific, and B. Braun - ResearchAndMarkets.com. The \"Knee Reconstruction (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"FDA issues Emergency Use Authorization to Vela Diagnostics' coronavirus PCR test. The ViroKey\u2122 SARS-CoV-2 RT-PCR Test receives Emergency Use Authorization from the FDA. FAIRFIELD, N.J. , Aug. 5, 2020 /PRNewswire/ -- Vela Diagnostics announced that the manual version of its coronavirus PCR test has obtained Emergency Use Authorization from the U.S. Food and Drug Administration (FDA). By targeting conserved regions of the viral genome, the probe-based reverse transcription PCR test detects SARS-CoV-2, the coronavirus that causes COVID-19. The EUA allows the emergency use of FDA medical products in qualified labs, thus facilitating widespread access to the diagnostic test.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program. - Phase 1a Clinical Trial to Begin in Q4 2020. TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (\"Galmed\" or the \"Company\"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on the Company's pipeline program.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update. Completed upsized IPO in June 2020 raising $319.3 million in gross proceeds\n\n\nAdvanced pipeline focused on rare hematologic diseases and cancers, including reporting favorable single-dose data for FT-4202 in sickle cell disease (SCD) from a randomized, multi-center, placebo-controlled Phase 1 trial\n\n\nAdditional data expected the second half of 2020 for FT-4202 in SCD and olutasidenib in acute myeloid leukemia (AML)\n\n\nFT-7051 for patients with metastatic castration-resistant prostate cancer (mCRPC) to begin Phase 1 trial in the fourth quarter of 2020. Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today reported financial results for the second quarter ended June 30, 2020. The Company also highlighted recent progress and upcoming milestones for its pipeline programs.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Major Challenges in Pharmaceutical Industry and How to Overcome Them | Learn More in Quantzig\u2019s Latest Article. Quantzig, a global data analytics and advisory firm that delivers actionable analytics solutions to resolve complex business problems, brings you comprehensive insights into the top challenges facing the global pharmaceutical industry in its recent article.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Joint American Academy of Dermatology & National Psoriasis Foundation New Care Guidelines for Medication Management of Psoriasis: Echosens Cites Need for Liver Disease Monitoring. Echosens , a high-technology company offering the FibroScan family of products, points to the critical importance of new guidelines issued jointly by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF), which include a detailed discussion and recommendations to assist prescribers on the efficacy and safety for the most commonly prescribed medications for psoriasis. This includes methotrexate, an immunosuppressive agent used in the therapy of psoriasis that has been associated with frequent but mild elevations in serum liver enzymes and, more importantly, development of chronic liver injury, progressive fibrosis, cirrhosis and portal hypertension . These guidelines serve as a pathway for the use of non-invasive liver assessment tools, such as VCTE, (FibroScan) a proprietary elastography technology developed by Echosens to identify and monitor liver health in people undergoing long term treatment with methotrexate.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Pressure Relief Devices Market Model: Analysis and Forecast (2020-2030) with COVID-19 Impact Assessment - ResearchAndMarkets.com. The \"Pressure Relief Devices (Wound Care Management) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Immune Health Supplements Market to surpass US$ 22,702.4 million by 2027, Says Coherent Market Insights (CMI). According to Coherent Market Insights, the global immune health supplements market is estimated to be valued at US$ 14,913.8 million in 2020 and is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Phased-in Approach to Re-opening Schools a Solid Plan\u2014CUPE BC. CUPE BC and the CUPE K-12 Presidents Council welcome Education Minister Rob Fleming\u2019s announcement today that schools will re-open the week of September 8\u201311 as scheduled, with orientation days in place for support staff, teachers and other workers in schools to familiarize themselves with procedures before students return to classrooms on September 10.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Market Tracking and Real World Drug Performance Analysis Helps a Pharmaceutical Firm Increase Market Share | Get in Touch to Learn More About Quantzig\u2019s Real World Evidence Analytics Capabilities. Premier analytics service provider, Quantzig announces the completion of its real world evidence analytics engagement . The success story offers comprehensive insights into how they helped a leading pharma company to analyze future growth opportunities and track market shares based on the performance of two newly launched oral oncolytic drugs.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Artificial Organs Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Increasing Prevalence of Chronic Disorders to Boost the Market Growth | Technavio. Technavio has been monitoring the artificial organs market and it is poised to grow by USD 11.07 billion during 2020-2024, progressing at a CAGR of almost 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Centrifuge Markets - Global Industry Analysis, Size, Share, Growth, Trends and Forecasts 2020-2030 - ResearchAndMarkets.com. The \"Centrifuge Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"U.S. Onychomycosis Market: Insights, Epidemiology & Forecast to 2030 - ResearchAndMarkets.com. The \"Onychomycosis - Market Insights, Epidemiology and Market Forecast - 2030\" drug pipelines has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Apnimed to Present at Oppenheimer\u2019s Private Life Sciences Company Call Series. Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced that the company will present at Oppenheimer\u2019s Private Life Sciences Company Call Series, held virtually August 17-19, 2020. The company\u2019s presentation is scheduled for Monday, August 17 th from 9:15 AM \u2013 9:50 AM ET.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Ureteroscopes - Global Market Analysis and Forecast Model 2015-2030 (COVID-19's Impact) - ResearchAndMarkets.com. The \"Ureteroscopes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Corporate Reputation of Pharma in Italy, 2019-2020: The Views of 100 Italian Patient Groups - ResearchAndMarkets.com. The \"The Corporate Reputation of Pharma in 2019 - The Patient Perspective - Italy Edition - The Views of 100 Italian Patient Groups\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Mercer and HLTH Announce Second Annual Employer Program at HLTH VRTL 2020. Dedicated Employer Program allows for personalized innovation experience and engagement with other employers and stakeholders across the health ecosystem\n\n\nMercer will also serve as lead sponsor for HLTH VRTL\u2019s \u201cHealth Equity Program\u201d focused on health disparities, systemic racism and other inequities in healthcare. Mercer, a global leader in redefining the world of work, reshaping retirement and investment outcomes, and unlocking real health and well-being, and a business of Marsh & McLennan (NYSE: MMC), and HLTH, the leading platform bringing together the entire health ecosystem, announced today the second annual \u201cEmployer Program\u201d taking place at HLTH VRTL 2020 . Based on the success of the inaugural Employer Program at HLTH 2019, attendees this year will have the ability to personalize their HLTH innovation experience, in a virtual setting, and engage with fellow employers, as well as with payers, providers, innovators, startups, investors, associations, policy makers, and the patient community.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine. Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"SoftWave Tissue Regeneration Technologies Announces Plan for Cellulite Trial. ATLANTA , Aug. 6, 2020 /PRNewswire/ --\u00a0SoftWave Tissue Regeneration Technologies, a disruptive bio-medical\u00a0device company, announces its plan to embark on a 60-patient study\u00a0for the treatment of cellulite. SoftWave\u00a0TRT has been issued a patent\u00a0for the use of shockwaves to treat cellulite and numerous other aesthetic\u00a0conditions. The lead investigator will be Dr. John Mullins MD, a\u00a0plastic surgeon and Chief of Surgery at Piedmont Hospital in Atlanta.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Intravascular Ultrasound System (IVUS) Catheters: COVID-19's Impact on the Industry 2020-2030 - ResearchAndMarkets.com. The \"Intravascular Ultrasound System (IVUS) Catheters (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Incontinence & Ostomy Care Market Worth $24+ Billion by 2026 - ResearchAndMarkets.com. The \"Incontinence and Ostomy Care Global Market - Forecast to 2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Monarch Medical Technologies Chief Clinical Officer is Speaker at American Diabetes Care and Education Specialists Annual Virtual Conference. Session Encourages Diabetes Clinicians to Gain Data Visualization Skills. Session Encourages Diabetes Clinicians to Gain Data Visualization Skills. Session Encourages Diabetes Clinicians to Gain Data Visualization Skills. Laurel Fuqua, RN, MSN, executive VP and chief clinical officer at Monarch Medical Technologies, will advise diabetes care and education specialists on \u201cData Visualization Skills for Diabetes Population Health Management\u201d as a speaker on opening day for the Association of Diabetes Care and Education Specialists (ADCES) virtual annual conference- ADCES20. Thousands of nurses, physicians, dietitians and other health professionals specializing in diabetes care are slated to attend the virtual event August 13-16. Ms. Fuqua\u2019s presentation focuses on a key issue of effective diabetes care management \u2013 data integration, analytics and communication. The importance of healthcare data analytics is rapidly growing. Using data to measure and monitor both clinical and financial performance and being able to communicate it effectively to stakeholders is a critical skill for diabetes clinical quality improvement initiatives. The session will provide a basic understanding of the importance of data visualization and data storytelling and how to use it to improve outcomes.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Insights on the Fusion Splicer Global Market to 2027 - 41 Companies Profiled Including 3SAE Technologies, Aurora Optics & Multicom - ResearchAndMarkets.com. The \"Fusion Splicer - Global Market Trajectory & Analytics\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Immunochemistry Analyzers Market 2015-2030 Featuring Roche, Danaher, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Labs, and Abbott Labs - ResearchAndMarkets.com. The \"Immunochemistry Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"FDA Approves Oral Treatment for Spinal Muscular Atrophy. SILVER SPRING, Md. , Aug. 7, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. This is the second drug and the first oral drug approved to treat this disease.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure. - Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol. RADNOR, Pa. and GENEVA , Aug. 6, 2020 /PRNewswire/ --\u00a0NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) \"Relief\" today announced that NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Mountain Valley MD Announces Successful Complexation of Ivermectin Drug in Quicksome\u2122 Oral Strip and Commencement of Pre-clinical Trials. VANCOUVER, BC , August 6, 2020 /CNW/ - Mountain Valley MD Holdings Inc. (the \" Company \" or \" MVMD \") (CSE: MVMD) (FRA:20MP) is pleased to announce the commencement of two pre-clinical trials designed to demonstrate the efficacy of its proprietary Quicksome\u2122 technology in overcoming key absorption limitations of the oral drug Ivermectin plus provide data on the pharmacokinetics of the Quicksome\u2122 oral strip sublingual technology. In preparation for these clinical trials, the company has successfully complexed ivermectin into its proprietary Quicksome\u2122 rapid dissolve oral strip technology.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics\u2122, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes. - Primary endpoint met assessing safety and tolerability in the Phase 1b monotherapy portion of the study -. - Preliminary results demonstrate an encouraging trend in C-peptide levels, a biomarker for T1D disease progression -. - Preliminary data shows an increase in the frequency of islet-specific Tregs, a potential mechanistic indicator of therapeutic activity -. ",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Digits Replacement Industry 2015-2030 and Impact of COVID-19 with Rank/Share Analysis of Integra LifeSciences, Stryker, Wright Medical Group and KLS Martin - ResearchAndMarkets.com. The \"Digits Replacement (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"H1 2020 Pipeline Review on Female Contraception - ResearchAndMarkets.com. The \"Female Contraception - Pipeline Review, H1 2020\" drug pipelines has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Diabetologia publishes results highlighting efficacy of the diabetes vaccine Diamyd\u00ae in genetically defined subgroups of type 1 diabetes. STOCKHOLM , Aug. 5, 2020 /PRNewswire/ -- Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) has published results from a meta study that demonstrates a highly significant and clinically relevant effect of Diamyd Medical's lead drug candidate Diamyd \u00ae (GAD-alum) on preserving endogenous insulin production in genetically defined subgroups of type 1 diabetes. The meta study, first reported in December 2019 , comprises more than 500 patients from three placebo controlled randomized clinical trials conducted in Europe and the USA assessing the therapeutic diabetes vaccine Diamyd \u00ae . The publication is co-authored by Dr. Ulf Hannelius , Diamyd Medical, Professor Craig Beam , Western Michigan University and Professor Johnny Ludvigsson , Link\u00f6ping University.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Impact of COVID-19 on the Worldwide Cartilage Repair Industry to 2030 - ResearchAndMarkets.com. The \"Cartilage Repair (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Phreesia Partners with AdventHealth to Provide Zero-Contact Intake Across its Hospital and Ambulatory Care Settings. Phreesia, the nation\u2019s leading patient intake platform, is proud to announce it has partnered with AdventHealth, one of the nation\u2019s largest faith-based healthcare systems, to provide patients with a safe, contactless intake experience across more than 1,000 AdventHealth hospitals, physician practices and urgent care centers.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"First patient in treatment in RhoVac's clinical phase IIb study in the USA. RhoVac AB (\"RhoVac\") announces today, August 10th 2020, that the first patient in the USA is included in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 (\"BRaVac\"). STOCKHOLM , Aug. 10, 2020 /PRNewswire/ -- The first patient in the USA is included in RhoVac's clinical phase IIb study, called BRaVac. The first US clinic to include a patient in the study was Carolina Urologic Research Center. BraVac is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. BRaVac is an international, multi-centre study, which will recruit over 175 patients in six European countries ( Denmark , Finland , Germany , Belgium , Sweden , and the UK) plus the USA . The study has already commenced in Denmark , Finland , Germany , Belgium and now in the USA . RhoVac anticipates recruitment to start very soon also in Sweden and the UK, and the company expects the phase IIb recruitment to be complete by end 2020, and the trial to conclude end 2021.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"MJH Life Sciences\u2122 Continues Moving All Live Events to Virtual Through First Quarter of 2021. Industry giant will continue to leverage its proprietary online virtual platform and technology through at least March 2021. MJH Life Sciences \u2122 confirmed today that all conferences, satellite symposia, award programs and educational programming produced by the privately owned health care media company will take place in virtual format through March 2021.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Applied StemCell Awarded ~USD 2 mil NIH grant for Advancing its TARGATT Technology for Therapeutic Gene Editing. Applied StemCell, Inc. (ASC), a leading gene editing company focused on the development of enabling tools for cell and gene therapy has been awarded close to $2.0 million US dollars in a Small Business Innovation Research (SBIR) grant from the NIH. This fast track Phase I/II grant award will support Applied StemCell (ASC) to advance and improve the efficiency of its proprietary TARGATT\u2122 integrase technology for human gene therapies (referred to as the hTARGATT\u2122) in a three part objective: (1) Develop and improve the efficiency of the TARGATT\u2122 technology in human cell lines including primary cells and stem cells; (2) Develop therapeutic transgenes and demonstrate optimal integration efficiencies as a functional demonstration of the platform\u2019s utility for ex vivo therapeutic applications; (3) Differentiate the above mentioned stem cells to desired somatic lineages and demonstrate regulatory induction of the transgenes.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders. Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the \u201cCompany\u201d or \u201cAppili\u201d), a biopharmaceutical company focused on anti-infective drug development, today announced the voting results from its annual and special meeting of shareholders held on Thursday, August 12, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Happify Health Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups. Happify Health recognized for achievements in Disease Management and Therapeutics. CB Insights today named digital therapeutics leader, Happify Health , to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. Happify Health has been recognized for their achievements in the ranking\u2019s Disease Management and Therapeutics category.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19. - University of California Irvine is the first California site participating in Celularity's CYNK-001-COVID-19 clinical trial NCT04365101 using Celularity's investigational immunotherapy to treat adults who tested COVID-19 positive in underserved and disproportionately affected populations. - CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells. FLORHAM PARK, N.J. , Aug. 5, 2020 /PRNewswire/ -- Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK) cells (CYNK-001) for the treatment of adults with COVID-19.\u00a0The University of California Irvine is the first CA site to open for patient enrollment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Puradigm, LLC announces successful tests of its proactive air and surface purification technology in deactivating SARS-CoV-2, the virus that causes COVID-19, as well as deactivating coronavirus 229E. Results from a study done by the University of Florida using the SARS-CoV-2 virus show a significant decrease in infectivity of the virus immediately after exposure to Puradigm's technology and show the virus was undetectable after 24 hours of exposure to their technology.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Impact of COVID-19 on the Global Reversible Contraceptive Devices Market, 2020-2030 - ResearchAndMarkets.com. The \"Reversible Contraceptive Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Varex Announces Financial Results for Third Quarter of Fiscal Year 2020. Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the third quarter of fiscal year 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Elios Therapeutics Personalized Cancer Vaccine Demonstrates Long-Term Survival Benefit Among High-Risk Melanoma Patients in Phase IIb Final Analysis. ~ 96 Percent of High-Risk Melanoma Patients Were Alive Three Years After Completing the Vaccine Series Compared to 77 Percent of those Treated with Placebo. ~~ 52 Percent of Patients Treated with the Vaccine Were Disease-Free at Three Years Compared to 27 Percent in the Placebo Arm. ~~ New Analysis Reveals Optimized Vaccine Formulation Results in Improved Clinical Outcomes. ~~ Treatment with Vaccine in Combination with Checkpoint Inhibitors Doubled Disease-Free Survival Rate Compared to Checkpoint Inhibitors Alone ~. AUSTIN, Texas , Aug. 5, 2020 /PRNewswire/ --\u00a0Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced final data from a prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating adjuvant use of its personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with Stage III or Stage IV melanoma at high risk of recurrence following complete surgical resection.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Verve Therapeutics to Participate in Oppenheimer\u2019s Private Life Sciences Company Call Series. Verve Therapeutics , a next-generation cardiovascular company, today announced that the company\u2019s management team will present a corporate overview as part of Oppenheimer\u2019s Private Life Sciences Company Call Series on Wednesday, August 19, 2020 at 2:15 p.m. ET.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Medidata Announces Launch of Medidata Detect, its Centralized Statistical Monitoring Solution for Clinical Trials. Medidata, a Dassault Syst\u00e8mes company, announced the launch of Medidata Detect, a centralized statistical monitoring solution that improves data quality and promotes patient safety in clinical trials for new medicines, vaccines and medical devices. Medidata Detect , part of Medidata\u2019s industry-leading, regulatory-compliant and unified Medidata Rave Clinical Cloud platform, helps customers manage data quality, monitor site performance and promote patient safety by uncovering and finding errors, trends and anomalies in data through statistical algorithms and tests.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"PPG Receives DOE Funding for Energy-Saving Automotive Paints and Coatings. Scientists to explore new algorithms and supercomputing resources to model paint flow, leveling for advanced multi-layer coatings systems. Scientists to explore new algorithms and supercomputing resources to model paint flow, leveling for advanced multi-layer coatings systems. Scientists to explore new algorithms and supercomputing resources to model paint flow, leveling for advanced multi-layer coatings systems. PPG (NYSE:PPG) today announced a partnership with the U.S. Department of Energy (DOE) Lawrence Berkeley National Laboratory (LBNL) for a research initiative aimed at developing energy-efficient coatings systems for the automotive industry. The PPG project \u2013 \u201cModeling Coating Flow and Dynamics during Drying\u201d \u2013 was selected to receive funding through the DOE High Performance Computing for Energy Innovation (HPC4EI) program.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Model N Continues to Lead in Life Sciences Market. Cloud Revenue Management Leader Grows Mid-Market Customer Base, Achieves Multiple Client Go-Live Events and Drives New SaaS Implementations. Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, announced today that it continues to achieve significant momentum within Life Sciences.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Excess Weight Among Pregnant Women May Interfere With Child's Developing Brain. Obesity in expectant mothers may hinder the development of the babies' brains as early as the second trimester, a new study finds. NEW YORK , Aug. 11, 2020 /PRNewswire/ --\u00a0Led by researchers at NYU Grossman School of Medicine, the investigation linked high body mass index (BMI), an indicator of obesity, to changes in two brain areas, the prefrontal cortex and anterior insula. These regions play a key role in decision-making and behavior, with disruptions having previously been linked to attention-deficit/hyperactivity disorder (ADHD), autism, and overeating.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"RapidAI Receives FDA Clearance of Rapid LVO For Identification of Suspected Large Vessel Occlusions. RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid LVO has received Food and Drug Administration (FDA) clearance for detecting suspected LVOs (Large Vessel Occlusions).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review. CARMIEL, Israel , Aug. 11, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx \u00ae plant cell-based protein expression system, or the Company, together with its development and commercialization partner Chiesi Global Rare Diseases, a unit of Chiesi, an international research-focused healthcare group, today announced that the U.S.\u00a0Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease. The BLA was submitted via the FDA's Accelerated Approval\u00a0pathway. Pegunigalsidase alfa is the Company's purposefully designed, long-acting recombinant, PEGylated, cross-linked \u03b1-galactosidase-A investigational product\u00a0candidate. The FDA set an action date of January 27, 2021 , under the Prescription Drug User Fee Act (PDUFA). The FDA also indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Trendlines Medical Shanghai Opens its Doors. Trendlines Medical Shanghai partners with Chinese medical companies, governmental programs, and entrepreneurs to develop novel medical technologies for the Chinese and global markets.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Worldwide Nanocopper Oxide Market to 2027 - COVID-19 Impact and Global Analysis - ResearchAndMarkets.com. The \"Nanocopper Oxide Market Forecast to 2027 - COVID-19 Impact and Global Analysis by End User; and Geography\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"PainTEQ Begins Novel Biomechanical Study on SI Joint Fusion. Data captured from study will advance research in the treatment of sacroiliac joint dysfunction using a cutting-edge therapeutic device. TAMPA, Fla. , Aug. 11, 2020 /PRNewswire/ -- PainTEQ , a leading medical device innovator, launched a first of its kind biomechanical study this month that explores the treatment of\u00a0sacroiliac (SI) joint pain through a minimally invasive outpatient procedure using a posterior approach.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"2020 Insights into the Global Chronic Kidney Disease Clinical Trial Pipeline - ResearchAndMarkets.com. The \"Global Chronic Kidney Disease Clinical Trial Pipeline Highlights - 2020\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials. JAN101 formulation ready for Phase 2b peripheral artery disease trials and for potential treatment of COVID-19 vascular inflammation. LAS VEGAS , Aug. 11, 2020 /PRNewswire/ --\u00a0JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, together with its manufacturing partner, has successfully completed the formulation of JAN101, its potential treatment for Peripheral Artery Disease (PAD) expected to soon be in Phase 2b trials. In addition, JAN101 is planned for use to treat COVID-19 vascular complications pending approval of the IND submission, expected to be completed in late August 2020 .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"The first Virtual Microscope of the human brain, developed by Darmiyan, accurately measures Alzheimer's-related abnormalities. Memory clinics and hospitals in the US and Canada validate BrainSee, The Virtual Microscope, finding that it has a remarkably high performance accuracy and consistency for 5-year prognosis of amnestic MCI. SAN FRANCISCO , Aug. 11, 2020 /PRNewswire/ -- Darmiyan, Inc. , is pleased to announce the successful completion of its third-party validation study aimed at blind-testing and validating BrainSee ( Darmiyan's proprietary, patent-protected technology ), in predicting the cognitive future (prognosis) of mild cognitive impairment patients in the actual clinical setting. The third-party investigators were from Stanford University , Baycrest Institute, Huntington Medical Research Institutes (HMRI), University Health Network (UHN), Knight Alzheimer's Disease Research Center (ADRC) at Washington University in St. Louis , and GERAS Hamilton Health Sciences (HHS). The Canadian trial sites were coordinated by CABHI (Centre for Aging & Brain Health Innovation) following a CABHI-I2P2 (Industry Innovation Partnership Program) grant that was awarded to Darmiyan in 2018.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World. - Named Patient Programs will allow Providers to treat patients with bone metastases pain palliation radiopharmaceutical treatment as of September, 2020. - Named Patient Programs will remain in place until the treatment has been commercialised in EU and ROW, which is expected to be completed in 2021. NEW YORK , Aug. 11, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today it is launching a Named Patient Program for its non-opioid bone metastases pain palliation drug, Strontium89 (Strontium Chloride Sr-89 Injection, USP). The Named Patient Program will be available to physicians and patients in the EU and throughout the world, and will be facilitated by Caligor Coghlan Pharma Services (CCPS).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Romark Initiates New Phase 3 Clinical Trial Of NT-300 For The Treatment Of COVID-19. NT-300 clinical program now comprises three pivotal trials for COVID-19. TAMPA, Fla. , Aug. 11, 2020 /PRNewswire/ -- Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today the initiation of a Phase 3 clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors. Phase I/II study in patients with solid tumors expected to commence in Q3 2020 at leading sites in the United States. JERUSALEM , Aug. 12, 2020 /PRNewswire/ -- KAHR Medical , a cancer immunotherapy company developing novel bi-functional fusion proteins, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug (IND) application for\u00a0the Company's lead product,\u00a0DSP107, a second generation CD47x41BB targeting compound that simultaneously target cancer cells, weaken their innate defenses and activate an effective, local response of both innate and adaptive immunity.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA\u00ae (lenvatinib) in Patients with Differentiated Thyroid Cancer. WOODCLIFF LAKE, N.J. , Aug. 11, 2020 /PRNewswire/ --\u00a0Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the efficacy and safety of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, comparing two starting doses (18 mg versus 24 mg daily) in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC). Results indicate that the lower starting dose (18 mg) of LENVIMA did not meet the non-inferiority requirement compared to the approved starting dose (24 mg) in patients with RAI-refractory DTC as measured by objective response rate (ORR) at week 24. The data from this study support the selection of 24 mg as an appropriate starting dose for patients with RAI-refractory DTC.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Dietary cholesterol and phytosterols contribute directly to heart disease. Genetic variability in cholesterol and phytosterol absorption affects cardiovascular disease risk. REYKJAVIK, Iceland , Aug. 6, 2020 /PRNewswire/ --\u00a0Scientists at deCODE genetics , a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system , University of Iceland , the Copenhagen University Biobank and the Danish Blood Donor Study , recently published a study in European Heart Journal , with new findings that point to harmful effects of dietary cholesterol and phytosterols.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Peer-reviewed research shows Babylon's latest Artificial Intelligence could help doctors improve diagnosis, particularly for complex cases. LONDON , Aug. 11, 2020 /PRNewswire/",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Anemia in Chronic Kidney Disease: 2020 Pipeline Research Monitor - ResearchAndMarkets.com. The \"Anemia in Chronic Kidney Disease Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA\u00ae (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020 Virtual Presidential Symposium. SUZHOU, China, Aug. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and Company (\"Lilly\", NYSE: LLY) that interim analysis data from ORIENT-11 were released today in an oral presentation at the IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium.\u00a0On the same day, the data was published online by the Journal of Thoracic Oncology. This trial was conducted to assess the efficacy of TYVYT\u00ae (sintilimab injection) in combination with ALIMTA \u00ae (pemetrexed) and platinum chemotherapy as a first-line treatment in people with nonsquamous non-small cell lung cancer (nsqNSCLC) without sensitive EGFR mutation or ALK rearrangement.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Eclipse Cofounders Publish Foundational Dataset Revealing Extensive Hidden Signals in Human Genes. eCLIP technology solved key problem in matching hundreds of RNA binding proteins to the instruction signals within the RNA code to uncover how RNA binding proteins regulate gene expression. ",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cardiff Oncology Announces Second Quarter 2020 Results and Highlights. SAN DIEGO , Aug. 11, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castrate-resistant prostate cancer and leukemia, today announced company highlights and financial results for the second quarter ended June 30, 2020 . The Company is issuing this press release in lieu of conducting a conference call.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck. OSLO, Norway and SAN FRANCISCO , Aug. 12, 2020 /PRNewswire/ -- Vaccibody AS and\u00a0Nektar Therapeutics (NASDAQ: NKTR) today announced that the first patient has been dosed\u00a0in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar's CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"JOMS study: For jaw cancer patients, in-house 3D printing allows quicker restoration of teeth. ROSEMONT, Ill. , Aug. 12, 2020 /PRNewswire/ --\u00a0In-house 3D printing allows patients with malignant disease to more quickly receive immediate tooth restoration \u2013 treatment that had been regarded as of low importance for these patients due to the severity of their disease, a new study found.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol. TARRYTOWN, N.Y. , Aug. 12, 2020 /PRNewswire/",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT\u00ae (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China. SUZHOU, China, Aug. 12, 2020 /PRNewswire/ --\u00a0Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today jointly announced with Eli Lilly and Company (\"Lilly\", NYSE: LLY) that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for TYVYT\u00ae (sintilimab injection) in combination with Gemzar\u00ae (gemcitabine) and platinum as first-line therapy in squamous non-small cell lung cancer (squamous NSCLC).\u00a0Recently, the NMPA accepted sNDA for TYVYT\u00ae (sintilimab injection) as first-line therapy in non-squamous NSCLC on Apr 23, 2020 .",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"miR Scientific Announces Validation of its Urine Based, Non-Invasive Prostate Cancer Test Published in the Journal of Urology. Validated Data Reinforces Capability to Molecularly Detect and Characterize Prostate Cancer with Concurrent Sensitivity and Specificity of Over 91%",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Rocket Science Health and Inez Jabalpurwala Team Up to Launch VINEx, a Multi-Disciplinary Exploration of the Virus-Brain Connection. VICTORIA , BC\u00a0and MONTREAL , Aug. 12, 2020 /CNW/ - Rocket Science Health and Inez Jabalpurwala have teamed up to launch VINEx \u2013 a multi-disciplinary exploration of how viruses directly and indirectly affect the central nervous system (CNS), and the potential impact on brain health in the immediate and longer term. VINEx aims to provide catalytic leadership to connect the people, knowledge and funding needed to advance research at the intersection of neuroscience/neurology, virology, immunology and data science \u2013 from basic science to clinical studies. The initial focus will be SARS-CoV-2 and other respiratory viruses which may have an olfactory entry point into the CNS. This work will address what could be a major health crisis in the months and years after the COVID-19 pandemic, and also contribute to the knowledge base around the impact of viruses on neurological health more generally.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Eggshell-based surgical material for skull injuries. MOSCOW , Aug. 13, 2020 /PRNewswire/ -- A bioactive polymer-ceramic composite for fixing implants and restoring bone defects in the skull was developed by an international group of materials scientists from the NUST MISIS Center for Composite Materials. An innovative composition of the material based on eggshell-derived bioceramic provides increased strength and biointegration of implants. The results of the work were published in the international scientific journal Journal of Asian Ceramic Societies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849, a Novel KRAS G12C Selective Inhibitor. --Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 for Patients with Advanced Solid Tumors Harboring a KRAS G12C Mutation--. ANN ARBOR, Mich. , Aug. 13, 2020 /PRNewswire/ -- Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced it has signed an agreement with Mirati Therapeutics, Inc. (NASDAQ:MRTX) to broaden patient identification and enrollment for Mirati's Phase 1/2 study of MRTX849 in patients with cancer having a KRAS G12C mutation ( clinicaltrials.gov identifier: NCT03785249 ). The multiple expansion cohort study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors who have a KRAS G12C mutation.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments. - NURTEC\u2122 ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share. - Company well-capitalized with recent non-dilutive financing of up to $950M from Sixth Street term loan and Royalty Pharma funding agreement. - Remains on timelines for NURTEC ODT sNDA filing for prevention of migraine in the coming months; additionally, completion of troriluzole Alzheimer's Disease Phase 2/3 trial in 4Q2020, and topline results with troriluzole in Alzheimer's Disease and Spinocerebellar Ataxia, and verdiperstat in Multiple System Atrophy in 2021. NEW HAVEN, Conn. , Aug. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:\u00a0BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended June 30, 2020 , and provided a review of recent accomplishments and anticipated upcoming milestones.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Phase III InPedILD\u2122 trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease. - First-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globally. - This new study builds on the Phase III INBUILD\u00ae trial and approval of Ofev\u00ae in adult patients with fibrosing ILDs with a progressive phenotype. - Global Phase III multicenter clinical trial is planned to be conducted in approximately 70 sites in 24 countries, including the United States. RIDGEFIELD, Conn. , Aug. 12, 2020 /PRNewswire/ --\u00a0Boehringer Ingelheim today announced that the first patient has enrolled in InPedILD\u2122, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Caris Life Sciences Partners with Elevation Oncology to Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions. Partnership explores innovative models for real-time identification, patient referral and enrollment of patients with solid tumors with a rare gene fusion. IRVING, Texas , Aug. 11, 2020 /PRNewswire/ --\u00a0Caris Life Sciences \u00ae , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that it has entered into a strategic partnership with Elevation Oncology to enhance patient enrollment practices for genomically-driven, tumor-agnostic clinical trials. Using Caris' suite of market-leading molecular profiling offerings, the Caris Pharmatech Just-In-Time (JIT) clinical trial solutions, and the Caris Precision Oncology Alliance \u2122 (POA) network, the companies will improve traditional enrollment in Elevation Oncology's registration-directed Phase 2 CRESTONE trial through the real-time, nationwide identification of eligible patients with neuregulin-1 (NRG1) fusion-positive tumors and use of flexible enrollment models for rapid initiation of study treatment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"MicuRx Announces CARB-X US$7.78 Million Funding for Development of MRX-8. --and FDA Clearance for Phase 1 Trial of the Novel Antibiotic--. FOSTER CITY, Calif. and SHANGHAI , Aug. 13, 2020 /PRNewswire/ --\u00a0MicuRx Pharmaceuticals Inc. today\u00a0announced that the global partnership Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has committed up to US$7.78 million of nondilutive financing for a Phase 1 clinical trial and related R&D activities of its\u00a0new antimicrobial agent MRX-8. Previously, CARB-X has funded investigational new drug (IND) enabling studies for MRX-8 in the US.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis. Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis. NEW YORK , Aug. 13, 2020 /PRNewswire/ --\u00a0Hoth Therapeutics, Inc. (NASDAQ:\u00a0HOTH), a biopharmaceutical company,\u00a0today announced\u00a0that it has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa for Atopic Dermatitis. The ethics submission was made to the Bellberry Human Research Ethics Committee in Australia .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"SWORD Health Becomes The Only Digital Musculoskeletal Care Provider With HITRUST\u00ae, SOC 2 And FDA Certifications. With HITRUST CSF Certification, SOC 2 compliance and an FDA-listed medical device, SWORD Health demonstrates its commitment to clinical-grade standards of patient security, safety, and privacy. NEW YORK , Aug. 13, 2020 /PRNewswire/ --\u00a0SWORD Health, a leading provider of digital musculoskeletal (MSK) care, today announced SWORD Health's digital therapy platform and several of its applications have earned Certified status for information security by HITRUST.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Personalized Stem Cells Announces Completion of Enrollment for FDA Approved Stem Cell Clinical Trial for Knee Arthritis. POWAY, Calif. , Aug. 5, 2020 /PRNewswire/ -- Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, has announced that enrollment is officially complete for their FDA approved stem cell clinical trial for treatment of knee osteoarthritis . 38 patients are participating in the clinical trial to have one knee treated with their own stem cells.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"National Survey Of Heart Valve Patients Reveals Importance Of Seeking Treatment Early With Active Living As Key Priority. New awareness campaign empowers patients to proactively manage treatment decisions as fears of hospital visits increase during COVID-19. TORRANCE, Calif. , Aug. 5, 2020 /PRNewswire/ --\u00a0A national survey released today by patient advocacy group Heart-Valve-Surgery.com with support by Medtronic, found that nearly half (49 percent) of heart valve patients say return to active living is a key factor in their treatment decision. The survey of more than 3,400 heart valve patients and caregivers uncovered real-world insights around managing heart valve disease \u2013 from diagnosis through treatment and beyond. The survey findings help kick off a new Active Living Awareness Initiative.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"PTC Therapeutics Announces FDA Approval of Evrysdi\u2122 (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older. - Evrysdi represents the first at home, oral treatment approved for infants, children and adults with all SMA types-. - Marketing Authorization Application submission to European Medicines Agency is imminent  -. - Risdiplam is the first approved therapy discovered and developed from PTC Therapeutics' proprietary splicing platform -. SOUTH PLAINFIELD, N.J. , Aug. 7, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi\u2122 (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children 2 months and older. Evrysdi showed clinically meaningful improvements in motor function and obtainment of developmental milestones across two trials in patients age two months and above and across all levels of disease severity, including types 1, 2, and 3 SMA. Infants achieved key motor milestones not normally seen in the natural course of the disease, such as the ability to sit without support. Evrysdi also preserved vital functions and improved survival at 12 months. In particular, Evrysdi improved survival without permanent ventilation compared to natural history when measured at 12 and 23 months.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Outlook on the Global Monoclonal Antibodies Market (2020 to 2024) - by Source, Application, End-users & Region - ResearchAndMarkets.com. The \"Global Monoclonal Antibodies Market (By Source, Application, End-Users & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma. SINGAPORE , Aug. 6, 2020 /PRNewswire/ -- Tessa Therapeutics (Tessa) , a clinical-stage cell therapy company developing next-generation cancer treatments, today announced the publication of results in the Journal of Clinical Oncology from two investigator-sponsored Phase 1/2 trials led by Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Center.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"DNA Sequencing Industry Outlook 2020-2025 - Increasing Application in Clinical Diagnosis & Drug Discovery is Driving Growth - ResearchAndMarkets.com. The \"Global DNA Sequencing Market: Growth, Trends & Forecast 2020-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sanford Health finds Keytruda\u00ae combined with chemotherapy and radiation improves outcomes for head and neck cancers. Breakthrough study could change the way head and neck cancers are treated, promising early results lead to phase III clinical trials. SIOUX FALLS, S.D. , Aug. 11, 2020 /PRNewswire/ -- Sanford Health, the largest provider of rural healthcare in the country, today announced the findings from a Phase 1b study using pembrolizumab (Keytruda\u00ae) in addition to the standard chemotherapy and radiation treatment for patients with head and neck cancers. The results from this first-in-human trial have been published in the Journal of Clinical Oncology .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis. NEW YORK , Aug. 10, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that, on August 7, 2020 , it was notified by the Food and Drug Administration (FDA) that Seelos may proceed with initiating a Phase IIb/III trial studying SLS-005 (trehalose) for the treatment of Amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Clearside Biomedical Announces Second Quarter 2020\u00a0Financial Results and Provides Corporate Update. IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - - Engaged New Contract Manufacturer for XIPERE \u2122 - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"CytoDyn to Hold Conference Call on August 12 to Discuss Impressive Results from its Phase 2 COVID-19 Trial. VANCOUVER, Washington, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (\u201cCytoDyn\u201d or the \u201cCompany\"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community conference call on Wednesday, August 12, 2020, to provide a comprehensive overview of the compelling results from the Company\u2019s recently completed Phase 2 CD10 trial for COVID-19 patients with mild-to-moderate symptoms, along with an update on its Phase 3 trial for COVID-19 patients with severe-to-critical indications and the regulatory path going forward.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"New Approach to Treating Osteoarthritis Advances. NEW YORK , Aug. 10, 2020 /PRNewswire/ -- Injections of a natural \"energy\" molecule prompted regrowth of almost half of the cartilage lost with aging in knees, a new study in rodents shows.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"AquaBounty Technologies, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock. MAYNARD, MASS., Aug. 07, 2020 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (\u201cAquaBounty\u201d or the \u201cCompany\u201d), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the pricing of its previously announced underwritten public offering of 11,000,000 shares of common stock of the Company at a price to the public of $2.50 per share. AquaBounty expects to receive aggregate gross proceeds of approximately $27.5 million from the offering. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to 1,650,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about August 11, 2020, subject to customary closing conditions.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients. -  Data from Phase 3 VIALE-A study showed venetoclax plus azacitidine reduced the risk of death by 34% compared to azacitidine plus placebo in newly-diagnosed patients with AML who are ineligible for chemotherapy. -  AML is one of the most aggressive blood cancers, with a very low survival rate and few options for patients who are unable to undergo intensive chemotherapy, the current standard of care(1,2). NORTH CHICAGO, Ill. , Aug. 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the New England Journal of Medicine (NEJM) . The study, which evaluated newly-diagnosed AML patients who had not yet been treated and were unable to tolerate traditional intensive chemotherapy, found that venetoclax in combination with azacitidine extended overall survival (OS) compared to azacitidine plus placebo. The manuscript titled, \" Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia ,\" was published in the August 13, 2020 issue of NEJM . 3",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis. - Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis\u00b9. - ASCLEPIOS I and II demonstrated significant reductions in risk of relapses, confirmed disability worsening and profound reduction of active or new brain lesions\u00b9. - The US Food and Drug Administration and European Medicines Agency are currently reviewing investigational ofatumumab for the treatment of relapsing forms of multiple sclerosis (RMS) in adults. - If approved, ofatumumab will be the first B-cell therapy that can be self-administered at home and has the potential to become a first-choice treatment for use in RMS patients. EAST HANOVER, N.J. , Aug. 5, 2020 /PRNewswire/ --\u00a0Novartis today announced that The New England Journal of Medicine (NEJM) published the positive results from the ASCLEPIOS I and II studies evaluating the safety and efficacy of ofatumumab (OMB157) 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with relapsing forms of multiple sclerosis (RMS). Both studies met the primary endpoints where ofatumumab showed a significant reduction in the number of confirmed relapses, evaluated as the annualized relapse rate (ARR). 1",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Dartmouth-Hitchcock Health Begins Patient Treatments with ViewRay's MRIdian Linac. Brings Benefits of MRI-Guided Radiation Therapy Closer to Home for Cancer Patients in New England. CLEVELAND , Aug. 13, 2020 /PRNewswire/ --\u00a0ViewRay, Inc. (Nasdaq: VRAY)\u00a0announced today that Dartmouth-Hitchcock Health in New Hampshire has begun patient treatments with the MRIdian \u00ae MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Crown Introduces \"Beauty and the Bacteria\" Microbiome Docu-series. Leaders in microbiome research uncover groundbreaking discoveries and offer an educational forum for industrywide discussion. JOHNSON CITY, Tenn. , Aug.\u00a011, 2020 /PRNewswire/ -- Crown, a leader in dermatology drugs, products and devices, announces the launch of their skin microbiome webinar series, \"Beauty and the Bacteria\", hosted by Chief Science Officer, Thomas Hitchcock , Ph.D. The series will investigate Crown's cutting-edge research into the world of the skin microbiome and debunk some of the fallacies associated with traditional skincare.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technology. LAKE FOREST, Calif. , Aug. 13, 2020 /PRNewswire/ --\u00a0InMode Ltd. (Nasdaq:\u00a0INMD) (\"InMode\"), a leading global provider of innovative medical technologies, is pleased to announce a new FDA clearance to market the Morpheus8 Body handpiece and Morpheus8 Platform.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Almac Clinical Services Launches Virtual Auditing Solution for Clients. Digitising conventional on-site audits to ensure continued quality and regulatory compliance for clinical trials. CRAIGAVON, Northern Ireland , Aug. 11, 2020 /PRNewswire/ -- Almac Clinical Services has digitised its conventional on-site auditing process and launched a virtual auditing solution for clients. This is to ensure continued quality and regulatory compliance during the current COVID-19 pandemic, maintain GMP standards and deliver on the terms of quality and technical agreements all whilst protecting employees and upholding social corporate responsibility to partners and suppliers. Global clients can realise clear advantages, saving time and money otherwise spent on travel and accommodation requirements.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"The KLAS Spotlight highlights Algorex Health's work of proactively surfacing social determinant of health (SDOH) risk and closing gaps in program design and fulfillment - all while measuring total impact on clinical and non-clinical outcomes. BOSTON , Aug. 11, 2020 /PRNewswire/ --\u00a0Algorex Health Technologies, a leader in measuring the effect of social determinants on patients' real lives, announced its recognition as an emerging healthcare services company in a new KLAS\u00ae Research Spotlight Report. The report, based on detailed feedback from Algorex Health customers regarding their satisfaction with Algorex Health's technology and approach to partnership, highlighted the company's ability to help healthcare organizations predict and invest in social determinant interventions for their respective populations.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"New Analyses of Ofev\u00ae data in patients with chronic fibrosing ILDs available during American Thoracic Society Congress. -- An analysis of the Phase III INBUILD\u00ae trial showed the proportion of patients with 10% or greater declines in lung function were lower in the Ofev\u00ae (nintedanib) group relative to placebo over 52 weeks. -- A separate data analysis affirmed the consistent effect of Ofev on reducing the annual rate of decline in forced vital capacity (FVC) in patients with chronic fibrosing ILDs, irrespective of demographic characteristics, lung function or ILD diagnosis. -- The FDA approval of Ofev as the first treatment for people with chronic fibrosing ILDs with a progressive phenotype was based on the results of the Phase III INBUILD study. RIDGEFIELD, Conn. , Aug.\u00a05, 2020 /PRNewswire/ --\u00a0Boehringer Ingelheim today announced new analyses of the Phase III INBUILD\u00ae trial that studied Ofev\u00ae (nintedanib) for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. These analyses were published online in conjunction with the American Thoracic Society (ATS) Virtual conference. The accepted abstracts are available here .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment. MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that it enrolled its first patient in its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"ARCADIA clinical studies to investigate potential new treatment for people with moderate-to-severe atopic dermatitis. ",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic. Cytovia developing novel CAR NK cell therapy and NK engager antibodies for cancer. NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing CAR NK cell therapy and NK engager antibodies for cancer, announced today that it has licensed from ProteoNic BV its 2G UNic\u2122 technology for boosting recombinant protein production, allowing for cost-effective manufacturing at large scale. Under the agreement, Cytovia gains non-exclusive, worldwide commercial rights for application of the technology to the development of a number of its proprietary NK Engager multifunctional antibodies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Organicell Completes Capital Raise from Retrograde Investments. MIAMI, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has completed an initial capital raise from Retrograde Investments LLC. The proceeds from the investment will be used to fund the costs associated with bringing current all financial audits and filings and maintaining SEC compliance, as well as help support the company\u2019s initial clinical trials for its prospective COVID-19 therapeutic treatment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Catalyst Pharmaceuticals\u2019 Firdapse\u00ae (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS. CORAL GABLES, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Canada\u2019s national healthcare regulatory agency, Health Canada, has approved the use of Firdapse\u00ae (amifampridine) for the treatment of patients in Canada with Lambert-Eaton myasthenic syndrome (LEMS), an ultra-rare, debilitating and potentially life-threatening neurodegenerative condition.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock. MAYNARD, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (\u201cAquaBounty\u201d or the \u201cCompany\u201d), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced that it has commenced a proposed underwritten public offering of common stock of the Company. In addition, the Company expects to grant the underwriters of the offering a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19. \u2022 BLA-type submission planned this month in U.K. for HIV combination therapy with 350 mg weekly dose \u2022 COVID-19 Phase 2 topline report to be submitted for consideration of emergency approval of leronlimab for patients with mild-to-moderate symptoms to U.K. and other countries following submission to the U.S. FDA next week",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space. Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Australian Therapeutic Goods Administration Approves the First Phase I Trial of ATG-017 for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies. SHANGHAI and MELBOURNE, Australia , Aug. 12 , 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company, announced today the authorization of the first-in-human trial of ATG-017 (ERASER trial) by the Australian Therapeutic Goods Administration (TGA). ATG-017 is a potent and selective small molecule extracellular signal\u2013regulated kinases 1 and 2 (ERK1/2) inhibitor. The study will enroll patients with advanced solid tumors and hematological malignancies. Today's milestone marks the first TGA trial authorization for Antengene and is the first clinical trial for ATG-017 globally.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Kaiser Permanente joins late-stage COVID-19 vaccine study. The phase 3 clinical trial will test the vaccine in 1,400 adults at sites in California and Oregon. OAKLAND, Calif. , Aug. 12, 2020 /PRNewswire/ --\u00a0Today, Kaiser Permanente began participating in a phase 3 clinical trial to test an investigational vaccine against SARS-CoV-2, the virus causing the current COVID-19 global pandemic. Kaiser Permanente plans to enroll approximately 1,400 participants at 4 sites in California and Oregon . The goal for this trial is to enroll up to 30,000 participants at more than 120 sites around the world. The investigational vaccine being tested in this trial is BNT162b2, one of the vaccine candidates in development by Pfizer, Inc., and BioNTech, which are also the sponsors of the study.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Southeastern Grocers Offers Contactless Prescription Delivery and Expands Commitment to Customer Safety. Grocer takes additional measures to ensure customer safety by partnering with ScriptDrop, Omnicell, Safe Rx\n\n\n\nSoutheastern Grocers is partnering with ScriptDrop to offer three convenient contactless prescription delivery options.\n\n\nGrocer to utilize technology solution from Omnicell Population Health Solutions to better connect with customers and provide useful information to help combat the ongoing opioid crisis.\n\n\nFresco y M\u00e1s, Harveys Supermarket and Winn-Dixie pharmacies now offer naloxone for opioid overdose emergencies.\n\n\nWinn-Dixie pharmacies rank third in J.D. Power\u2019s 2020 \u201cU.S. Pharmacy Study.\u201d. Southeastern Grocers, Inc. (SEG), parent company and home of BI-LO, Fresco y M\u00e1s, Harveys Supermarket and Winn-Dixie grocery stores, is expanding its commitment to customer safety during the pandemic by offering contactless prescription delivery. In partnership with ScriptDrop, Fresco y M\u00e1s, Harveys Supermarket and Winn-Dixie customers can choose between three convenient delivery options: free curbside pickup, two-day shipping for $4.99 or same-day delivery, if within five miles of their local store, for $7.99. Customers can utilize any one of these options by simply contacting their local pharmacist to coordinate a delivery method of choice.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Rasmussen College Expands Master of Science in Nursing Program and Relaunches Program with New, Flexible Learning Option. College adds third MSN specialization and relaunches program in a competency-based education learning format. Rasmussen College, a regionally accredited private college, today announced the expansion of its Master of Science in Nursing (MSN) program. The CCNE-accredited, online Master\u2019s degree program is now available with three in-demand specializations: Nursing Education, Nursing Leadership and Administration and the newly added Healthcare Technology, Simulation and Informatics 1 . In addition to adding a third specialization, the College relaunched the MSN program in its Flex Choice \u00ae competency-based education (CBE) learning format which ensures graduates actively demonstrate skills required to flourish in their career. Enrollment in the MSN program\u2019s new CBE format as well as the Healthcare Technology, Simulation and Informatics specialization is immediately available with classes beginning in October.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Biologics Market and Curative Oncology and Rare Disease Therapies to 2024 - COVID-19 Impact Analysis - ResearchAndMarkets.com. The \"Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020-2024\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights on the Global Biosurgery Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio. Technavio has been monitoring the biosurgery market and it is poised to grow by USD 4.81 billion during 2020-2024, progressing at a CAGR of almost 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Purdue\u2019s Avrio Health L.P. Reports Preliminary In Vitro Test Results on Study Assessing Betadine Gargle Against COVID-19. . THIS RELEASE DISCUSSES INVESTIGATIONAL USES OF BETADINE AND IS NOT INTENDED TO CONVEY CONCLUSIONS ABOUT ITS EFFICACY OR SAFETY IN TREATING AND/OR PREVENTING COVID-19 OR ANY OTHER VIRUSES. BETADINE ANTISEPTIC PRODUCTS HAVE NOT BEEN DEMONSTRATED TO BE EFFECTIVE AGAINST SARS-COV-2 OR ANY OTHER VIRUSES IN VIVO , NOR HAVE ANY CLINICAL STUDIES BEEN CONDUCTED TO ASSESS ITS SAFETY OR EFFECTIVENESS AS A VIRUCIDAL AGENT. THERE IS NO GUARANTEE THAT STUDIES EVALUATING THE EFFECTIVENESS OF BETADINE AGAINST THE VIRUS CAUSING COVID-19 WILL BE SUCCESSFUL.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Intracranial Pressure Monitoring Market 2020-2025: Opportunities, Trends and Players - ResearchAndMarkets.com. The \"Intracranial Pressure Monitoring Market - Growth, Trends, and Forecasts (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Quantzig Launches Advanced Clinical Data Analytics Solutions To Help Healthcare, Pharma, and Lifesciences Companies Lead Their Way Out of the Pandemic with Data-Driven Insights. Quantzig, a premier analytics solutions provider, launched a comprehensive portfolio of clinical data analytics solutions as part of the company\u2019s commitment to transform the way pharma, biopharma, and life sciences companies access market and business intelligence services for their strategic needs. Request a FREE proposal to learn more about our ability to solve complex business problems, present analysis findings and communication of status, issues, and market risks.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights on the Worldwide Phenylketonuria Industry to 2024 - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com. The \"Global Phenylketonuria Market and Competitive Landscape - 2020\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Infectious Disease Diagnostics Industry Worth $26 Billion by FY2027 - Impact of COVID-19, Supply Chain Analysis, Market Shares of Major Players - ResearchAndMarkets.com. The \"Infectious Disease Diagnostics Global Market - Forecast to 2027\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Pipeline Review on Heart Transplant Rejection - H1 2020 - ResearchAndMarkets.com. The \"Heart Transplant Rejection - Pipeline Review, H1 2020\" drug pipelines has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sleep Number Announces New Sleep Innovations, Deepens Ongoing Commitment to Research Linking Sleep to Health. Analysis of nearly 1 billion sleep sessions from 360\u00ae smart beds fuels latest innovations and research. Today Sleep Number Corporation (Nasdaq: SNBR) announced its latest product innovations and the next steps in its ongoing commitment to demonstrate the direct link between quality sleep and health. The company\u2019s award-winning 360 \u00ae smart beds - which have been proven to deliver up to 100 hours more restful sleep per year \u2013 are at the heart of Sleep Number\u2019s efforts to meaningfully advance the science of sleep 1 . Enabled by its proprietary SleepIQ \u00ae technology, the operating system of the 360 smart bed, the company is benefitting from analyzing nearly 1 billion total sleep sessions of longitudinal sleep and biometric data points. The highly-accurate data is fueling new research insights and technologies that deliver on Sleep Number\u2019s mission of improving lives by individualizing sleep experiences, and thus improving health.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Kalion Inc. Receives NSF Phase II SBIR Grant to Develop Bio-based Glucaric Acid. MILTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Kalion Inc. (pronounced KAL-LEE-ON) has been awarded a National Science Foundation (NSF) Phase II Small Business Research (SBIR) grant for $746,822 to conduct research and development work improving the bio-based production of glucaric acid. Glucaric acid and its related compounds enhance sustainability as well as improve the chemical properties of products ranging from water treatment, polymers & textiles, coatings, detergents and pharmaceuticals.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Samaritan Marks 40th Anniversary Milestone with Top Patient Satisfaction Award, Expanded Services and Refreshed Brand. \u201cSamaritan,\u201d formerly Samaritan Healthcare & Hospice , has been rebranded, offering the not-for-profit organization an opportunity to better illuminate its proud legacy of service and communicate its expanded services.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CONMED Corporation Announces Quarterly Cash Dividend. CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2020 to all shareholders of record as of September 15, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Urovant Sciences Reports Fiscal First Quarter 2020 Results. Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Aptinyx Reports Second Quarter 2020 Financial Results and Highlights. Completed enrollment in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in 4Q 2020\n\n\nRecommencement of Phase 2 studies of NYX-2925 in chronic pain expected soon\n\n\nConference call today at 5:00 p.m. ET. Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the company\u2019s clinical-stage pipeline of novel NMDA receptor modulators.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"PFENEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pfenex Inc. - PFNX. Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Pfenex Inc. (NYSE: PFNX) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of Pfenex will receive $12.00 in cash, and a one-time contingent value right of $2.00 in the event a predefined regulatory milestone is achieved by December 31, 2021, for each share of Pfenex that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Gaurdie Banister Jr. elected to Dow Board of Directors. Dow (NYSE: DOW) today announced that Gaurdie Banister Jr. , former president and CEO of Aera Energy LLC, an oil and gas exploration and production company jointly owned by Shell Oil Company and ExxonMobil, has been elected to Dow\u2019s Board of Directors, effective immediately.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Dow declares quarterly dividend of 70 cents per share. Dow (NYSE: DOW) has declared a dividend of 70 cents per share, payable September 11, 2020, to shareholders of record on August 31, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results. Conference Call to be held Thursday, August 13, 2020 at 5:00 pm EDT. Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"CORRECTING and REPLACING FDA Approves Gadavist\u00ae (gadobutrol) Imaging Bulk Package. The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite. Please replace the release with the following corrected version due to multiple revisions.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights. Repare Therapeutics Inc. (\u201cRepare\u201d) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2020, as well as recent operational highlights.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"BioSpyder Files Action Against HTG Molecular Diagnostics in Federal Court. On Wednesday, August 12, 2020, BioSpyder Technologies, Inc. (\u201cBioSpyder\u201d) filed a civil action in the federal court for the Northern District of California, seeking a declaratory judgment that the BioSpyder TempO-Seq gene expression profiling assay does not infringe any valid claim in U.S. Patent No. 8,741,564 (\u201cthe \u2019564 patent\u201d) for Quantitative Nuclease Protection Assay (QNPA) and Sequencing (QNPS) Improvements.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"NMS Labs Appoints Dan Monahan as President and Chief Executive Officer. NMS Labs, one of the nation\u2019s leading forensic science and bioanalytical toxicology laboratories, announced today that Dan T. Monahan is the now President and Chief Executive Officer of the Company. Mr. Monahan will build upon NMS Labs\u2019 success and provide leadership in advancing the organization\u2019s strategic growth and expansion initiatives.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"NextGen Healthcare Commemorates 2020 National Health Center Week. Supplies Donated to 30 U.S. Community Health Centers Recognized for Patient Advocacy and Civic Action During COVID-19. NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced its recognition of National Health Center Week from August 9-15, honoring 30 participating community health centers (CHCs), federally qualified health centers (FQHC) and their clinical teams for providing affordable care to medically underserved communities. In support of National Health Center Week, NextGen Healthcare is providing meals and personal protective equipment (PPE) for CHC staff, as well as delivering COVID-19 \u2018care kits\u2019 at several CHCs that provide care to the homeless.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Phase 2/3 trial suggests that AMZELL's new topical treatment (AMZ001) for the treatment of knee osteoarthritis symptoms is effective. The phase 2/3 trial of AMZ001, a novel once daily topical diclofenac formulation, provides efficacy and safety results in the relief of pain associated with knee osteoarthritis (OA). HOOFDDORP, Netherlands , Aug. 14, 2020 /PRNewswire-PRWeb/ --\u00a0This phase 2/3 multi-center, randomized, double-blind trial investigated the effect of a new 3.06% diclofenac sodium gel formulation (AMZ001) for the relief of knee OA pain, in 444 patients exposed to either AMZ001 once daily (QD), AMZ001 twice daily (BID) or placebo. The trial also included an exploratory comparator treatment arm, Voltaren\u00ae Gel 1 % four times daily (QID).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"MJH Life Sciences\u2122 Hosts Expert-Driven \u201cDebating the Road Back to School\u201d Live Webinar. An expert panel discussion for clinicians on the most important factors surrounding a safe return-to-school plan, including testing, masking, social distancing, vaccine prioritization and more. To support pediatricians, pharmacists and primary care physicians as schools reopen during the pandemic, MJH Life Sciences\u2122 today announced it will host \u201c Debating the Road Back to School ,\u201d a free, live, one-hour webinar on Thursday, Aug. 20, at 6 p.m. EDT.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Company Profile for NMS Labs. NMS Labs is a leading bioanalytical toxicology and forensic sciences laboratory providing esoteric clinical and forensic services to physicians, attorneys, the criminal justice system, clinical reference labs, pharmaceutical companies, and consumer products manufacturers. As part of our services, NMS Labs\u2019 professionals interpret our laboratory testing results to resolve client-specific issues and provide expert witness testimony and consulting support for both civil and criminal judicial proceedings.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"COVID-19 Impacts: Biostimulants Market Will Accelerate at a CAGR of Over 12% Through 2020-2024 | Demand for Organic Food to Boost Growth | Technavio. Technavio has been monitoring the biostimulants market and it is poised to grow by $ 2 bn during 2020-2024, progressing at a CAGR of 12% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cardax Reports Q2 2020 Results. -  Operating loss decreased vs. Q2 2019. -  Net loss increased vs. Q2 2019. -  ZanthoSyn\u00ae revenues increased vs. Q2 2019. -  Cardax submits invited federal grant application for COVID-19 clinical trial. HONOLULU , Aug. 14, 2020 /PRNewswire/ --\u00a0Cardax, Inc. (OTCQB:CDXI) reported its Q2 2020 results. Highlights:",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Organigram Sends First Shipment of Indoor-Grown Dried Flower to Israeli Cannabis Producer, Canndoc Ltd. Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the \u201cCompany\u201d or \u201cOrganigram\u201d), a leading licensed producer of cannabis, today announced that it has sent its first shipment of bulk dried flower to Canndoc Ltd. (\u201cCanndoc\u201d), one of Israel\u2019s largest and most established medical cannabis producers, and a subsidiary of InterCure Ltd. (TASE: INCR). The shipment is part of Organigram\u2019s multi-year deal with Canndoc and is estimated to be worth approximately $2.4M CDN.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Premier Medical Laboratory Services Named Among Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook. Premier Medical Laboratory Services (PMLS) announces today that they have been named one of the Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook, a leading national healthcare publication. The designation, earned by the Greenville, SC laboratory, comes with recognition for their providing the most advanced diagnostic testing solutions with accuracy and efficiency through employing the latest in science and technology.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"USA TODAY Names \u201c100 Women of the Century\u201d to Commemorate the 100th Anniversary of the 19th Amendment. USA TODAY spotlights 100 notable women as \u201cWomen of the Century,\u201d as part of effort to commemorate the 100th anniversary the 19th Amendment. In addition, more than 260 Gannett properties combine forces to recognize 500+ women with outstanding achievements in fields including arts, literature, civil rights, sports, science and education. USA TODAY, part of Gannett Co., Inc. (NYSE: GCI), names \u201c100 Women of the Century\u201d as part of its ongoing \u201cWomen of the Century\u201d project to recognize the accomplishments of American women in commemoration of the 100th anniversary of the 19th Amendment. USA TODAY selected 100 influential women for its national list, and USA TODAY NETWORK properties across the country recognized more than 500 notable women across every state, the District of Columbia and the inhabited U.S. territories.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamide. Aims to accelerate development and commercialization of dry powder forms of niclosamide as a new potential treatment for COVID-19\n\n\nAgreement provides for UNION therapeutics\u2019 potential payment of development, regulatory and sales-related milestone payments of up to $210 million as well as tiered royalties. TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has entered into a worldwide exclusive licensing agreement with UNION therapeutics A/S (UNION) for its TFF technology used in combination with niclosamide.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Healthline Media Acquires PsychCentral, Bolstering Healthline\u2019s Role as the Top Digital Health Publisher. Healthline Media today announced it has acquired the popular website PsychCentral, adding a mental health property to Healthline\u2019s roster of powerful digital brands that help people live their strongest and healthiest lives. Since its founding in 1995, PsychCentral has become one of the largest and most trusted sites about psychology and mental health issues.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Novanta to Present at the Baird Global Healthcare Conference on Wednesday, September 9, 2020. Novanta Inc. (Nasdaq: NOVT) (the \"Company\"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird Global Healthcare Conference on Wednesday, September 9, 2020, which is being held virtually.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Global Body Temperature Monitoring Device Market (2019 to 2025) - by Type and Application - ResearchAndMarkets.com. The \"Body Temperature Monitoring Device Market 2019-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Russia Registers First COVID-19 Vaccine - ResearchAndMarkets.com. ResearchAndMarkets.com published a new article on the COVID-19 vaccine industry \"Russia Registers First COVID-19 Vaccine\"",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Lupin Presents Phase 3 Data for Solosec\u00ae (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis. -  Results presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting. -  Single-dose treatment with Solosec\u00ae resulted in a highly statistically significant response rate, or microbiological cure, in 92-95% of patients versus 1.5-1.7% in placebo. -  Lupin plans to submit a supplemental New Drug Application for Solosec\u00ae to the FDA for the treatment of trichomoniasis later this year. BALTIMORE , Aug. 14, 2020 /PRNewswire/ -- Lupin Pharmaceuticals Inc. (Lupin) announced today results from its pivotal Phase 3 clinical trial to assess efficacy and safety of single-dose Solosec \u00ae (secnidazole) 2g oral granules in female patients with trichomoniasis, the most common non-viral, curable sexually transmitted infection (STI) in the U.S. The trial results showed a clinically and statistically significant response rate, or microbiological cure, in patients treated with Solosec \u00ae as compared to placebo (p<0.001). The data were presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Coast Diagnostics Growing to Meet Needs of COVID-19 Rapid Testing. While many concerned Gulf Coast residents wait for days to receive results from COVID-19 testing, a newly-expanded local lab is processing up to 4,000 rapid tests per day with results in 24-48 hours.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Spain Uses GoAigua COVID Sewer Surveillance Technology for Widespread Infection Monitoring. 20 cities across Spain monitor almost 10 million people daily to contain virus spread. 20 cities across Spain monitor almost 10 million people daily to contain virus spread. 20 cities across Spain monitor almost 10 million people daily to contain virus spread. Spain\u2019s largest cities are using GoAigua technology to test their population for COVID-19 spread. These cities have implemented a widespread surveillance system that is efficiently testing entire cities every day, at a neighborhood and building level, by detecting the virus in sewer systems.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sensorion to present at the Oppenheimer Life Sciences Company Call Series and Virtual World Orphan Drug Congress USA. Regulatory News:",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Global Dental Diagnostics & Surgical Equipment Market to 2026 - Impact of COVID-19 & Company Analysis - ResearchAndMarkets.com. The \"Global Dental Diagnostics & Surgical Equipment Market (By Segment and Region), Impact of COVID-19, Company Analysis - Forecast to 2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Hearing Aids Market (2019 to 2026) - North America Generates the Highest Revenue from Hearing Aids - ResearchAndMarkets.com. The \"Global Hearing Aids Market: Consumer Behavior Analysis by Countries, Buying Pattern Analysis, Demographics, Trends Analysis, Survey Findings and Results, Leading Companies and their Market Strategies\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update. AgeX Therapeutics, Inc. (\u201cAgeX\u201d; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Formsense, a Leading Smart Apparel Company, Is Part of a Task Force Led by the Spaulding Rehabilitation Hospital, to Study the Role of mHealth Technology in Mitigating the Effects of the COVID-19 Pandemic. Formsense, a leading smart apparel company, has taken on the unusual role as part of an expert task force working together with Mass General Brigham Health System and its Spaulding Rehabilitation Network to publish a study on the role of mHealth in the COVID-19 pandemic. The outcome of the task force is a published study entitled \u201cCan mHealth Technology Help Mitigate the Effects of the COVID-19 Pandemic? \u201d in the newest issue of IEEE Open Journal of Engineering in Medicine and Biology .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Smart Pulse Oximeters Market Insights and Forecasts 2020-2025 - ResearchAndMarkets.com. The \"Smart Pulse Oximeters Market - Growth, Trends, and Forecasts (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Hydrogen Peroxide for Disinfection/Sterilization - Impact of COVID-19 on the Global Industry 2020-2027 - ResearchAndMarkets.com. The \"Hydrogen Peroxide for Disinfection/Sterilization Market Forecast to 2027 - COVID-19 Impact and Global Analysis by End Use Industry\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Baxter Obtains U.S. FDA Emergency Use Authorization for Regiocit Replacement Solution Used in CRRT. Only authorized citrate-based replacement solution available in the U.S. for use in continuous renal replacement therapy (CRRT) during COVID-19 pandemic\n\n\nSupports need for regional citrate anticoagulation in patients at increased risk of bleeding during CRRT\n\n\nMarks Baxter\u2019s fourth FDA\u00a0Emergency Use Authorization during COVID-19 pandemic, reinforcing its commitment to addressing the needs of critically ill patients. Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Regiocit , the company\u2019s replacement solution that contains citrate for regional citrate anticoagulation of the extracorporeal circuit. Under the EUA, Regiocit is authorized to be used as a replacement solution only in adult patients being treated with continuous renal replacement therapy (CRRT) and for whom regional citrate anticoagulation is appropriate during the COVID-19 pandemic.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins, \u2018Can We Cure Cancer with Artificial Intelligence?\u2019. LOS ANGELES, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkWire \u2014 Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (\u201cAI\u201d) to personalized medicine and drug discovery, today announces that Mark Collins, Ph.D., chief innovation officer of its Helomics subsidiary, recently appeared on DojoLIVE! , a lively podcast and interview forum that brings together a broad roster of technology, business and thought leaders from a wide range of software companies and startups.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Outlook on the Cardiac Safety Services Global Market to 2026 - Featuring Bioclinica, BioTelemetry & Banook Group Among Others - ResearchAndMarkets.com. The \"Global Cardiac Safety Services Market 2020-2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global miRNA Sequencing and Assay Marketplace 2020-2025 - ResearchAndMarkets.com. The \"Global miRNA Sequencing and Assay Market - Growth, Trends and Forecasts (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Medical Holography Market (2020 to 2026) - by Product Type, Application and End-user - ResearchAndMarkets.com. The \"Medical Holography Market 2020-2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Association of Community Cancer Centers Releases Lung Cancer Care Quality Improvement Model. Online Tool Available for Cancer Programs. ROCKVILLE, Md. , Aug. 14, 2020 /PRNewswire/ -- The Association of Community Cancer Centers (ACCC) has just released a model framework for cancer care providers to use in improving care coordination for lung cancer patients covered by Medicaid. \"Improving Care Coordination: A Model for Lung Cancer\" is a first-of-its-kind quality improvement tool, now available to cancer programs and practices nationwide.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Equillium Announces Pricing of Public Offering of Common Stock. LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock at a public offering price of\u00a0$7.00\u00a0per share. In addition, Equillium has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price less the underwriting discount.\u00a0Equillium anticipates its gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately\u00a0$35 million, excluding any exercise of the underwriters\u2019 option to purchase additional shares. The offering is expected to close on or about\u00a0August 18, 2020, subject to customary closing conditions.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Insights on the Global Single-use Negative Pressure Wound Therapy Devices Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio. Technavio has been monitoring the single-use negative pressure wound therapy devices market and it is poised to grow by USD 374.41 million during 2020-2024, progressing at a CAGR of almost 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights on the Global Fecal Occult Testing Market 2020-2024 |COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio. Technavio has been monitoring the fecal occult testing market and it is poised to grow by USD 75.15 million during 2020-2024, progressing at a CAGR of over 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Tetanus Toxoid Vaccine Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com. The \"Tetanus Toxoid Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Worldwide Diagnostic Imaging Equipment Industry to 2025 - Technological Advancements and the Increasing Number of Aged Populations are Driving Growth - ResearchAndMarkets.com. The \"Diagnostic Imaging Equipment Market 2019-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Masimo PVi\u00ae Receives FDA Clearance as an Indicator of Fluid Responsiveness on Mechanically Ventilated Patients. Masimo (NASDAQ: MASI) today announced that PVi \u00ae has received FDA clearance as a continuous, noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients. PVi, or pleth variability index, is a measure of the dynamic changes in perfusion index that occur during the respiratory cycle.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"World Thermal Scanners Market 2020-2027: Increasing Demand for Thermal Scanners for Elevated Body Temperature Detection Amid COVID-19 Pandemic - ResearchAndMarkets.com. The \"Thermal Scanners Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; Wavelength; End Use, and Geography\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights on the Global Gastrointestinal Diseases Therapeutics Market 2020-2024 |COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio. Technavio has been monitoring the gastrointestinal diseases therapeutics market and it is poised to grow by USD 22.82 billion during 2020-2024, progressing at a CAGR of almost 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"ProtoKinetix AAGP\u00ae Moves to Whole Organ Transplantation Testing. ProtoKinetix, Incorporated ( www.protokinetix.com ) (the \"Company\" or \"ProtoKinetix\") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that due to the results that AAGP\u00ae has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Stepper Motor Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com. The \"Stepper Motor Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; Technology\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"McKesson to Distribute Future COVID-19 Vaccines in Support of Operation Warp Speed. The Centers for Disease Control is Exercising an Option of an Existing Contract with McKesson for This Effort. A global leader in the healthcare industry, McKesson Corporation (NYSE: MCK) will expand its existing partnership with the Centers for Disease Control (CDC) to support the U.S. government\u2019s Operation Warp Speed (OWS) team as a centralized distributor of future COVID-19 vaccines and ancillary supplies needed to administer vaccinations. Vaccines and related supplies will be delivered to point-of-care sites across the country at the U.S. government\u2019s direction.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Solvent Evaporation Market 2020-2025: Shares of Nitrogen Blowdown, Rotary, Centrifugal, and Spiral Air Flow Evaporators - ResearchAndMarkets.com. The \"Solvent Evaporation Market - Growth, Trends and Forecast (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Outlook on the Brain Implants Global Market to 2025 - Increased Incidences of Neurological Disorders is Driving Growth - ResearchAndMarkets.com. The \"Brain Implants Market 2019-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer\u2019s Disease Has Reached Enrollment Milestone of 500 Patients. - Open label extension is currently active for GAIN Trial completers in the United States with robust conversion of eligible patients\n\n\n- Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020. Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer\u2019s disease (AD) has reached 500 patients toward the study\u2019s previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme\u2019s lead investigational medicine, in patients with mild to moderate AD. The GAIN Trial\u2019s protocol includes an interim analysis on the study\u2019s co-primary cognitive and functional endpoints after approximately 300 patients reach 24 weeks of treatment; this interim analysis is expected to occur before year-end 2020. Top-line results of the GAIN Trial\u2019s final analysis, to be performed once all study subjects complete the one-year study, are expected in Q4 2021.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Fuse Medical, Inc. Ranked Among Top 150 Public Companies in Dallas-Fort Worth Metroplex. Fuse Medical, Inc., (OTCPINK: FZMD), (\u201cFuse\u201d or the \u201cCompany\u201d) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced that it has been ranked number 136 on the 2020 list of Dallas-Fort Worth\u2019s 150 largest public companies, by the Dallas Morning News.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Worldwide Endpoint Security Industry to 2027 - Impact of COVID-19 - ResearchAndMarkets.com. The \"Endpoint Security - Global Market Outlook (2019-2027)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Two PPD Senior Leaders Recognized for Life Sciences Industry Leadership. Named to PharmaVOICE 100 list of most inspiring leaders. PPD, Inc. (Nasdaq: PPD ) today announced that two PPD senior leaders have been named to the 2020 PharmaVOICE 100 list of the most inspiring people in the life sciences industry: Karen Kaucic, M.D ., chief medical officer of PPD and president of Evidera , and Rhonda Henry , vice president of patient-centered trials.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sonoma Pharmaceuticals Reports First Quarter 2021 Financial Results. Highest Quarterly Revenues in Company History\n\n\nRevenues of $7.3 Million Grow by 65% Compared to Same Period Last Year Fueled by International Growth\n\n\nReduction in Operating Expenses of $1.3 Million Compared to Last Year\n\n\nNet Quarterly Income of $1.0 million. Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced financial results for its first fiscal quarter ended June 30, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update. JERUSALEM , Aug. 13, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M\u2013001 universal influenza vaccine candidate, today announced that the Annual General Meeting of Shareholders of the Company will be held on September 2, 2020 in Tel Aviv, Israel . Details, including a link to the Proxy Statement and voting card, are available on the SEC website at https://www.sec.gov/Archives/edgar/data/1611747/000121390020020357/ea125062-6k_biondvaxpharma.htm . Shareholders are invited to contact their broker for voting procedures. Note that votes must be received prior to the deadline noted on the proxy.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Canadian Biotech JN Nova Pharma Inc. Partners with the Government of Canada to Develop Therapeutic Platform for COVID-19. JN Nova Pharma Inc. has entered into collaboration with the National Research Council of Canada\u2019s (NRC) Pandemic Response Challenge program to develop a therapeutic pipeline for severe pathologies observed in COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Viral Vectors & Plasmid DNA Market 2020 and Beyond - Surge in Demand due to Massive Volume of COVID-19 Cases on a Global Scale - ResearchAndMarkets.com. The \"Global Viral Vectors & Plasmid DNA Market 2020-2030: COVID-19 Implications and Growth\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"2020 Study on the Innovations in Live Cell Imaging, Portable Imaging and Screening Devices, and Digital Screening and Diagnostics Solutions - ResearchAndMarkets.com. The \"Innovations in Live Cell Imaging, Portable Imaging and Screening Devices, and Digital Screening and Diagnostics Solutions\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Combating Skin Cancer on the Front Lines: DermaSensor Inc. Unveils Its Decade Of Clinical Research on Elastic Scattering Spectroscopy and Skin Cancer. MIAMI , Aug. 14, 2020 /PRNewswire/ --\u00a0DermaSensor Inc., a health technology company designing tools to\u00a0better equip primary care providers (PCPs) to detect skin cancer, is unveiling its decade of clinical work ahead of its commercial pilot later this summer. The company has nearly completed its fourth IRB-approved clinical study and four other clinical studies are in progress.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Laser Therapy Market Forecasts to 2027 with COVID-19 Impact Analysis by Type, Application, End-user and Geography - ResearchAndMarkets.com. The \"Laser Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; Application; End User, and Geography\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cardiovascular and Soft Tissue Repair Patches Market 2020-2025: Analyzed by Raw Material, Application and Geography - ResearchAndMarkets.com. The \"Cardiovascular and Soft Tissue Repair Patches Market - Growth, Trends, and Forecasts (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Metagenomics Industry Outlook and Forecast 2020-2025 - ResearchAndMarkets.com. The \"Metagenomics Market - Growth, Trends, and Forecasts (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Healthcare Contract Research Organizations (CRO) Services Market 2020-2027 - Rising Biosimilars and Biologics Market Presents a Lucrative Growth Opportunity - ResearchAndMarkets.com. The \"Healthcare Contract Research Organizations Services Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Service Type; Therapeutic Indication; End User; and Geography\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Izabela Podgorski, Ph.D., researcher at Karmanos Cancer Institute receives RO1 grant to continue research on metastatic prostate cancer. DETROIT , Aug. 14, 2020 /PRNewswire/ -- Izabela Podgorski , Ph.D., co-leader of the Prostate Cancer Research Team at the Barbara Ann Karmanos Cancer Institute and associate professor of Pharmacology at Wayne State University (WSU) School of Medicine has recently obtained a new five-year, $2,028,733 million RO1 grant from the National Institutes of Health/National Cancer Institute to continue her studies into the ways that prostate cancer cells are affected by bone marrow fat and how they adapt and survive in bone in an effort to identify new ways of treating metastatic prostate cancer. The grant number is CA251394-01. Dr. Podgorski was the first researcher to suggest a link between bone marrow fat cells (adipocytes) and metastatic prostate cancer in 2010.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"ADDING MULTIMEDIA\u00a0FDA Approves Genentech\u2019s Enspryng for Neuromyelitis Optica Spectrum Disorder. \u2013 First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks \u2013\n\n\n\u2013 First and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology \u2013\n\n\n\u2013 Approval supported by one of the largest clinical trial programs undertaken for this rare disease \u2013. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng \u2122 (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, lifelong and debilitating autoimmune disorder of the central nervous system, often misdiagnosed as multiple sclerosis, that primarily damages the optic nerve(s) and spinal cord, causing blindness, muscle weakness and paralysis.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"FDA Approves Genentech\u2019s Enspryng for Neuromyelitis Optica Spectrum Disorder. \u2013 First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks \u2013\n\n\n\u2013 First and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology \u2013\n\n\n\u2013 Approval supported by one of the largest clinical trial programs undertaken for this rare disease \u2013. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng \u2122 (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, lifelong and debilitating autoimmune disorder of the central nervous system, often misdiagnosed as multiple sclerosis, that primarily damages the optic nerve(s) and spinal cord, causing blindness, muscle weakness and paralysis.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China. SHANGHAI and GAITHERSBERG, Md., Aug. 17, 2020 /PRNewswire/ -- I-Mab (the \"Company\") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed with plonmarlimab (also known as TJM2) in a Phase 1b study (CXSL1900100; NCT04457856) to evaluate its use in treating patients with rheumatoid arthritis (RA) in China .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia. DUBLIN , Aug. 17, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, American Journal of Psychiatry . ENLIGHTEN-2 was a six-month study evaluating the weight gain profile of ALKS 3831 compared to olanzapine in 561 patients with stable schizophrenia. Positive topline data from the ENLIGHTEN-2 study were first reported in November 2018 .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Results of Axcella\u2019s AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology. Data support AXA1665\u2019s potential to address hyperammonemia, amino acid dysregulation and physical dysfunction in subjects with cirrhosis. Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the publication of results from the company\u2019s AXA1665-001 clinical study in Clinical and Translational Gastroenterology entitled \u201cSafety, tolerability, and physiological effects of AXA1665, a novel composition of amino acids, in subjects with Child\u2013Pugh A and B cirrhosis.\u201d The AXA1665-001 study, which was completed in late 2018, investigated AXA1665\u2019s effect on safety, tolerability, and biomarkers related to hepatic and muscle metabolism and function. Axcella also recently reported positive top-line data from its second clinical study of AXA1665, AXA1665-002.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology\u2019s TRITON2 Clinical Trial Evaluating Rubraca\u00ae (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations. Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca \u00ae (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations were published online in the Journal of Clinical Oncology . These results supported the May 2020 U.S. Food and Drug Administration (FDA) accelerated approval of Rubraca for the treatment of mCRPC patients who have a deleterious BRCA mutation (germline and/or somatic) and who have previously received androgen receptor-directed therapy and taxane-based chemotherapy.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research. The Edogawa NICHE Prize for the year 2020 has been awarded to Dr. John Craig Venter for his contribution to research and development pertaining to the Human genome. This honor reflects Dr. Venter's lifetime accomplishments in the power of the genomics and specifically in the identification of the human genome which has radically transformed healthcare according to Prof. Gary Levy, chair, Edogawa NICHE awards committee ( www.edogawanicheprize.org ).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Seneca Therapeutics Announces Appointment of James M. Hussey as Chief Executive Officer and a Director. Hussey is a Veteran CEO with more than 30 years in the biotech/pharmaceutical industry. Seneca Therapeutics, Inc. (\u201cSeneca Therapeutics\u201d) announced today the appointment of James M. Hussey as Chief Executive Officer and member of the Board of Directors. Jim has been a CEO or President for nearly 20 years and a C-Suite member at several successful biotech/pharmaceutical companies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"LabShares Newton Announces Next Launch@LabShares Winner. Concerto Biosciences to Receive Free Lab Space worth $50,000. LabShares Newton , a shared office and laboratory incubator for emerging biotechnology and life science companies, announced today that Concerto Biosciences is a winner of the Launch@Labshares grant of 1 year of free lab and office space which is valued at $50,000.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"PerkinElmer Launches Modular and Scalable explorer\u2122 Workstations for High-throughput COVID-19 Detection. Enables Labs to Quickly Ramp up Testing Capacity and Generate Results Faster. PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a series of explorer\u2122 workstations for SARS-CoV-2 testing capable of preparing and running up to 10,000 COVID-19 tests per day. These modular and scalable workstations enable laboratories to ramp up SARS-CoV-2 testing capacity quickly to generate results.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Gamida Cell to Provide Webcast of Its Annual Meeting of Stockholders. Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET (5:00 p.m. Israel time) at 12 Leshem Street, Kiryat Gat, 8258412, Israel. During the meeting, Julian Adams, Ph.D., Gamida Cell\u2019s chief executive officer, will present an overview of the company.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Medical Device Executive Nelson Whistance Joins Gynesonics As Vice President of U.S. Sales. Gynesonics, a women\u2019s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Nelson Whistance has been named Vice President of U.S. Sales. Mr. Whistance reports directly to the President and CEO, Christopher M. Owens.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Axial Biotherapeutics to Present at The JMP Securities CNS Forum. Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that management will participate in a fireside chat at The JMP Securities CNS Forum on Wednesday, August 19, 2020 at 2:00 PM ET.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model. VANCOUVER,\u00a0BC, Aug. 17, 2020 /PRNewswire/ --\u00a0Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral. In a series of experiments conducted by Dr. Stephen Barr , Associate Professor in the Department of Microbiology and Immunology at Western University , both BOLD-100 and remdesivir were tested head-to-head in a cytopathic effect assay against a live Wuhan strain of SARS-CoV-2 (COVID-19) in Vero E6 cells. Consistent with prior experiments, BOLD-100 showed low nanomolar IC 50 values, a magnitude lower (1/10 th ) than the IC 50 values of Gilead's remdesivir, the only currently approved therapeutic for COVID-19. This data clearly demonstrates that BOLD-100 is a highly potent antiviral agent.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"OneOncology and Foundation Medicine Unveil First-of-its-Kind Partnership to Advance Personalized Medicine at Community Oncology Practices. Groundbreaking Collaboration Advances Precision Oncology Informed by Comprehensive Genomic Profiling in Community Cancer Care, Where the Majority of Patients in the U.S. Are Treated. Foundation Medicine, Inc. and OneOncology today announced a new joint initiative that is intended to better enable OneOncology partner practice physicians to unlock the potential of precision oncology through comprehensive genomic profiling (CGP) and research, informed by CGP and real world evidence. This unique partnership will empower physicians across OneOncology's nearly 170 community oncology care sites to better drive personalized treatment plans, inclusive of targeted therapies, immunotherapies and clinical trials.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Flu Shots Now Available at All Walgreens Pharmacies. Walgreens taking proactive measures in preparation for flu season to meet customer demand and ensure the health and safety of communities during COVID-19 pandemic. With the upcoming flu season expected to coincide with the ongoing COVID-19 pandemic, Walgreens is now offering flu shots daily at all of its nearly 9,100 1 pharmacies with additional safety measures in place. The Centers for Disease Control and Prevention (CDC) is urging everyone over 6 months of age to get a flu shot 2 to help protect themselves and their communities from vaccine-preventable illnesses.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer\u2019s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801. Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers \u2013 A Key Driver of Alzheimer\u2019s Disease \u2013 Show Positive Clinical Effects and Consistent Biomarker Results\n\n\nSelectivity for Amyloid Oligomers and Pharmacological Profiles Define Magnitude of Clinical Benefit & Risk and Ease of Administration. Alzheon, Inc. , a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer\u2019s disease (AD) and other neurodegenerative disorders, announced today the publication of a peer-reviewed research paper, \u201cAducanumab, Gantenerumab, BAN2401 and ALZ-801 \u2013 the First Wave of Amyloid-Targeting Drugs for Alzheimer\u2019s Disease with Potential for Near Term Approval,\u201d in Alzheimer\u2019s Research & Therapy journal, available through open access at: https://doi.org/10.1186/s13195-020-00663-w .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update. Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the second quarter 2020 and provided a business update.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Applied DNA Positions LinearDNA\u2122 Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing. - Patent Application Relates to Production of Adeno-Associated Virus (AAV) via Use of LinearDNA\u2122 Amplicons; AAV Viral Vectors Used in Gene and Redirected Cell Therapies; Current Production of AAV Relies Heavily on Use of Plasmid-derived DNA -. Applied DNA Sciences, Inc. (NASDAQ: APDN) (\u201cApplied DNA\u201d or the \"Company\"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it has filed a nonprovisional patent application with the United States Patent and Trademark Office (USPTO) entitled \u201cMethods and Systems of PCR-Based Recombinant Adeno-Associated Virus (AAV) Manufacture\u201d (the \u201cPatent\u201d). The Patent claims priority to a previously filed provisional patent application filed with the USPTO in August of 2019.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update. \u2014 GAIN Trial enrollment on track to complete in Q4 2020\n\n\n\u2014 GAIN Trial interim analysis on schedule to complete by year end 2020\n\n\n\u2014 Clinical pipeline expansion anticipated in 2021. Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer\u2019s and other degenerative diseases, today announced financial results for the second quarter 2020 and provided an update on its business.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Optime Care Highlights Patient-First Strategy to Maximize Therapeutic Opportunities for Personalized Medicines and Contain Costs of Rx for Orphan and Rare Disorders. Optime Care , a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, points to its role in taking a patient-first approach for providing personalized medicine as a more precise basis to predict the prognosis of genetic diseases. This model recognizes the important, growing role of personalized medicine , an evolving field in which physicians use diagnostic tests to identify specific, often genetic, biological markers, to help determine which medical treatments and procedures will work best for each patient. Listen to the \u201cRare Voices\u201d podcast series here .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Spinal Non-Fusion Industry Analysis and Forecast 2015-2030 - COVID-19 Impact Assessment - ResearchAndMarkets.com. The \"Spinal Non-Fusion (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors. Dr. Menzel brings significant leadership in the global healthcare sector. Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Garry E. Menzel, Ph.D., to both its Board of Directors and Compensation Committee.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Nemaura Medical Reports Results and Provides Business Update for the First Quarter Ended June 30, 2020. Nemaura Medical Inc. (NASDAQ: NMRD) (\u201cNemaura\u201d) , a medical technology company commercializing sugarBEAT\u00ae, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT\u2122diabetes, a health subscription service designed to help people with diabetes and pre-diabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and on August 14, 2020 released financial results for the quarter ended June 30, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Endospan Receives FDA IDE Approval to Initiate a Pivotal Study of the NEXUS\u2122 Aortic Arch Stent Graft System. Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease received approval from FDA of an investigational device exemption, or IDE, to start the TRIOMPHE study on the NEXUS\u2122 Aortic Arch Stent Graft System (hereinafter referred to as NEXUS TM ). Earlier this year, FDA granted NEXUS TM designation as a breakthrough device. This designation acknowledges the NEXUS TM may provide a more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Hengrui Therapeutics, Inc. Companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients who may benefit from pyrotinib. CARLSBAD, Calif. , Aug. 17, 2020 /PRNewswire/ --\u00a0Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Hengrui Therapeutics, Inc. (HTI), a U.S. subsidiary of Chinese pharmaceutical company Jiangsu Hengrui Medicine Co., Ltd. (JHM), to develop a CDx that will leverage the Oncomine Precision Assay , which runs on the new Ion Torrent Genexus System . Once commercialized, the CDx will be used to identify non-small cell lung cancer (NSCLC) patients who may be eligible for pyrotinib, JHM's novel, irreversible pan- HER2 tyrosine kinase inhibitor.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity. BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"SwaddleDesigns Face Mask Has Been PROVEN to be One of the Most Effective on the Market. Recent lab test proves SwaddleDesigns 3-layer cloth masks are extremely effective. Given face masks are worn to reduce the risk of spreading COVID-19 and other pathogens, it is important to select a mask based upon data. SwaddleDesigns 3-layer cotton mask has been proven to be one of the most effective face masks on the market. Designed by Lynette Damir, RN, SwaddleDesigns masks are fitted to minimize leakage around the nose, on the side of the face, and under the chin. Using the most-current research, SwaddleDesigns masks yield superior filtration of aerosolized droplets by using three layers of tightly woven 180 thread count cotton fabric. SwaddleDesigns masks are breathable and comfortable and can be worn for long periods of time without discomfort.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease. Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies\u2019 previously announced $2 billion strategic financing collaboration to accelerate the advancement of RNAi therapeutics.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"XS Financial Streamlines Costs and Remains Well Capitalized to Continue to Grow Its Leasing Portfolio. XS Financial Inc., (\u201cXS Financial\u201d, \"XSF\" or the \"Company\") (CSE: XSF) (OTCQB: XSHLF) a specialty finance company engaged in equipment leasing to owner operators of cannabis and hemp companies in the United States, is pleased to provide a corporate update highlighting some recent cost optimizations which will serve to improve bottom-line performance and profitability. With the current portfolio of revenue-generating leases and the Company\u2019s ongoing access to capital through Archytas Ventures LLC (\u201c Archytas \u201d) and KushCo Holdings Inc. (\u201c KushCo \u201d) stock, XS remains well capitalized to continue to grow its leasing portfolio.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"The Orthopedic Braces & Supports Industry 2020-2025: Market Dynamics, Reimbursement & Regulatory Scenario, and COVID-19's Impact on the Industry - ResearchAndMarkets.com. The \"Orthopedic Braces & Supports Market by Product (Knee, Ankle, Hip, Spine, Shoulder, Neck, Elbow, Hand, Wrist), Category (Soft, Hard, Hinged), Application (Ligament (ACL, LCL), Preventive, OA), Distribution (Hospital) & Region - Global Forecast to 2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Peninsula Regional Medical Center Extends Partnership With Omnicell to Enhance Safety and Efficiency in Sterile Compounding. Combination of technology, services, and data supports more cost-effective workflows. Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Maryland-based Peninsula Regional Medical Center has chosen the Company\u2019s industry-leading medication management platform to support their in-house sterile compounding operations.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19. Company leverages its unprecedented antibody drug discovery and development engine empowered by proprietary single-cell profiling technology to identify, engineer, and evaluate multiple neutralizing antibodies against SARS-CoV-2. HiFiBiO Therapeutics , a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, today announced a collaboration with the Coronavirus Immunotherapy Consortium (CoVIC), a global, academic-industry, non-profit research alliance headquartered at the La Jolla Institute for Immunology (LJI). CoVIC was established to accelerate discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2. It has received support from the COVID-19 Therapeutics Accelerator, which was launched in March 2020 by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard with additional funding from a range of donors.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"ClinTex's Ongoing CTi Presale Gives Unparalleled Access to the $350bn Medical Trials Market. LONDON , Aug. 17, 2020 /PRNewswire/ -- ClinTex announce details of their CTi Token Presale , which will give participants access to the $350bn /year Clinical trials market with a 50% price discount until 25th September 2020 .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients. - MAU868 has the potential to be the first therapeutic to prevent and treat BKV-associated diseases in transplant patients. SAN DIEGO , Aug. 17, 2020 /PRNewswire/ -- Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that the first patient has been dosed in its Phase 2 clinical trial evaluating the efficacy and safety of MAU868 for the treatment of BK viremia in kidney transplant recipients. MAU868 is a novel, human monoclonal antibody that potently neutralizes all four major genotypes of BK virus (BKV). BKV-associated nephropathy is a leading cause of kidney allograft loss.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Sequencing Reagents Market: Growth, Trends & Forecast 2020-2025 - ResearchAndMarkets.com. The \"Sequencing Reagents Market: Growth, Trends & Forecast 2020-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"New Martinsville Spero Health Clinic Brings Addiction Treatment Services with Telehealth Visits. Spero Health, a CARF-accredited organization specializing in local, affordable, outpatient care for individuals suffering from substance use disorder, just announced it is opening a new clinic in Martinsville, VA located at 314 Fairy Street. This new clinic joins a network of more than 40 Spero Health locations throughout Kentucky, Ohio, Tennessee, Indiana, and Virginia providing care for more than 7,500 patients each month. Spero Health accepts Virginia Medicaid and most commercial insurance plans. The Martinsville clinic will open its doors on August 19 th and will offer a combination of in-person and telehealth visit options. Individuals who need addiction treatment services are encouraged to walk in for help or can call: 276-201-1647 for more information or to schedule an appointment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso\u00ae For Pulmonary Hypertension Associated With Interstitial Lung Disease. SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 17, 2020 /PRNewswire/ --\u00a0United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso \u00ae (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency's review to be complete in April 2021.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Lumbar Disc Replacement Devices Market to surpass US$ 2,044.8 million by 2027, Says Coherent Market Insights (CMI). According to Coherent Market Insights, the global lumbar disc replacement devices market is estimated to be valued at US$ 740.3 million in 2020 and is expected to exhibit a CAGR of 13.5% during the forecast period (2020-2027).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa. GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax\u2019 COVID-19 vaccine candidate. Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will lead the clinical trial, which is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation. NVX\u2011CoV2373 is a stable, prefusion protein made using Novavax\u2019 proprietary nanoparticle technology and includes Novavax\u2019 proprietary Matrix\u2011M\u2122 adjuvant.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"BioAgilytix Labs Launches COVIDence\u2122 Program for COVID-19 Workforce Testing with Support from BRIO Systems. End-to-End Service Handles All Aspects of Sample Collection Logistics, Testing, and Results Reporting for Employers & Guides Effective COVID-19-Related Risk Mitigation Strategies. End-to-End Service Handles All Aspects of Sample Collection Logistics, Testing, and Results Reporting for Employers & Guides Effective COVID-19-Related Risk Mitigation Strategies. End-to-End Service Handles All Aspects of Sample Collection Logistics, Testing, and Results Reporting for Employers & Guides Effective COVID-19-Related Risk Mitigation Strategies. BioAgilytix Labs, a premier global bioanalytical laboratory with a specialized diagnostic testing division, has announced the launch of COVIDence \u2122, a complete COVID-19 workforce testing service supporting employers across the U.S. in their efforts to mitigate COVID-19 exposure and spread within their workforces. The company has engaged BRIO Systems , an innovative technology company with a robust platform built to broaden access to COVID-19 testing, to provide the technology and logistics infrastructure that powers the COVIDence testing program. Together, they offer employers a one-stop solution to rapidly deploy and easily manage employee testing, backed by reliable testing and results that can be used to effectively guide COVID-19-related risk mitigation strategies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002. ETD002 is a novel TMEM16A chloride channel potentiator\n\n\n\n\nTherapy applicable to all cystic fibrosis patients, independent of genotype. Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD002. The first-in-man safety study is being conducted in healthy participants with ETD002, a TMEM16A potentiator aimed at treating all people with cystic fibrosis (CF).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Wafer Cleaning Equipment Market with COVID-19 Impact Analysis 2020-2025 - ResearchAndMarkets.com. The \"Wafer Cleaning Equipment Market with COVID-19 Impact Analysis by Equipment Type (Single-Wafer Spray System, Batch Spray Cleaning System, and Scrubbers), Application, Technology, Operation Mode, Wafer Size, and Geography - Global Forecast to 2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"AngioDynamics Announces First Patient Enrolled in PATHFINDER I Registry Examining Long-Term Effectiveness and Safety of Auryon Atherectomy System. AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the enrollment of the first patient in the PATHFINDER I: Post-Market Registry (PATHFINDER I-Registry, EX-PAD-05).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"In Times of Social Distance, DCI Edge and NSK Come Closer Together to Launch a New Integration Solution. The New Integrated Electric Motor System will allow dental practices to expand the possibilities of dental treatment. With over 120 combined years serving dentistry, DCI Edge, the fastest growing dental equipment and dental furniture manufacturer, and NSK, the #1 selling electric handpiece manufacturer in the US, introduce a seamlessly integrated electric motor system to be built into all DCI Edge delivery systems. The co-engineered system fully integrates the NLZ E Electric Motor and its licensed differentiators, including WaveOne \u00ae technology.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Oita Chuo Pacific Management Comments on Sanofi as They Agree to Acquire U.S. Biotech Firm Principia Biopharma. Financial executives at wealth management advisory Oita Chuo Pacific Management have commented on Sanofi S.A. agreeing to acquire U.S. biotech firm Principia Biopharma Inc. in a deal worth $3.4 billion, as the French drug manufacturer shifts towards innovative treatments to boost growth under latest Chief Executive Officer Paul Hudson.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Neuroptika Completes Enrollment In Phase 2 Clinical Trial For Dry Eye Disease. CAMBRIDGE, Mass. , Aug. 17, 2020 /PRNewswire/ -- Neuroptika, a privately held biotechnology company focused on the development of novel regenerative treatments for ophthalmic diseases, today announced completion of enrollment in a Phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease.\u00a0NRO-1 is a novel therapeutic with the potential to regenerate corneal nerves in ophthalmic diseases.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Patient Monitoring Devices Market to 2027 - by Devices, Portability, End-users & Region - ResearchAndMarkets.com. The \"Patient Monitoring Devices Global market - Forecast to 2027\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Phoropters Market Forecast 2020-2025 with Profiles of Major Players Briot USA, Huvitz, Marco, NIDEK, and Reichert Among Others - ResearchAndMarkets.com. The \"Phoropters Market - Growth, Trends, and Forecast (2020-2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Lygos Successfully Validates Novel Fermentation Process for Sustainable and Rare Cannabinoids. After rapid integration of NIH-funded Librede technology, company now focused on scaling to commercial quantities and launching new consumer products. Lygos, Inc. , a full-stack provider of sustainable specialty ingredients that deliver high-value performance without environmental toxicity, has announced the successful validation of a novel cannabinoid production pathway using its proprietary fermentation and processing technology. A direct result of the recent Librede acquisition and integration of additional Lygos technology advances, the new fermentation process enables the production of any cannabinoid and cannabinoid-based product of interest in an environmentally safe, sustainable and cost-effective manner at industrial scale (>100 kg) for numerous consumer markets.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"BTG Specialty Pharmaceuticals announces the European Medicines Agency has accepted for review a marketing authorisation application for Voraxaze\u00ae. LONDON , Aug. 17,\u00a02020 /PRNewswire/ --\u00a0BTG Specialty Pharmaceuticals, a division of Boston Scientific (NYSE:BSX), today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorisation Application (MAA) for Voraxaze \u00ae (glucarpidase). BTG Specialty Pharmaceuticals is seeking marketing authorization of Voraxaze \u00ae for the treatment of adults and children (from 28 days of age) at risk of methotrexate toxicity due to delayed methotrexate elimination.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Dr. Anthony Fauci Joins Healthline Live Town Hall on Coronavirus. Nation\u2019s top epidemiologist joins other healthcare professionals to answer the public\u2019s questions about COVID-19. Healthline Media will hold a free online live town hall meeting featuring Director of the National Institute of Allergy and Infectious Diseases (NIAID) Dr. Anthony S. Fauci, M.D. and other renowned medical professionals to address concerns about COVID-19, debunk myths and examine conflicting information about how the virus is spread.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Medrio, Inc. Names Nicole Latimer as Chief Executive Officer. Nicole Latimer appointed to Chief Executive Officer of Medrio, Mike Novotny ends his tenure as CEO. SAN FRANCISCO , Aug. 17, 2020 /PRNewswire-PRWeb/ -- Medrio Inc., the leading provider of eClinical technology to pharmaceutical, biotech, medical device, diagnostics, and animal health markets, announced the appointment of Nicole Latimer to Chief Executive Officer. Nicole will be replacing Mike Novotny , former CEO and Founder of Medrio as he has chosen to take a sabbatical after leading Medrio's growth for 15 years. Mike will, however, remain on the Board of Directors.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Boundless Bio Announces Publication in Nature Genetics Detailing the Association Between Extrachromosomal DNA-Based Oncogene Amplification and Poor Cancer Outcomes. Boundless Bio researchers and scientific founders author a study describing the broad prevalence of extrachromosomal DNA (ecDNA) in tumors across multiple cancers and that patients with these tumors have significantly shorter survival outcomes\n\n\nStudy results represent the first clinical outcome data across a range of solid tumors possessing ecDNA-driven amplifications, further supporting the urgent need for ecDNA-directed therapies. Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced research published in the journal Nature Genetics that demonstrates that ecDNA-based oncogene amplification drives poor outcomes for patients across many cancer types.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Cala Health Announces Continued Growth and Momentum with Clinical, Product Development, and Management Milestones to Support Cala Trio Therapy for the Treatment of Essential Tremor. - New PROSPECT data, from the largest therapeutic essential tremor study to date, published in Tremor and Other Hyperkinetic Movements further underscores Cala Trio therapy as a safe and effective option for patients -\n\n\n- Industry veterans, Mr. Ali Samiian and Mr. Bobby Thomas, recently joined Cala Health management -. Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today announced that data from its landmark PRO spective study for S ym P tomatic relief of E ssential tremor with C ala T herapy (PROSPECT), was published in Tremor and Other Hyperkinetic Movements . This important study demonstrated that the company's FDA cleared, neuromodulation therapy, Cala Trio\u2122, repeatedly used at home over three months resulted in safe and effective hand tremor reduction and improved quality-of-life for adults with essential tremor (ET). Additionally, Cala Health added to its strong management team with the appointment of industry veterans Ali Samiian, Head of Market Access and Reimbursement, and Bobby Thomas, Vice President, Digital.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CytoDyn Will Attempt to Duplicate Berlin and London Patients\u2019 HIV Cure by Using Leronlimab During Bone Marrow Transplant for 5 HIV Patients Who also have Cancer. HIV monotherapy trials update: 215 patients completed almost one year of monotherapy. Only some were allowed to continue in extension arm; five patients reached almost 6 years. Twenty-five reached 2 to 4 years and 20 patients are 1 to 2 years",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody. HANGZHOU , China\u00a0and SHAOXING, China , Aug. 16, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Start of bridging pharmacokinetic and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator O304. Betagenon /Balticgruppen Bio AB announces the start of a bridging PK and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator compound O304. STOCKHOLM , Aug. 17, 2020 /PRNewswire/ -- In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O304 was administered as a suspension and with limited oral bioavailability. A novel formulation of O304 has now been developed that unexpectedly improved oral bioavailability markedly in animals. A patent application (matter of composition) with priority date to 2039 without extensions has been submitted.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse\u2122 Immunotherapy to Treat HPV-associated Cancers. - First-in-class investigational, off-the-shelf immunotherapy utilizing AdenoVerse\u2122 platform designed to activate the immune system to recognize and target HPV-positive solid tumors -. - HPV-associated cancers represent a significant global health burden -. GERMANTOWN, Md. , Aug. 17, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen's PRGN-2009, a first-in-class,\u00a0off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse \u2122 platform designed to activate the immune system to recognize and target HPV + solid tumors (clinical trial identifier: NCT04432597 ). HPV-associated\u00a0cancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"The Future of Fitness: Americans Embrace a Hybrid of Home Exercise and Gym Workouts. The Beachbody Company survey reveals 9 in 10 Americans who plan to return to the gym will continue at-home workouts. Even as gyms begin to welcome back guests, the at-home workout phenomenon appears here to stay according to a new survey just released from The Beachbody Company, the leading innovator in digital fitness, wellness and nutrition.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion. SHANGHAI , Aug. 17, 2020 /PRNewswire/ -- CARsgen Therapeutics, a leader in developing novel CAR-T cell therapies against solid tumors, today announced its publication of the 7\u00d721 CAR-T technology in CLINICAL CANCER RESEARCH. The article is titled \"Coexpression of IL-7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion.\"",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"China's First Trastuzumab Biosimilar Approved by NMPA. SHANGHAI , Aug. 17, 2020 /PRNewswire/ --\u00a0Shanghai Henlius Biotech, Inc. (2696.HK) announced on August 14 that the trastuzumab biosimilar HLX02 , developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). On 27 th July, HLX02 (EU brand name Zercepac \u00ae ) has also been approved by the European Commission (EC), making HLX02 the first China -developed mAb biosimilar to be approved both in China and in the EU. The common name of HLX02 is trastuzumab injection (150mg/vial, without preservative) and it is indicated for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer. Trastuzumab has been included in China's National Reimbursement Drug List (NRDL) in 2017. According to the \"Interim Measures for the Administration of Drugs in the NRDL\", drugs in the NRDL are managed by their common names, and drugs with common names that have been listed in the NRDL will automatically enter the NRDL.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Schr\u00f6dinger Announces Closing of Public Offering. Schr\u00f6dinger, Inc. (the \u201cCompany\u201d) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the closing of its underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $66.00 per share. The offering consisted of 5,250,000 shares sold by the Company, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, and 500,000 shares sold by a selling stockholder. The gross proceeds to the Company in the offering were $346.5 million. The Company did not receive any of the proceeds from the sale of the shares by the selling stockholder.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration. \u2013 Gilead to Make $125 Million Upfront Payment and $20 Million Equity Investment \u2013\n\n\n\u2013 Under Agreement, Gilead will Have Rights to Opt-in to up to 15 Targets for up to $410 Million per Program in Total Payments \u2013. Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics today announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immune evasion therapies for patients with cancer.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Deciphera Announces Publication of QINLOCK\u2122 (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology. - Results Consistent with Those Presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Support Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST -. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company\u2019s switch-control tyrosine kinase inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumor (GIST). The article, entitled \"Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor (GIST): a phase 1 study of ripretinib,\" is now available online and will be published in a future print issue of Journal of Clinical Oncology .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Executive War College Discusses Distress of Clinical Laboratory Industry as COVID-19 Pandemic Disrupts Supply Chain and Health Insurers Deny Payment for SARS-CoV-2 Tests. Remarkable things are happening as the nation\u2019s medical laboratories and anatomic pathology groups answer the challenges of the COVID-19 pandemic and the need for ever-greater numbers of SARS-CoV-2 tests. Despite acute shortages of essential test kits and supplies, many labs are adding COVID-19 test capacity.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Huami Corp Partners with Aspen Imaging Healthcare. Companies to Advance Product Development Connecting Health with Technology. Huami Corp. and Huami-USA (NYSE: HMI) and Aspen Imaging Healthcare today announced signing a letter of intent for joint future development.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"ISB Researchers Show Genetic Risk for Disease Often Reflected in Our Blood. Diseases develop gradually over years, sometimes decades, before symptoms appear, and are due to malfunctioning physiological processes brought about by our genes and environment. In just-published research, ISB researchers have shown how an individual's genetic risk for disease is often reflected in their blood. SEATTLE , Aug. 17, 2020 /PRNewswire-PRWeb/ --\u00a0Humans do not develop disease overnight. Rather, diseases develop gradually over years -- sometimes decades -- before symptoms appear, and are due to malfunctioning physiological processes brought about by our genes and environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Probo Medical Named to 2020 Inc. 5000 List of Fastest-Growing Private Companies. Probo Medical (\u201cProbo\u201d), a leading provider of medical imaging equipment, parts, repair and service, announced today it was ranked 649 by Inc . magazine as one of the nation\u2019s fastest growing private companies 2020. This is Probo\u2019s second consecutive appearance on the Inc . 5000 list.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord. Third FDA-Approved Therapy in Just Over a Year for Neuromyelitis Optica Spectrum Disorder Gives Patients Another Treatment Option. SILVER SPRING, Md. , Aug. 17, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody \u2013 patients who are anti-aquaporin-4 or AQP4 antibody-positive. NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord. Enspryng is the third approved treatment for the disorder.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"President Bill Clinton to Keynote Unite For Safe Care Virtual Event On September 17. Patient Safety Movement Foundation Hosts Global Virtual Event On World Patient Safety Day To Mandate Patient Safety Innovation During Pandemic. Patient Safety Movement Foundation Hosts Global Virtual Event On World Patient Safety Day To Mandate Patient Safety Innovation During Pandemic. Patient Safety Movement Foundation Hosts Global Virtual Event On World Patient Safety Day To Mandate Patient Safety Innovation During Pandemic. Today, the Patient Safety Movement Foundation announced that President Bill Clinton, the 42nd President of the United States, will be the closing keynote speaker at the Foundation\u2019s Unite For Safe Care Virtual Event. The event will be hosted online, available globally, September 17th at 5pm Eastern Daylight Time.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock. Seres Therapeutics, Inc. (Nasdaq: MCRB) (\u201cSeres\u201d), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today announced the closing of an underwritten public offering of 12,075,000 shares of its common stock, at a public offering price of $21.50 per share, before underwriting discounts and commissions, and including the exercise in full of the underwriters\u2019 option to purchase an additional 1,575,000 shares of common stock. The net proceeds from the offering, together with the net proceeds from a substantially concurrent registered direct offering of 959,002 shares of common stock to Soci\u00e9t\u00e9 des Produits Nestl\u00e9 S.A., after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $263.7 million. All of the shares in the offerings were sold by Seres.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Chronic Inflammatory Conditions. LG Chem Life Sciences (\u201cLG Chem\u201d), a division of LG Chem, and TransThera Biosciences Co. Ltd. (\u201cTransThera\u201d), a clinical-stage biotechnology company based in Nanjing, China, announced today that LG Chem has entered an exclusive license agreement with TransThera, for the development and commercialization of TransThera\u2019s TT-01025, a highly selective oral small molecule inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) that has shown promising efficacy in pre-clinical investigation in non-alcoholic steatohepatitis (NASH). TT-01025 is expected to enter Phase I trial in early 2021 in the US.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Tango Therapeutics Announces $50 Million Equity Financing. - Funding coincides with expanded oncology collaboration with Gilead Sciences \u2013. Tango Therapeutics , a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies, today announced the closing of $50 million in equity financing.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Baxter to Present at the 2020 Wells Fargo Virtual Healthcare Conference. Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 2020 Wells Fargo Virtual Healthcare Conference via webcast on Wednesday, September 9, 2020. Jay Saccaro, Baxter\u2019s chief financial officer, is scheduled to present at 10:00 a.m. Eastern Time.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"PerkinElmer to Present at Baird's 2020 Virtual Global Healthcare Conference. PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at Baird's 2020 Virtual Global Healthcare Conference on Thursday, September 10, 2020 at 8:30 a.m. ET.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology. - CONTROL Trial Investigates Anti-diarrheal Strategies Including Dose Escalation in Neratinib-treated Patients with Early Stage HER2-positive Breast Cancer\n\n\n- Dose Escalation Resulted in Reduced Rate, Severity and Duration of Grade \u22653 Diarrhea Compared to Phase III ExteNET Trial, Lower Diarrhea-related Discontinuations and Dose Reductions in Multiple CONTROL Cohorts. Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume 31, Issue 9) of Annals of Oncology . The publication entitled, \u201cImproved Tolerability of Neratinib in Patients with HER2+ Early-Stage Breast Cancer: Diarrheal Toxicity in the CONTROL Trial,\u201d can also be accessed online here .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol. TARRYTOWN, N.Y. , Aug. 19, 2020 /PRNewswire/",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"KBRA Releases Research \u2013 Coronavirus (COVID-19): CRE Secular Trends Upended by Pandemic Disruptions. Kroll Bond Rating Agency (KBRA) releases a report, which discusses how many of the secular trends that were shaping the future of commercial real estate (CRE) over the past several years were accelerating prior to COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others. . Regulatory News:",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Assistive Technology Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Increasing Orthopedic Disorders to Boost the Market Growth | Technavio. Technavio has been monitoring the assistive technology market and it is poised to grow by USD 8.39 billion during 2020-2024, progressing at a CAGR of almost 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET. Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it will conduct a conference call with investors to review financial results of its second quarter and provide an update on clinical and corporate developments, including its advanced stage drug candidates Piclidenoson and Namodenoson.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Coronavirus Test Kits Market in North America Analysis Highlights the Impact of COVID-19 (2020-2024) | Regional Outbreak of Coronavirus to Boost the Market Growth | Technavio. Technavio has been monitoring the coronavirus test kits market in North America and it is poised to grow by USD 116.27 million during 2020-2024, decelerating at a CAGR of about -31% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Pelvital Announces FDA Clearance of Flyte\u2122, In-Home Pelvic Floor Muscle Treatment for Stress Urinary Incontinence. Pelvital, a medical technology company focused on women\u2019s health, announced it has received U.S. Food and Drug Administration (FDA) clearance for Flyte \u2122 , a first-of-its-kind, non-invasive, intravaginal home-use device that is intended for strengthening of the pelvic floor muscles, which has been found to help women with stress urinary incontinence.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Good Neighbor Pharmacy Receives \u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d from J.D. Power. Pharmacy network takes top honor among chain drug stores for 4th year in a row. Today, Good Neighbor Pharmacy \u2013 a national independent pharmacy network offered through AmerisourceBergen \u2013 announced that it has been ranked \u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. Power 2020 U.S. Pharmacy Study SM , with a score of 915 out of 1,000. This marks the ninth time Good Neighbor Pharmacy has earned the achievement in the last eleven years.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Terns Pharmaceuticals to Present Data on Multiple NASH Programs at The Digital International Liver Congress\u2122 2020. -Single doses of TERN-201 were safe and well tolerated and demonstrated potent, selective, and sustained inhibition of SSAO in a Phase 1 clinical trial, with near complete inhibition of plasma SSAO activity observed-\n\n\n-TERN-501 demonstrated potent and selective THR-\u03b2 agonism, and significantly reduced liver steatosis, fibrosis, and serum markers of liver damage in NASH preclinical rodent models-. Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing best-in-class, single-agent and combination therapies to treat liver disease, announced today three poster presentations on two lead programs at The Digital International Liver Congress\u2122 2020, taking place August 27-29, 2020. The presentations include clinical and preclinical data for TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, and in vivo rodent model data for TERN-501, a preclinical thyroid hormone receptor beta (THR-\u03b2) agonist, both for the treatment of non-alcoholic steatohepatitis (NASH).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Virus Spread Correlates With Climate Change in U.S. According to Healthline Study. Study takes a fresh look at the relationship between infectious diseases and climate change, with a focus on the West Nile virus in the U.S. Rising temperatures brought on by climate change have contributed to a prevalence of cases of West Nile virus in the United States, according to a study released today. The study, West Nile virus in the U.S.: A case study on climate change and health , is published in Medical News Today, sister site of Healthline.com , the flagship digital health brand of Healthline Media. The study features two interactive maps with new data points from the Centers for Disease Control and Prevention (CDC) that show temperature fluctuations in the U.S. and the concurrent spread of West Nile virus from the years 1900 to 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Bayer Announces Resolution of U.S. Essure\u2122 Claims. Bayer announced today that it has reached agreements with plaintiff law firms to resolve approximately 90% of the nearly 39,000 total filed and unfiled U.S. Essure\u2122 claims involving women who allege device-related injuries. The settlements include all of the jurisdictions with significant volumes of Essure\u2122 cases, including the state of California Joint Council Coordinated Proceedings (JCCP) and Federal District Court for the Eastern District of Pennsylvania (EDPA). The company will pay approximately 1.6 billion U.S. dollars (1.35 billion euros) to resolve these claims, including an allowance for outstanding claims, and is in resolution discussions with counsel for the remaining plaintiffs.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Blue J Launches Free Tools to Help Determine COVID-19 Relief Eligibility. Innovative tools direct individuals and businesses to applicable relief resources. Blue J, the leading provider of AI-backed legal predictions, announced today the launch of its COVID-19 relief programs and credits guided analysis tools for the United States and Canada.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"ITEC Entertainment Announces Value-Add Reseller Agreement with BioAway LLC. BioAway to Include ITEC\u2019s Touchless Temperature Kiosks in Turnkey Solutions. ITEC Entertainment Corporation, an industry leader of worldwide entertainment solutions, today announced an agreement with BioAway LLC, a leading Florida-based provider of disinfection services. The value-add reseller agreement enables BioAway to offer the Touchless Temperature Kiosks developed by ITEC\u2019s Technologies Division in the company\u2019s turnkey disinfection remediation and safety solutions for commercial properties.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer\u2019s Disease. Study to Evaluate ALZ-801 as a Precision Medicine Approach to Early Alzheimer\u2019s Disease in Patients with APOE4/4 Genetic Profile\n\n\nGrant Supports Advancement of the First Oral Agent with Potential for Disease Modification in Alzheimer\u2019s Patients at High Risk of Disease Progression. Alzheon, Inc. , a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer\u2019s disease (AD) and other neurodegenerative disorders, announced today that the U.S. National Institute on Aging (NIA) of the National Institutes of Health has awarded the company a grant (NIA grant number R01AG065253) expected to total $47 million over 5 years to support a Phase 3 clinical study with ALZ-801 \u2013 an oral agent that blocks the formation of neurotoxic soluble amyloid oligomers. The study will enroll Early AD patients, who have two copies of the apolipoprotein \u03b54 allele (APOE4/4), as a cutting-edge precision medicine approach to Alzheimer\u2019s disease. AD patients with this genetic profile have been shown to have a higher risk of rapid disease progression and to be responsive to agents targeting pathogenic amyloid oligomers.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"TechnoVax and CUNY Med School Report COVID-19 Vaccine Breakthrough. TechnoVax, Inc , a biotechnology developer of novel vaccines and The CUNY School of Medicine at The City College of New York, announce a breakthrough in their collaborative effort to develop a vaccine for COVID-19. Scientists from the two organizations have generated and characterized SARS-CoV-2 virus-like particles (VLPs) which are structural mimics of the native virus in size, morphology and surface composition but devoid of viral, infection causing, genetic material. These features of the VLP platform make it an ideal candidate for COVID-19 vaccine development.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Condom Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Rising Demand for Female Condoms to Boost the Market Growth | Technavio. Technavio has been monitoring the condom market and it is poised to grow by USD 3.44 billion during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Quidel to Update Packaging of Point-of-Care Sofia\u00ae SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs. Quidel Corporation (NASDAQ: QDEL) (\u201cQuidel\u201d), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for Quidel\u2019s Emergency Use Authorization (EUA) for the Sofia\u00ae SARS Antigen FIA has been amended to include either nasal or nasopharyngeal swabs.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Low-Cost Nafamostat Blocks SARS-CoV-2 Infection in Human Lung Cells, Preclinical Study Finds. Covistat repurposing generic pancreatitis remedy for oral, inhaled COVID-19 treatments. SAN DIEGO , Aug. 20, 2020 /PRNewswire/ --\u00a0A preclinical study testing the low-cost generic drug nafamostat in human cells shows it can help block SARS-CoV-2 infection, raising excitement around Covistat's work to develop prophylactic and therapeutic COVID-19 treatments.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac\u00ae Abstracts Accepted for Oral and Poster Presentations at EASL 2020. The presentation details and schedules are as follows:",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners. Technology expansion provides AbCellera with the ability to combine any two antibodies generated through its discovery platform to create full IgG bispecifics\n\n\nComputational protein engineering expert Dr. Tim Jacobs joins AbCellera from Dualogics. AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). OrthoMab is a clinically validated platform that uses the most advanced computational and experimental protein engineering methods to create IgG-like bispecific antibodies from any two antibody sequences. By integrating OrthoMab into its existing technology stack, AbCellera provides the industry with a rapid and complete solution for generating tailored, stable and developable bispecific antibodies that meet the needs of the growing $140B biologics market.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Baxter to Present at the Virtual Morgan Stanley 18th Annual Global Healthcare Conference. Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the virtual Morgan Stanley 18 th Annual Global Healthcare Conference via webcast on Wednesday, September 16, 2020. Jay Saccaro, Baxter\u2019s chief financial officer, is scheduled to present at 12:30 p.m. Eastern Time.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Polaryx Therapeutics Receives FDA Fast Track Designation to PLX-200 for the Treatment of Patients With Juvenile Neuronal Ceroid Lipofuscinosis. PARAMUS, N.J. , Aug. 20, 2020 /PRNewswire/ --\u00a0Polaryx Therapeutics Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3) patients.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Europe Allogeneic Human Chondrocyte Market to Surpass US$ 3,440.5 Million by 2027, Says Coherent Market Insights (CMI). According to Coherent Market Insights, the Europe allogeneic human chondrocyte market is expected to be valued at US$ 3,440.5 million in 2027 and is expected to exhibit a CAGR of 10.2 % during the forecast period (2020-2027).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Hercules' AhR inhibitor HP163 blocks viral replication in Zika infection and potentially in Covid-19. Secured additional funding for Covid-19 testing and back-up drug discovery. LEIDEN, Netherlands , Aug. 20, 2020 /PRNewswire/ -- Hercules Pharmaceuticals , a Dutch biopharmaceutical company focusing on developing small molecule inhibitors of the Aryl Hydrocarbon Receptor (AhR) for treatment of cancer and viral infections, today announced the publication of promising preclinical in-vivo trial results, showing efficacy of its Aryl Hydrocarbon Receptor (AhR) inhibitor HP163 against Zika virus infection and potentially against Corona-virus infection. On top of this, the company secured new funding to test the efficacy of the compound against Covid-19 and to generate back-up AhR inhibitors.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Pulse Oximeters Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com. The \"Pulse Oximeters Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Seoul Viosys to Promote Innovative Violeds Technology Solution Proven to Sterilize New Coronaviruses for Air Conditioning and Heating Systems. Seoul Viosys (KOSDAQ:092190), a leading compound semiconductor solution provider, announced that it promotes new Violeds technology solution, the world\u2019s first ultraviolet LED technology proven to sterilize new coronaviruses, for air conditioning and heating systems.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Disposable Respirator Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Frequent Outbreaks of Epidemics to boost the Market Growth | Technavio. Technavio has been monitoring the disposable respirator market and it is poised to grow by USD 478.58 million during 2020-2024, progressing at a CAGR of over 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Half of U.S. Physicians Say Patient Disbelief in the Risk of COVID-19 Infection Likely to Impact Widespread Vaccine Adoption. New Physician Insights Reveal Building Patient Trust and Education Will Be Crucial for Successful Vaccine Rollout. A global survey of nearly 2,000 physicians across 31 countries conducted from August 8-11, reveals nearly half of physicians surveyed see significant barriers to COVID-19 vaccine adoption, both for themselves and for their adult patients.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"U.S. FDA grants rare pediatric disease designation to AmideBio's glucagon analog for the treatment of congenital hyperinsulinism. BOULDER, Colo. , Aug. 20, 2020 /PRNewswire/ --\u00a0AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Offices of Pediatric Therapeutics and Orphan Products Development granted a rare pediatric disease designation to AmideBio's glucagon analog (AB-G023) for the treatment of congenital hyperinsulinism (CHI). AB-G023 is a solution stable, soluble glucagon analog designed to overcome the limitations of glucagon \u2013 an effective treatment for CHI, but rendered impractical for long term administration given its instability in solution. The development of AB-G023 was funded through Small Business Innovation Research (SBIR) Phase I and II grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Division of the National Institutes of Health (NIH). It was granted Orphan Drug designation in April of this year.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine. Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance and evaluate vaccine candidates in Phase 1 clinical trials. APT is the only biotechnology company with a phage-based COVID-19 vaccine program projected to enter clinical trials in 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Flow Cytometry Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com. The \"Flow Cytometry Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights into New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market to 2025 - ResearchAndMarkets.com. The \"New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Gynesonics Announces Publication of OPEN Clinical Trial Results, Demonstrating No Intrauterine Adhesion Formation Following Treatment with the Sonata System. Clinical Study Demonstrates No Adhesion Formation at Second-Look Hysteroscopy Performed Six Weeks After Transcervical Fibroid Ablation with the Sonata System. Gynesonics, a women\u2019s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of the OPEN clinical trial results, demonstrating a lack of intrauterine adhesion formation after Transcervical Fibroid Ablation (TFA) with the Sonata\u00ae System. Adhesions are often seen with other treatment modalities. Studies involving apposing fibroids have reported a significant (up to 78 percent) risk of adhesiogenesis after hysteroscopic myomectomy. The OPEN trial included women with apposing fibroids, all of whom were free from intrauterine adhesions after TFA. The Sonata technology platform integrates the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Kubota Vision Receives Orphan Products Clinical Trials Grants to Emixustat for Stargardt Disease. Kubota Vision Inc. (\u201cKubota Vision\u201d), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded an orphan products clinical trial grant to support the ongoing phase 3 study of emixustat in Stargardt disease (Clinicaltrials.gov identifier: NCT03772665).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Quidel Concludes Sofia\u00ae SARS Antigen Investigation From Vermont. Extensive Analysis Shows No Issues with Tests or Testing Sites. Quidel Corporation (NASDAQ: QDEL) (\u201cQuidel\u201d), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has completed its investigation regarding a report of discordant results (False Positives) at a testing location in Vermont, and found no testing site- or product-related issues with the Sofia\u00ae 2 instrument or the Sofia\u00ae SARS Antigen FIA.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Antibe Therapeutics Announces Results of Annual and Special Meeting. Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information circular (the \u201cCircular\u201d) were approved, including:",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Defibrillators Market by Type, End User and Region - Opportunity Analysis and Industry Forecast to 2026 - ResearchAndMarkets.com. The \"Defibrillators Market by Type, and External Defibrillators), by End User, by Geography Global Opportunity Analysis and Industry Forecast up to 2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Xeris Pharmaceuticals Appoints John Shannon President and Chief Operating Officer. Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced that its Board of Directors has promoted John P. Shannon to the position of President and Chief Operating Officer, effective immediately. In his new role, Mr. Shannon will be responsible for commercial operations, commercial development activities, finance, manufacturing, regulatory and clinical operations, and human resources. Mr. Shannon will continue to report to Paul R. Edick, who remains as Xeris\u2019 Chairman and Chief Executive Officer.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials. Selects Worldwide Clinical Trials as Contract Research Organization Partner. HOUSTON , Aug. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced it has engaged Worldwide Clinical Trials (\"Worldwide\") as the contract research organization (\"CRO\") for its upcoming Berubicin clinical trials.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Medidata\u2019s Dr. Rama Kondru Named One of 2020\u2019s 100 Most Inspiring People by PharmaVoice. Dr. Rama Kondru, executive vice president, chief information officer and chief technology officer at Medidata, a Dassault Syst\u00e8mes company, has been selected by PharmaVOICE magazine as one of 2020\u2019s 100 Most Inspiring People (PharmaVOICE 100) in the life science industry. Kondru is cited by PharmaVOICE for inspiring and motivating his teams, propelling Medidata\u2019s mission of powering smarter treatments and healthier people, and his role in helping to lead the digital transformation of the life science industry.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cardiovascular Systems, Inc. Announces Kelvin Womack Joins Board of Directors. Cardiovascular Systems, Inc. (CSI \u00ae ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Kelvin Womack.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Myomo\u00ae Receives First Australian Insurance Authorization for MyoPro\u2122. Additional Authorizations Across Australia are Expected to Follow. Myomo, Inc. (NYSE American: MYO) (\u201cMyomo\u201d or the \u201cCompany\u201d), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that a Myomo-trained Orthotic & Prosthetic (\u201cO&P\u201d) practice in Australia has received its first insurance authorization to fit a patient with a custom MyoPro device. This is the first authorization following Myomo\u2019s entry into Australia as part of its international expansion initiative.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Creative Medical Technology Holdings Identifies Novel Mechanism of Action of AmnioStem\u2122 Adult Stem Cell Product in Stroke. New Data Supports Current Push for FDA Clearance of Universal Donor Amniotic Fluid Derived Stem Cell Product. PHOENIX , Aug. 20, 2020 /PRNewswire/ --\u00a0Creative Medical Technology Holdings Inc., trading under the ticker symbol CELZ, announced today new data demonstrating effective suppression of stroke associated pathological molecules by AmnioStem\u00ae universal donor stem cells.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Guidewires Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Prevalence of Chronic Disorders to boost the Market Growth | Technavio. Technavio has been monitoring the guidewires market and it is poised to grow by USD 656.92 million during 2020-2024, progressing at a CAGR of about 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"KPMG to Offer New COVID-19 Convalescent Plasma Donor Matching Solution. -- Technology architecture is designed to connect recovered patients with current patients participating in clinical trials. -- Data & analytics can provide insight to healthcare and government decision makers. NEW YORK , Aug.\u00a020, 2020 /PRNewswire/ --\u00a0Recognizing the need for technologies to help advance the response and recovery to the COVID-19 pandemic, KPMG LLP has built the technology architecture for a solution that can match patients in clinical trials for convalescent plasma therapy to recovered patients willing to donate their antibodies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress\u2122 2020. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that clinical data from Enanta\u2019s wholly-owned development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) have been accepted for presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress 2020 being held August 27-29, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Eric Feinstein Joins Navitus Health Solutions as Senior Vice President, Human Resources and Chief People Officer. Navitus Health Solutions, a full pass-through pharmacy benefit manager (PBM), announced today that Eric Feinstein has joined the company as Senior Vice President, Human Resources and Chief People Officer.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights on the Ophthalmic Devices Global Market to 2026 - Major Deals, Trends, Key Players Analysis and Recent Developments - ResearchAndMarkets.com. The \"Ophthalmic Devices Market (By Applications, Products, End Users, Regions), Major Deals, Trends, Key Players Analysis, Recent Developments - Global Forecast to 2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights on the Intraoperative Imaging Global Market to 2027 - Featuring Koninklijke Philips, Medtronic & NeuroLogica Among Others - ResearchAndMarkets.com. The \"Intraoperative Imaging - Global Market Trajectory & Analytics\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Wolters Kluwer Adds AI to Clinical Surveillance for Faster C. Difficile Infection Prediction. Sentri7\u2019s predictive C. diff infection risk score helps hospitals identify at-risk patients sooner and proactively address modifiable risk factors to prevent infection and improve outcomes. Wolters Kluwer, Health has announced that its Sentri7 clinical surveillance solution has been enhanced with artificial intelligence (AI) to identify patients at risk for Clostridioides difficile ( C. diff ) infection. The solution uses a highly advanced and validated algorithm to produce C. diff infection (CDI) risk scores for individual patients, empowering clinicians to proactively alter patient care to reduce risks for infection and improve outcomes.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Kentuckians Urged to Update Vaccines Following Drop in Immunization Rates During Pandemic. Kentucky Medical Association, Anthem Blue Cross and Blue Shield, Kentucky Foundation for Medical Care, and Foundation For A Health Kentucky team up to launch \u201cRaise Your Guard, KY\u201d campaign. A new campaign designed to counter the sharp decline in vaccination rates among Kentucky children launched today across the state. Raise Your Guard, KY urges Kentuckians to contact their physicians to get themselves and their families back on track with scheduled immunizations to prevent dozens of life-threatening diseases and illnesses. The month-long, multimedia campaign also reminds residents to get their annual flu shots starting in September to help keep their immune systems strong.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Dietary Supplement Usage Up Dramatically During Pandemic, New Ipsos-CRN Survey Shows. The Council for Responsible Nutrition (CRN), the leading trade association for the dietary supplement and functional food industry, issued results of a COVID-19-focused consumer survey today that discovered more than two in five (43 percent) of dietary supplement users have changed their supplement routines since the start of the pandemic. Among those who altered their regimens due to COVID-19, 91 percent report increasing their supplement intake which includes adding new supplements to their existing routines (46 percent); taking the same supplements more regularly (25 percent); or increasing dose(s) (22 percent).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Axcella Announces Upcoming Later-Breaker Presentation at The Digital International Liver Congress 2020. Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced an upcoming late-breaker poster presentation at The Digital International Liver Congress\u2122 2020 (EASL), which is being held virtually from August 27 to 29. This presentation will discuss key data from AXA1125-003, a placebo-controlled, randomized, multi-arm clinical study assessing the impact of AXA1125 and AXA1957 on safety, tolerability and effects on structures and functions of the liver in 102 adult subjects with non-alcoholic fatty liver disease (NAFLD).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Morehouse School of Medicine and UnitedHealth Group Collaborate to Help Expand COVID-19 Research and Health Equity for Individuals with Sickle Cell. Study will assess COVID-19 risk and severity among individuals with sickle cell trait. Morehouse School of Medicine (MSM) and UnitedHealth Group (NYSE: UNH) have joined forces to determine if people with sickle cell trait are at greater risk of contracting COVID-19 and if the trait results in more severe cases of the disease.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Participants Boosted Health, Reduced Risk of Severe COVID-19 Outcomes in Free Plant-Based Nutrition Classes. Next Fight COVID-19 With Food Class Series Starts on Aug. 25. A free online nutrition course taught by doctors with the Physicians Committee for Responsible Medicine is helping people across the country to lose weight, improve their health, and minimize their risk for severe COVID-19 outcomes.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Insights on the Global Medical Robots Market | COVID-19 Impact and Analysis of Related Markets Drivers, Opportunities and Threats | Technavio. Technavio predicts the global medical robots market to grow steadily at a CAGR of over 21% by 2023. One of the primary drivers of the market is the advantages of robot-assisted training in rehabilitation therapy. Robot-assisted therapy helps to improve the gait function in patients. Also, the high-intensity training provided by rehabilitation robots helps patients suffering from motor disorders caused by stroke or spinal cord diseases. Many such benefits are fueling the growth of the global medical robots market. Download Free Sample Report with COVID-19 Impact Analysis",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Color and Researchers from Massachusetts General Hospital and the Broad Institute Discover Key Finding to Determine Risk of Genomic Diseases. The research, published August 20 in Nature Communications, unveils the relationship between monogenic variants and polygenic risk for coronary artery disease, breast cancer, and colorectal cancer. SAN FRANCISCO , Aug. 20, 2020 /PRNewswire/ --\u00a0Today, the journal Nature Communications published new research, led by scientists from Color, Massachusetts General Hospital and the Broad Institute of MIT and Harvard , that sheds light on the risk of developing three diseases: coronary artery disease, breast cancer and colorectal cancer. Their research shows that in order to fully understand the risk of developing these diseases, individuals and their healthcare providers should consider more genetic information than previously thought.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Pear Therapeutics and Serve You Rx Announce Formulary Coverage for Prescription Digital Therapeutics reSET\u00ae & reSET-O\u00ae and People with Substance and Opioid Use Disorders. Serve You Rx teams with Pear to lead access to prescription digital therapeutics (PDTs) with proven outcomes in treating substance use disorder (SUD) and opioid use disorder (OUD) and to support members in recovery \n\n\nreSET and reSET-O are added to Serve You Rx\u2019s standard national formularies and covered as pharmacy benefits for all its commercial members \n\n\nServe You Rx and Pear will collaborate to close gaps and improve quality of addiction care by expanding on PBM core offerings to combat the nation\u2019s public health crisis of substance abuse and addiction, and the associated problem of rising healthcare costs. Pear Therapeutics, Inc. and Serve You Rx announced today that reSET\u00ae and reSET-O\u00ae, the first two prescription digital therapeutics (PDTs) to receive authorization to treat disease from the U.S. Food and Drug Administration (FDA), have been added to Serve You Rx\u2019s standard formularies and are being administered as standard pharmacy benefits for its members.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Twist Bioscience Synthetic DNA Stores New Netflix Original Series \u2018BIOHACKERS\u2019. -- World\u2019s First Series Stored in DNA --. Twist Bioscience Corporation (Nasdaq: TWST) today announced that for the first time, an episode of a Netflix Original Series has been stored in Twist\u2019s synthetic DNA.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"First Reported \u201cLong-Hauler\u201d Post COVID-19 Patient Treated with Zofin\u2122 Produces Excellent Preliminary Results. Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat one \u201clong-hauler\u201d patient on August 1, 2020, and two additional patient approvals on August 17, 2020.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"COVID-19 (Novel Coronavirus): Therapeutic Pipeline for Vaccines - 2020 - ResearchAndMarkets.com. The \"COVID-19 (Novel Coronavirus): Therapeutic Pipeline for Vaccines - 2020\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Dilated Blood Vessels in the Lung May Explain Low Oxygen Levels in Severe Cases of COVID-19. A new pilot study from the Icahn School of Medicine at Mount Sinai suggests that COVID-19 is causing significant dilation of the blood vessels of the lung, specifically the capillaries. NEW YORK , Aug. 20, 2020 /PRNewswire-PRWeb/ --\u00a0A new pilot study from the Icahn School of Medicine at Mount Sinai suggests that COVID-19 is causing significant dilation of the blood vessels of the lung, specifically the capillaries. This vasodilation is contributing to the very low oxygen levels seen in COVID-19 respiratory failure and also helps explain why the disease behaves differently than classic acute respiratory distress syndrome (ARDS). The study was published in the American Journal of Respiratory and Critical Care Medicine.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Outlook on the Intracranial Pressure Monitoring Global Market to 2025 - Featuring Integra Lifesciences, LINET & Medtronic Among Others - ResearchAndMarkets.com. The \"Intracranial Pressure Monitoring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Visceral Pain Treatment Market to Reach Up To US$ 16,709.8 Million by 2027, Says Coherent Market Insights (CMI). According to Coherent Market Insights, the global visceral pain treatment market is estimated to be valued at US$ 11,673.8 million in 2020 and is projected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Operating Room Integration Market Analysis 2020-2026 - ResearchAndMarkets.com. The \"Global Operating Room Integration Market By Component, By Application, By End Use, By Devices, By Region, Industry Analysis and Forecast, 2020 - 2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Qosina\u2019s Swab Inventory Ranges in Application from COVID-19 Testing to Cleaning and Polishing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200820005578/en/",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sage Therapeutics to Host Sage FutureCast Webcast. Sage FutureCast will discuss the Company\u2019s research and development strategy, and review clinical progress in programs throughout the depression, neurology and neuropsychiatric franchises, including zuranolone, SAGE-324 and SAGE-718, respectively.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Clinical Research Trials Underway to Study COVID-19 Impact on Dialysis Patients. DaVita Clinical Research investigating presence of COVID-19 antibodies and genetic contributions to infection severity in patients. DENVER , Aug. 20, 2020 /PRNewswire/ --\u00a0DaVita Clinical Research (DCR), a subsidiary of DaVita Inc., has begun enrollment on two\u00a0clinical research trials to study how COVID-19 affects people with end stage kidney disease (ESKD) who are currently receiving dialysis.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function. NEW YORK , Aug. 20, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),\u00a0a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of intestinal barrier function. Based on preclinical data, the compound appears to represent a novel and paradigm-shifting approach to the treatment of gastrointestinal diseases by potentially restoring intestinal barrier function while maintaining immunocompetency. Immunic's Australian subsidiary, Immunic Australia Pty Ltd., received clearance from the Bellberry Human Research Ethics Committee in Australia to begin a phase 1 trial of IMU-856 under the Clinical Trial Notification (CTN) scheme of the Australian Therapeutic Goods Administration (TGA). The phase 1 clinical program includes single and multiple ascending dose parts in healthy volunteers. Subsequently, Immunic also plans to extend this program to assess biomarker, safety and drug trough levels in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), ulcerative colitis (UC) and Crohn's disease (CD).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells. SHANGHAI , Aug. 20, 2020 /PRNewswire/ --\u00a0CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application for the first-in-class drug candidate CT041, autologous chimeric antigen receptor (CAR) T cells for the treatment of claudin18.2-positive solid tumors.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Clinical Trials Testing New Paradigms For Advanced Therapies Treating Metastatic Cancer Conditions. Financialnewsmedia.com News Commentary. PALM BEACH, Fl. , Aug. 20, 2020 /PRNewswire/ -- Various reports on the global metastatic cancer treatment market all project continued growth in the next several years. One such report from Industry Research says that the global metastatic cancer treatment market size is projected to reach $52.6 billion by 2026, up from $50.2 million in 2020, at a CAGR of 4.4% during 2021-2026. Another report from Statista projects even higher revenues saying that the total global market for metastatic cancer treatment is estimated that the market will grow to almost $100 billion dollars by 2025.\u00a0An article from the American Brain Tumor Association added: \"The treatment is directed towards not only metastatic brain tumors but their symptoms as well. Longer survival, improved quality of life and stabilization of neurocognitive function for patients with brain metastasis is the goal of treatment. There have been numerous advances in the treatment of metastatic brain tumors in the last decade\u2026\" Active biotech and pharma companies in the markets this week include CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Momenta Pharmaceuticals,\u00a0Inc. (NASDAQ: MNTA), AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Clovis Oncology, Inc. (NASDAQ: CLVS).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"AMRA Medical Will Present a Study on MRI-Based Body Composition in Liver Disease at The Digital International Liver Congress\u2122 2020. AMRA Medical and Link\u00f6ping University collaborated on a liver biopsy-controlled MRI-based body composition study and will present the results at the congress. LINK\u00d6PING, Sweden , Aug. 20, 2020 /PRNewswire/ -- AMRA , in partnership with Link\u00f6ping University, investigated body composition in liver needle biopsy-controlled patients with various chronic liver diseases using magnetic resonance imaging (MRI) and will share the results at EASL's The Digital International Liver Congress\u2122\u00a02020, 27-29 August.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Gevo Exceeds $1.5B in Long-Term Revenue Contracts with Signing of Trafigura. Gevo and Trafigura Enter into Contract for Low-Carbon Premium Gasoline and Sustainable Aviation Fuel. ENGLEWOOD, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) announced today that it has entered into a binding Renewable Hydrocarbons Purchase and Sale Agreement, dated August 17, 2020 (the \u201cAgreement\u201d) with Trafigura Trading LLC, a wholly-owned subsidiary of Trafigura Group Pte Ltd (\u201cTrafigura\u201d). The Agreement is a long term, take or pay contract and is the largest contract in Gevo\u2019s history. Trafigura is one of the world\u2019s leading independent commodity trading companies with over $171B and over $54B in revenue and assets, respectively. Under this contract Trafigura is expected to take delivery of 25MPGY of renewable hydrocarbons, the majority of which is expected to be low-carbon premium gasoline with a smaller portion of the volume for sustainable aviation fuel (\u201cSAF\u201d), starting in 2023.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"To Avoid Delay, the FDA Recommends CytoDyn Conduct Its Type A Meeting in Writing with FDA Response Goal Date of September 4. VANCOUVER, Washington, Aug. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (\u201cCytoDyn\u201d or the \u201cCompany\"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it will conduct its Type A meeting in writing in lieu of a teleconference with the U.S. Food and Drug Administration (FDA). The FDA has agreed to respond to the Company\u2019s questions by September 4, 2020 concerning the additional information the FDA requires to resubmit the Biologics License Application (BLA) for leronlimab as a combination therapy for HIV.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.\u2019s MHRA Accepts CytoDyn\u2019s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms. Patient enrollment to commence immediately",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"U.S. FDA Approves New DARZALEX\u00ae (daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma. Approval broadens DARZALEX label to include fifth treatment option in the relapsed/refractory setting and represents the eighth approved indication for DARZALEX. HORSHAM, Pa. , Aug. 20, 2020 /PRNewswire/ --\u00a0The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX \u00ae (daratumumab) in combination with Kyprolis \u00ae (carfilzomib) and dexamethasone (DKd) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy. DARZALEX \u00ae has been approved in combination with two carfilzomib dosing regimens, 70 mg/m2 once weekly and 56 mg/m2 twice weekly, based on positive results from the Phase 3 CANDOR and Phase 1b EQUULEUS studies, representing the first-ever approval of an anti-CD38 with carfilzomib.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Black Health Matters Launches Breast Cancer Initiative In  research Clinical Study. Raising Awareness of Clinical Trial Participation Using Social Media. NEW YORK , Aug. 20, 2020 /PRNewswire/ --\u00a0Black Health Matters, the leading health and chronic disease management platform for African Americans will launch a social media campaign to raise awareness of breast cancer and clinical trial participation. This focus will introduce new content to be socialized on Facebook, Twitter and Instagram in a campaign that will speak to people of color with breast cancer. The campaign will capture the voice of the female and male breast cancer patient based on insights unique to their journey. Men diagnosed with breast cancer represent <1% of the population, but should not be dismissed.\u00a0The campaign is designed is to speak directly to those with ER+/HER2- breast cancer. This campaign is funded by Bristol Myers Squibb to provide educational information about clinical trial participation and relatable information for caregivers.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress\u2122 2020. Oral Presentation to Highlight New Efficacy Data Measured at Week 16 and Additional Week 12 Efficacy Data Stratified by Baseline Characteristics and Risk Factors. SAN DIEGO , Aug. 20, 2020 /PRNewswire/ --\u00a0Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company's 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C) will be presented at the Digital International Liver Congress \u2122 2020. The study results will be featured in an oral presentation at the annual meeting of the European Association for the Study of the Liver (EASL), being held virtually August 27-29, 2020 .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Science 37\u00ae Raises $40 Million to Extend Its Leadership in the Decentralized Clinical Trial Market. In a significantly oversubscribed offering, Science 37 attracted capital to support its rapid growth, expand its technology platform and accelerate global expansion. LOS ANGELES , Aug. 20, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round. Existing investors Lux Capital, Redmile Group, and PPD, Inc. (Nasdaq: PPD) led the round, and are joined by existing investors Novartis, Amgen, Sanofi Ventures, GV, and Glynn Capital. Notable new investors include LifeSci Ventures and Mubadala Ventures.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"FDA Approves New KYPROLIS\u00ae (carfilzomib) Combination Regimen With DARZALEX\u00ae (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens. Approval Based on the CANDOR and EQUULEUS Studies in Patients With Relapsed/Refractory Multiple Myeloma. THOUSAND OAKS, Calif. , Aug. 20, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS \u00ae (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX \u00ae (daratumumab) plus dexamethasone (DKd) in two dosing regimens \u2014 once weekly and twice weekly \u2014 for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM) who have received one to three previous lines of therapy.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen. HANGZHOU\u00a0and SHAOXING, China , Aug. 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today\u00a0that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Ultimovacs ASA: Second Quarter 2020 Result Presentation. Ultimovacs ASA (\"Ultimovacs\", ticker ULTIMO), a pharmaceutical company developing novel immunotherapies against cancer, announces its second quarter 2020 results today. A presentation by the company's management team will take place today on a webcast at 09:00 CEST.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Analysis on Impact of COVID-19: Medical Cyclotron Market 2020-2024 | Benefits Of Medical Cyclotrons to Boost the Market Growth | Technavio. Technavio has been monitoring the medical cyclotron market and it is poised to grow by USD 55.98 mn during 2020-2024, progressing at a CAGR of almost 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Wolters Kluwer Podcast Series Launched to Educate Lenders Navigating COVID-19 Impacts. Expert insights help lenders manage regulatory, operational challenges brought about by the pandemic. Wolters Kluwer Compliance Solutions has initiated a series of informative podcasts to help lenders adapt under the COVID-19 pandemic environment and address its broad-reaching impacts for their lending practices. With topics ranging from effectively managing regulatory change to clarifying loan forgiveness requirements under the CARES Act Paycheck Protection Program (PPP), the episodes feature Wolters Kluwer regulatory consultants and other industry experts sharing insights to assist lenders in serving their banking customers.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-linked Myotubular Myopathy. Audentes Therapeutics, Inc., an Astellas company, today announced that a third study patient has passed away in the ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy (XLMTM), which is a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death. Preliminary findings indicate that the immediate cause of death was gastrointestinal bleeding.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"goMoxie\u2019s Earns 2020 Stevie\u00ae Award For its Response to COVID-19. Additionally, Company\u2019s Mission to \u201cBe There\u201d for Employees Earns it Employer of the Year Award. goMoxie\u00ae, the leading provider of digital guidance solutions, has received two Stevie\u00ae Awards for the COVID-19 Response - Most Valuable Employer and Employer of the Year categories in the Fifth Annual Stevie Awards for Great Employers.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Ontrak Announces Pricing of Public Offering of Non-Convertible Preferred Stock. Company to use non-dilutive capital for working capital, M&A, investment in technology. Ontrak, Inc. (NASDAQ: OTRK) (\u201cOntrak\u201d or the \u201cCompany\u201d), a leading AI-powered and telehealth enabled, virtualized outpatient healthcare treatment company, today announced that it has priced its previously announced underwritten public offering of 1,700,000 shares of its 9.50% Series A Cumulative Perpetual Preferred Stock (the \u201cSeries A Preferred Stock\u201c) at $25.00 per share, for gross proceeds to the Company of $42.5 million. B. Riley FBR, Ladenburg Thalmann and William Blair are acting as book-running managers for the offering. ThinkEquity, a division of Fordham Financial Management, Inc. is acting as Lead Manager. Incapital, The Benchmark Company, Boenning & Scattergood, Colliers Securities and Kingswood Capital Markets, a Division of Benchmark Investments, Inc. are acting as co-managers. The Company has granted the underwriters a 30-day option to purchase up to an additional 255,000 shares of Series A Preferred Stock initially sold to the public. The Company has filed an application to list the shares of the Series A Preferred Stock to be sold in the offering on the Nasdaq Global Select Market under the symbol \u201cOTRKP.\u201d The offering is expected to close on or about August 25, 2020, subject to the satisfaction of customary closing conditions.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Lung Therapeutics Receives SBIR Award for Kidney Fibrosis Research; Principal Investigator BreAnne Mackenzie Will Speak at 4th Annual IPF Summit 2020/Digital. Lung Therapeutics, Inc. , a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, has been awarded a Small Business Innovation Research (SBIR) Grant of $300,228 from the National Institutes of Health (NIH) to study potential therapies that target fibrotic processes in the kidneys.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Hemorrhagic Shock Treatment Market to be Valued at US$ 230.9 Million by 2027, Says Coherent Market Insights (CMI). According to Coherent Market Insights, the global hemorrhagic shock treatment market is estimated to be valued at US$ 175.4 million in 2020 and is expected to exhibit a CAGR of 4.0% during the forecast period (2020-2027).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"2020 Global Market Overview for Medical Plastics - ResearchAndMarkets.com. The \"Medical Plastics - A Global Market Overview\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"PDC Wellness & Personal Care Co. Promotes Pete Columbia to Chief Executive Officer; Chris Baldwin Named Executive Chairman. PDC Wellness and Personal Care Co. and its subsidiaries (\u201cPDC\u201d or the \u201cCompany\u201d), a leading growth-oriented wellness and personal care company, announced today that Pete Columbia, the Company\u2019s President, has been promoted to Chief Executive Officer and a member of the Company\u2019s Board of Directors effective September 1, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Preventive Vaccines Market Growth, Trends and Forecasts to 2025 - Hepatitis Vaccines are Expected to Exhibit High Growth - ResearchAndMarkets.com. The \"Preventive Vaccines Market - Growth, Trends, and Forecast (2020 - 2025)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Odonate Therapeutics to Hold Conference Call on Monday, August 24, 2020 at 8:30 a.m. ET. Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will hold a conference call on Monday, August 24, 2020 at 8:30 a.m. ET. To participate in the call, please dial (866) 300-4090 (domestic) or (636) 812-6660 (international) and use conference ID 2881009.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Nanox Announces Pricing of Upsized Initial Public Offering. NANO-X IMAGING LTD (\u201cNanox\u201d or the \u201cCompany\u201d), an innovative medical imaging technology company, announced today the pricing of its initial public offering of 9,178,744 ordinary shares at a price to the public of US$18 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nanox, are expected to be US$165.2 million. In addition, Nanox has granted the underwriters a 30-day option to purchase up to an additional 1,376,812 ordinary shares at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Nanox.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19. Phase 1b clinical trial will evaluate the safety and pharmacological activity of SAB-185 in COVID-19 patients\n\n\nSecond study initiated this month testing SAB-185 for the treatment of COVID-19. SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce targeted polyclonal antibodies, today announced the dosing of the first patient in its Phase 1b clinical trial evaluating the safety and pharmacological activity of SAB-185, a COVID-19 therapeutic. SAB-185, developed from SAB\u2019s novel technology platform that leverages the native human immune response to offer a differentiated high-potency therapeutic option that potentially addresses virus mutations, is currently being tested in an ongoing Phase 1 trial in healthy volunteers for the treatment of COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"South Carolina Resin and Fiber Manufacturer Ascend Performance Materials Hosts Rep. Joe Wilson During District Stop in Aiken. Representative Wilson briefed on company\u2019s groundbreaking antimicrobial technology Acteev Protect\u2122. Ascend Performance Materials had the opportunity to welcome Congressman Joe Wilson (SC-02) during a district bus tour recently in Aiken, S.C., to provide a briefing about the company\u2019s new Acteev\u2122 antimicrobial technology, currently in use in non-woven and fabric masks and textile applications. The technology can be used in numerous applications, including textiles, and provides a first line of defense against microbes and other pathogens.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Medical Device Industry to 2025 - Featuring Abiomed, Accuray & Affectiva Among Others - ResearchAndMarkets.com. The \"Medical Device Market by Device Type, Function, Durability, Therapeutic Segment, Risk Classification, Manufacture Method, Delivery/Acquisition, Operational Support Model, Connectivity and Region 2020 - 2025\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"QIAGEN announces new Chairman of Supervisory Board. Lawrence A. Rosen appointed by Supervisory Board as new Chairman with immediate effect\n\n\n\n\nAppointment comes after Dr. H\u00e5kan Bj\u00f6rklund decided to step down as Chairman of the Supervisory Board and as a Supervisory Board member. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced today a transition in the leadership of its Supervisory Board after an extraordinary meeting of the Supervisory Board and Managing Board.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications. -Introduction to JanOne scientific team. -Strategy for upcoming planned Phase 2b trial of JAN101. -Business development updates, including planned COVID-19 treatment study and focus on commercialization and production capabilities. LAS VEGAS , Aug. 21, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it intends to provide a public business update via teleconference regarding the advancements made through its lead drug candidate JAN101. The company believes that JAN101 is a potential treatment for peripheral artery disease (PAD) and may have applications for COVID-19 vascular complications. The briefing will be held on Tuesday, August 25, 2020 at 4:15 PM ET .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"COVID-19 Impacts: Enteral Feeding Devices Market Will Accelerate at a CAGR of Over 6% Through 2020-2024 | Growing Number of Strategic Alliances to Boost Growth | Technavio. Technavio has been monitoring the enteral feeding devices market and it is poised to grow by USD 1.07 billion during 2020-2024, progressing at a CAGR of over 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Tyme Technologies to Present at the 2020 CHINABIO\u00ae Partnering Forum. Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs\u2122), announced that leadership will present at the 2020 Cross-Border Healthcare Webinar Series on Wednesday, August 26, 2020. The Company will present its corporate overview with a focus on:",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Forbes names ICON in list of Best Employers in America for Women. ICON recognised as top employer for women in anonymous survey of 75,000 employees. ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries today announced that it has been recognised in the 2020 Forbes List of America\u2019s Best Employers for Women for the second consecutive year.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Pulse Oximeter Market (2019 to 2028) - Surging Prevalence of Respiratory Diseases Presents Opportunities - ResearchAndMarkets.com. The \"Global Pulse Oximeter Market 2019-2028\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"European Automated Compounding Systems Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product Type; End User, and Country - ResearchAndMarkets.com. The \"Europe Automated Compounding Systems Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product Type; End User, and Country\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Finding Clues to a Successful Immune Response in the T Cells of Recovered COVID-19 Patients. While antibodies may fade fast, T cells appear to be long-lived and might confer lasting immunity. SAN FRANCISCO , Aug. 21, 2020 /PRNewswire/ --\u00a0When news about a novel coronavirus switched from a chronicle of its progress in China to headlines about a worldwide COVID-19 pandemic, Gladstone Institutes scientist Nadia Roan , PhD , was in the midst of publishing several papers on T cells and their role in HIV spread and long-lasting infections .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Walgreens Contributes to American Red Cross Aid for Parts of Iowa and Illinois Hit by Derecho Storm; Quickly Reopens Stores for Prescriptions and Other Essential Needs. All but one of the Walgreens stores affected by the storm have reopened, Company donating $10,000 and accepting donations for American Red Cross Relief. Walgreens is supporting American Red Cross relief efforts for tens of thousands of Iowans and Illinoisans still recovering from the derecho storm that recently impacted an expansive region of the bordering states. Walgreens will donate $10,000 toward American Red Cross derecho assistance and, from Aug. 22 to Aug. 26, local Walgreens stores in Illinois and Iowa will be accepting donations at point of sale, with 100 percent of proceeds benefitting the American Red Cross.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"IGC Reports Financial Results for the Quarter Ended June 30, 2020 While Preparing for Its FDA-Approved Cannabinoid Clinical Trials on Alzheimer\u2019s Patients. India Globalization Capital, Inc. (NYSE American: IGC) today announced financial results for the quarter ended June 30, 2020, which is the first quarter of its 2021 fiscal year.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CORRECTING and REPLACING IGC Reports Financial Results for June 30, 2020 Quarter and Prepares for Phase 1 Cannabinoid Clinical Trial for Alzheimer\u2019s Patients. Please replace the release dated August 19, 2020 with the following corrected version due to multiple revisions.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Consolidated Theatres Announces the Reopening of Select Locations on August 21. Guests invited to enjoy the ultimate moviegoing experience once again with new and comprehensive safety measures in place. Consolidated Theatres, owned and operated by Reading International, Inc. (NASDAQ: RDI), will be welcoming back valued guests on Friday, August 21, 2020 with extensive sanitization and safety measures in place. Four Consolidated Theatres - Ward Village, Town Center at Mililani, Pearlridge Center and `\u014clino at Ka Makana Ali\u2019i - will reopen on August 21, with the remaining Consolidated Theatres to follow at a later date. In a safe and carefully planned way, and in line with the state and county\u2019s latest orders, audiences can return to share the magic of movies again on the big screen.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine. Avid Well Positioned to Meet Significant Scale-Up Requirements for NIH-Licensed SARS-CoV-2 Spike Protein Vaccine Candidate. Oragenics, Inc. (NYSE American: OGEN) and Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that the companies have entered into a process development and drug substance manufacturing agreement. Under terms of the agreement, Avid will provide Oragenics with analytical method development, process development and drug substance manufacturing services to support development of Oragenics\u2019 novel SARS CoV-2 (COVID-19) spike protein vaccine candidate, Terra CoV-2.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Adagio Therapeutics Announces Appointment of Howard Mayer, M.D., to its Board of Directors. Adagio Therapeutics, Inc., a company focused on the development of best-in-class antibodies to provide broad protection against SARS-CoV-2, SARS-CoV-1 and additional circulating bat coronaviruses, today announced that Howard Mayer, M.D., Executive Vice President and Head of Research and Development at Ipsen Pharmaceuticals, has joined its board of directors.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Erasca Recruits Michael Varney, Ph.D., as Chairman of Research & Development and Scientific Advisory Board Member. Dr. Varney\u2019s First Leadership Role Since Retiring from Genentech. Erasca, a company whose mission is to erase cancer, today announced that Michael Varney, Ph.D., has joined the organization\u2019s Scientific Advisory Board (SAB) and will also serve as Chairman of Research & Development (R&D).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio. Forbius\u2019s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis. Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases, today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will acquire Forbius. Forbius has developed a portfolio of highly selective and potent inhibitors of TGF-beta 1 & 3, which are key mediators of immunosuppression and fibrosis. The transaction includes an upfront payment and future success-based milestone payments. Prior to closing, Forbius\u2019 non-TGF-beta assets will be transferred to a newly formed private company, which will be retained by Forbius\u2019 existing shareholders.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Leading Biochemist Charles Brenner, Ph.D., Joins City of Hope as Chair of First Department Focused on Diabetes and Cancer Metabolism. Brenner is also the inaugural Alfred E. Mann Family Foundation Chair, seeking better treatments for diabetes and cancer. Biochemist Charles Brenner , Ph.D., has joined City of Hope to lead the nation\u2019s first research department focused on the intersection between cancer and diabetes. He is also the inaugural holder of the Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism, an endowed chair made possible by a generous donation from the Alfred E. Mann Family Foundation.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin\u00ae (Bevacizumab) Biosimilar BAT1706 in China. Bio-Thera Solutions, Ltd., a commercial stage biopharmaceutical company (688177.SH) and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), today announced that the companies have executed a license, distribution, and supply agreement for China for Bio-Thera\u2019s BAT1706, an investigational biosimilar to Avastin \u00ae (bevacizumab). The China National Medical Products Administration (NMPA) recently accepted Bio-Thera\u2019s Biologics License Application (BLA) for BAT1706. Bevacizumab has been approved in China for advanced, metastatic, or relapsed non-small cell lung cancer and metastatic colorectal cancer. The agreement is subject to approval by the shareholders of Bio-Thera at a meeting to be held in September 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Medable Achieves 400% Growth in First Half 2020, Expands Ecosystem for Decentralized Clinical Trials. Founder: \u201cCOVID-19 Has Accelerated Decentralized Trial Adoption by Five Years\u201d. Medable Inc. , the leading software provider for decentralized clinical trials, today announced strong momentum in the first half of 2020 as pharma and biotech companies quickly shifted clinical trials to digital platforms in response to COVID-19. Specifically, Medable grew its revenues by more than 400 percent year over year, including the addition of nine large pharma customers, an expanded partnership with PPD, and new partnerships including Datavant, AliveCor and MRN. (Click here for a full list of news.)",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Diomics Announces Development of Diocheck\u2122 Visual Antibody Indicator. Proprietary Diomat\u2122 Technology Enables Long-Term Antibody Detection to Assist in COVID-19 Monitoring. Diomics, a San Diego-based biotech company, today announced that it is currently developing the Diocheck\u2122 Antibody Indicator, which provides a simple way for individuals to monitor for the presence of antibodies to SARS-CoV-2 over an extended period of time.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA\u00ae Cream, in the US. Collaboration accelerates a Q1 2021 comprehensive launch of MC2's WYNZORA\u00ae Cream to patients with plaque psoriasis in the US\n\n\nWYNZORA\u00ae Cream is the first drug based on PAD\u2122 Technology - providing innovative solutions to unmet needs in chronic inflammatory conditions\n\n\nWYNZORA\u00ae Cream offers a unique combination of high efficacy, favorable safety, and excellent treatment convenience in a single product. MC2 Therapeutics, a commercial stage pharmaceutical company focused on innovative topical therapies for chronic inflammatory conditions, announced today its Collaboration Agreement with EPI Health, LLC on the commercialization of WYNZORA Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US. WYNZORA Cream was approved by the U.S. Food and Drug Administration (FDA) on July 20 th , 2020 for the topical treatment of plaque psoriasis in adults, 18 years of age or older.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Cutera Reverses Aging, Unveils Powerful Technology. Fraxis PRO Marries CO2 and Microneedling for Collagen Building + Total Skin Resurfacing. CUTERA, INC ., (Nasdaq: CUTR) , a leading provider of laser, light and other energy-based aesthetic systems, today announced the launch of its new powerful Fraxis PRO progressive dermal remodeling technology.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer. CONTESSA Achieved Primary Endpoint \u2013 Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard Ratio=0.716; p=0.003)\n\n\nMedian PFS Was 9.8 Months for Tesetaxel Plus a Reduced Dose of Capecitabine Versus 6.9 Months for the Approved Dose of Capecitabine Alone, an Improvement of 2.9 Months\n\n\nCompany to Host Conference Call Today at 8:30 a.m. ET. Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced positive top-line results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer (MBC).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics. Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the product. NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"SAFE Certification Launches Compliance Solution to Help Entities Combat Spread of Viruses, Infectious Diseases and Bacteria. New Tool Aids Broad Range of Businesses, Facilities and Establishments as they Strive to Ensure COVID-19 Public Health, Safety and Compliance; Creates Levels of Accountability and Protection. SAFE Certification , creator of the first and only accountability and compliance tool used by businesses, facilities and establishments to help keep employees, guests and the public as safe as possible, announced today the introduction of its new SAFE Certified solution.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference. Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr. Jed Latkin, Chief Executive Officer, will present at the LD Micro 500 investor conference. The virtual conference will be held on September 1-4, 2020. Mr. Latkin will present on Tuesday, September 1 at 4:40 p.m. EDT in Track 4, which will be webcast.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Avero Diagnostics Expands COVID-19 Testing Capabilities with Launch of Serology Testing. Avero Diagnostics , a physician-owned laboratory, is pleased to announce the expansion of its COVID-19 testing portfolio with the addition of the Roche Elecsys\u00ae Anti-SARS-CoV-2 antibody test. Serological testing supports the Centers for Disease Control and Prevention (CDC) efforts to more accurately understand how many people have been infected with SARS-CoV-2, the virus that causes COVID-19, and how it is spreading. This offering, available now, will complement Avero\u2019s existing COVID-19 molecular testing program, which Avero launched in May 2020 to support the diagnostic needs of area hospitals, health systems, multi-specialty family practices, urgent care centers, and county health departments.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Publix Opens In-Hospital Pharmacy at Jupiter Medical Center. Publix Pharmacy and Jupiter Medical Center opened the doors today to a new pharmacy in the Anderson Family Cancer Institute at Jupiter Medical Center in Jupiter, Florida. In addition to services available at Publix pharmacies, this location provides access to medications not typically available in traditional pharmacies, including, but not limited to, those used to treat carcinomas, leukemias, lymphomas, melanomas and sarcomas.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Trialbee Partners with Clinerion for Expanded Access to Global Real-World Data to Accelerate Patient Recruitment for Clinical Trials. Trialbee, a leading global technology provider for patient matching and engagement in clinical trials, today announced a partnership with Clinerion, a worldwide leader in medical data informatics with a global research network comprised of 30.2 million patients online across 69 healthcare organizations in 15 countries. This partnership will accelerate time to market by shortening patient recruitment and enrollment timelines and will reduce costs associated with patient recruitment and loss-to-follow-up.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cerebain Biotech Signs Letter of Intent with PKG, Inc. Cerebain Biotech Corp. (OTC: CBBT), (the \u201cCompany\u201d or \u201cCerebain\u201d) today announced that it has entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Facedrive\u2019s TraceSCAN selected by Riverside Natural Foods for COVID19 Solution Implementation. Facedrive Inc. (\u201cFacedrive\u201d) (TSXV: FD), a Canadian \u201cpeople-and-planet first\u201d technology ecosystem, is pleased to announce that its health services division Facedrive Health shall be conducting a first stage implementation starting this week for its flagship COVID19 contact tracing app TraceSCAN with Riverside Natural Foods.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"iVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development. National Eye Institute awards iVeena SBIR Phase II Grant. National Eye Institute awards iVeena SBIR Phase II Grant. National Eye Institute awards iVeena SBIR Phase II Grant. iVeena, a clinical stage biopharmaceutical company with products in development for unmet needs in ophthalmology, announces the successful completion of the Series B preferred stock bridge round. The company was also awarded with a SBIR Phase II grant award from the National Eye Institute (NEI) of the National Institutes of Health (NIH). These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric high myopia and adult low myopia.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Fitbit Debuts Sense, Its Most Advanced Health Smartwatch; World\u2019s First With EDA Sensor for Stress Management,1 Plus ECG App,2 SpO2 and Skin Temperature Sensors. Fitbit also launches Versa 3, adding GPS and a speaker; brings enhanced design and Active Zone Minutes (AZM) to Inspire 2\n\n\nNew Health Metrics dashboard for Premium lets users track heart rate variability, breathing rate, skin temperature variation and more3. Fitbit (NYSE:FIT) today announced Fitbit Sense TM , the company\u2019s most advanced health smartwatch, bringing innovative sensor and software technology with the world\u2019s first electrodermal activity (EDA) sensor on a smartwatch to help manage stress, along with advanced heart rate tracking technology, new ECG app, 2 and an on-wrist skin temperature sensor, 4 all powered by 6+ days of battery life. 5 Paired with a free six-month trial of Fitbit Premium TM , 6 it can help you track key trends in your health and wellbeing, like heart rate variability (HRV), breathing rate, and SpO2 with the new Health Metrics dashboard. 3 Fitbit is also introducing Fitbit Versa 3 TM , with exciting new health, fitness, and convenience features, including GPS and the addition of Google Assistant. 7 Last, Fitbit has enhanced its most accessible tracker, Fitbit Inspire 2 TM , increasing battery life up to 10 days, 5 adding more health and fitness features like AZM, and adding a one-year free Premium trial. 6 By making these powerful tools and resources available and more accessible to everyone, the Fitbit platform helps you better understand and take control of your wellbeing during this unprecedented time.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Free ME From Lung Cancer Achieves Accreditation From BBB Wise Giving Alliance. Highlighting Excellence in Leadership, Finances and Mission-Driven Work. By meeting key standards of board oversight, finances, results reporting and fundraising appeals, Free ME from Lung Cancer achieved accreditation by the BBB Wise Giving Alliance. This accreditation signifies that Free ME from Lung Cancer is deserving of donor trust as they are a well-run nonprofit organization.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"IGES: Contribution to the Online Platform for Sustainable and Resilient Recovery From COVID-19. IGES is pleased to announce its contributions to the ministerial meeting and Online Platform for sustainable and resilient recovery from COVID-19 (\u201cPlatform for Redesign 2020\u201d), an initiative led by the Ministry of the Environment, Japan and supported by the United Nations Framework Convention on Climate Change (UNFCCC) Secretariat.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio. - First-in-class, non-opioid, mechanism interrupts pain pathways\n\n\n- Phase 2 initiation planned for the first half of 2021. ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. The lead development program is a unique Reactive Species Decomposition Accelerant (RSDAx), a first-in-class mechanism focused on interrupting pathways that sensitize neurons to pain. The portfolio contains additional preclinical stage molecules, including brain penetrant molecules, with potential for symptomatic and disease modifying treatment utility in neurodegenerative diseases.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Sleep Apnea Diagnostic and Therapeutic Devices Market Forecast to Reach $8.2 Billion by 2027 - ResearchAndMarkets.com. The \"Sleep Apnea Diagnostic and Therapeutic Devices - Global Market Trajectory & Analytics\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Nemaura Medical to Present at The LD 500 Virtual Conference. Nemaura Medical, Inc. (NASDAQ: NMRD) (\u201cNemaura\u201d or the \u201cCompany\u201d), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT\u00ae, its non-invasive and flexible continuous glucose monitor (\u201cCGM\u201d), together with BEAT\u2122diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced that its CEO Dr. Faz Chowdhury will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 10:20 a.m. ET.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization. Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on Total Ig antibodies (IgA, IgM, IgG) \n\n\nNew test based on QIAGEN partner Ellume\u2019s proprietary technology, addresses current test shortfalls in terms of automation and convenient read-out of results \n\n\nDigital eHub and eStick system provides rapid qualitative serological in-vitro detection of total antibodies to SARS-CoV-2 in plasma and serum\n\n\nU.S. launch set to start in late August 2020 after submission for FDA Emergency Use Authorization, European CE-IVD marking and commercialization start planned in coming weeks. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of the new Access Anti-SARS-CoV-2 Total test, an easy-to-use digital test done on a portable device that provides results in about 10 minutes to detect antibodies in people exposed to the SARS-CoV-2 virus, which is the case of COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"World Markets for Mobile Cardiac Telemetry Systems, 2020-2026 - ScottCare Corporation is the Major Forerunner of the Industry - ResearchAndMarkets.com. The \"Global Mobile Cardiac Telemetry Systems Market By Application (Lead based and Patch Based), By End User (Hospitals, Cardiac centers and Other End-user), By Region, Industry Analysis and Forecast, 2020-2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Pharmacy Times\u00ae and Parata Systems Announce the 2020 Next-Generation Pharmacist\u00ae Finalists. The 11th annual national awards program will take place online this year and recognize 30 exceptional pharmacy professionals in 10 categories. Pharmacy Times \u00ae, the leading media resource for pharmacists, in conjunction with Parata Systems, a leading provider of pharmacy automation, reveal the 30 finalists for the 2020 Next-Generation Pharmacist\u00ae awards. The 11 th annual virtual awards program will take place virtually on Oct. 21 st at 7:30 p.m. EST.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Back-to-School Season Is a Mental Health Crisis for Parents and Children, Healthline Survey Finds. 75% of American parents would love to send their kids back to school, but only 10% feel comfortable doing so. American parents of school-age children face a difficult autumn, according to the results of a survey released today by Healthline.com , the flagship digital health information site of Healthline Media. The survey looked at how parents will cope with at-home learning, work and the cost of additional childcare if their child\u2019s school isn\u2019t reopening \u2014 and the stress of potential health risks if it does.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Electromagnetic Navigation Systems Market 2019-2024 - Market Size, Unit Volumes, Average Selling Prices, Sales, Competitor Sales & Market Shares - ResearchAndMarkets.com. The \"Global Electromagnetic Navigation Systems Market\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sonde Health Acquires NeuroLex Labs, Creating the Global Leader in Voice Science. Sonde Health , a leading vocal biomarker technology platform that detects health symptoms from a few seconds of voice, today announced it has acquired NeuroLex Laboratories, Inc., a leading voice-enabled survey and data acquisition platform. Jim Schwoebel, the chief executive officer of NeuroLex, will join Sonde\u2019s leadership team as Vice President, Data and Research.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Prescription Drug Safety Network Doubles Student Reach During the 2019-2020 Academic Year. -- 80 percent of students in Purdue Pharma\u2019s sponsored regions reported they felt prepared to avoid prescription drug misuse after completing the course\n\n\n-- In response to an increase in distance learning, Prescription Drug Safety course is now available outside of school settings. Purdue Pharma L.P. (\u201cPurdue\u201d), a founding member of the Prescription Drug Safety Network (\u201cthe Network\u201d), commends EVERFI for its efforts in reaching more than 780,000 students i across the country with its Prescription Drug Safety course since the program\u2019s inception in 2017.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222. Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford\u2019s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent\u2019s commercial gene therapy manufacturing facility located in Harmans, Maryland.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"NovaBay Appoints CEO Justin Hall to its Board of Directors. NovaBay \u00ae Pharmaceuticals, Inc . (NYSE American: NBY) announces the appointment of President and CEO Justin Hall to the Company\u2019s board of directors, effective August 21, 2020. Mr. Hall has been with NovaBay for seven years in various capacities, and fills a vacancy on the board following the resignation of Xiaopei (Ray) Wang. Board membership remains at six, including three independent directors.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Lumeon Launches Virtual Care Solutions in Response to COVID-19. New Solutions Keep Patients Safe at Home While Reducing the Burden on Care Teams. Lumeon , the leader in care automation, today announced a series of new virtual care solutions to help healthcare providers orchestrate care delivery and engage patients at home amid COVID-19. The solutions enable providers to virtualize care processes at scale, minimizing face-to-face contact to reduce the risk of infection within care settings, while alleviating overburdened clinical teams.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"The SIB Swiss Institute of Bioinformatics Chooses WekaFS\u2122 to Enable Secure Scientific Research. The HPC storage solution ensures secure data access coupled with high performance. Since installing WekaFS, SIB supports a growing number of biomedical research projects. WekaIO\u2122 (Weka) , the innovation leader in high-performance, scalable, and parallel file storage, announced today that the SIB Swiss Institute of Bioinformatics has selected the Weka File System (WekaFS\u2122) to ensure data security with zero application performance degradation. SIB chose WekaFS because it provides a secure high-performance compute (HPC) and storage platform that prevents unauthorized users from accessing sensitive personal biodata while ensuring immediate access to the same data for authorized researchers who use it to accelerate research for critical public health issues, such as cancer or diabetes. Since installing WekaFS, SIB supports a growing number of projects on the cluster, in particular, because the researchers can trust the security of the sensitive data.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (\u201cAmneal\u201d or the \u201cCompany\u201d) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patch, 5% is the generic version of Lidoderm Patch, 5% for treatment of post-herpetic neuralgia.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Amid North America Push, DreaMed Appoints New General Manager. Through fostering partnerships with large organizations in the U.S. healthcare system, newly appointed General Manager Ryan Hovey will spearhead the company\u2019s B2B commercial efforts. DreaMed Diabetes Ltd. , the developer of personalized, AI-based diabetes management solutions, announces the hiring of Ryan Hovey to lead and execute DreaMed\u2019s commercial strategy in the U.S. healthcare market. Ryan brings with him a wealth of experience in health solutions and business leadership, with a great track record of success leading growth strategies, new product launches and expansions, as well as establishing the infrastructure required to rapidly grow a business.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Atrial Septal Occlusion Devices Market 2019-2024: Market Size, Unit Volumes, Average Selling Prices, Sales, Competitor Sales & Market Shares - ResearchAndMarkets.com. The \"Global Atrial Septal Occlusion Devices Market\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Worldwide Arthroscopy RF Systems and Wands Industry to 2030 - Market Analysis and Forecast Model - ResearchAndMarkets.com. The \"Arthroscopy RF Systems and Wands (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Kronos Bio Announces $155 Million Private Financing. Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription, today announced a private financing of approximately $155 million of convertible notes, with $148 million in funding received to date and the remaining $7 million to be funded by mid-September pursuant to binding commitments. The financing was led by Perceptive Advisors and included funds and accounts managed by BlackRock, Inc., funds affiliated with Casdin Partners, Commodore Capital, EcoR1 Capital, Fidelity Management and Research Company, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., Woodline Partners, and a large diversified asset manager on the west coast, as well as existing investors including GV (formerly Google Ventures), Invus, Nextech Invest, Omega Funds, Polaris Partners, and Vida Ventures, LLC.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers. Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that findings from APPEAL-2 ( A llergy to P eanuts Im P acting E motions A nd L ife-2), the largest cross-sectional, pan-European, qualitative study to evaluate the psychosocial burden of living with peanut allergy, were published in Clinical & Experimental Allergy , the official journal of the British Society for Allergy & Clinical Immunology. The study highlights the substantial impact of peanut allergy (PA) on the lives of children, teenagers, and their caregivers. The study demonstrates how coping and management of PA are driven by fear of accidental exposure and reaction to peanut, and the resulting emotional, social, relationship, and work effects.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Ligand Announces Amgen\u2019s KYPROLIS\u00ae Approved by FDA as Combination Regimen with DARZALEX\u00ae and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma. KYPROLIS is an Amgen product that utilizes Captisol\u00ae in its formulation\n\n\nApproval based on the CANDOR and EQUULEUS Studies. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug Administration (FDA) approval for the expansion of the KYPROLIS \u00ae (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX \u00ae (daratumumab) plus dexamethasone (DKd) in once- and twice-weekly dosing regimens for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM) who have received one to three previous lines of therapy.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX\u00ae (cabozantinib) in Combination With Opdivo\u00ae (nivolumab) for Advanced Renal Cell Carcinoma. \u2013 Submission based on the phase 3 pivotal CheckMate -9ER trial, which met its primary endpoint of significantly improving progression-free survival and secondary endpoints of overall survival and objective response rate \u2013. Exelixis, Inc. (NASDAQ:EXEL) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CABOMETYX \u00ae (cabozantinib) in combination with Opdivo \u00ae (nivolumab) for patients with advanced renal cell carcinoma (RCC).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"ADDING MULTIMEDIA Leading Biochemist Charles Brenner, Ph.D., Joins City of Hope as Chair of First Department Focused on Diabetes and Cancer Metabolism. Brenner is also the inaugural Alfred E. Mann Family Foundation Chair, seeking better treatments for diabetes and cancer. Biochemist Charles Brenner , Ph.D., has joined City of Hope to lead the nation\u2019s first research department focused on the intersection between cancer and diabetes. He is also the inaugural holder of the Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism, an endowed chair made possible by a generous donation from the Alfred E. Mann Family Foundation.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities. Accelerates Plans to Enhance its Board Composition by Committing to Add a New Independent Director Following a Professionally-Managed Search Process that Includes Stockholder Input\n\n\nAugments Existing Cost Reduction Efforts by Capping Management Compensation and Director Fees at Their Current Levels For the Next Two Years \n\n\nReaches Agreement with Stockholder, Resulting in a Withdrawal of his Nomination Notice and Certain Other Demands Relating to the 2020 Annual Meeting. CytRx Corporation (OTCQB: CYTR) (\u201cCytRx\u201d or the \u201cCompany\u201d), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it is taking several steps to strengthen the Company\u2019s corporate governance and support its strategic priorities, including its previously stated focus on achieving operational efficiencies and preserving capital. CytRx also announced that it has reached an agreement with stockholder Jerald A. Hammann, who will withdraw his notice of nomination and not stand for election to the Board of Directors (the \u201cBoard\u201d) at the Company\u2019s 2020 Annual Meeting of Stockholders (the \u201c2020 Annual Meeting\u201d) that is scheduled for September 3, 2020. The details included in the agreement can be found in the Current Report on Form 8-K that CytRx will file with the Securities and Exchange Commission.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Receives Two New Approvals in Japan. KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications\n\n\nSix-Week Dosing Schedule for KEYTRUDA Now Approved in Japan, US and Europe. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck\u2019s anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA). KEYTRUDA monotherapy is now approved for the treatment of patients whose tumors are PD-L1-positive, and have radically unresectable, advanced or recurrent esophageal squamous cell carcinoma (ESCC) who have progressed after chemotherapy. Additionally, KEYTRUDA was approved for use at an additional recommended dosage of 400 mg every six weeks (Q6W) administered as an intravenous infusion over 30 minutes across all adult indications, including KEYTRUDA monotherapy and combination therapy. This new dosage option will be available in addition to the current dose of 200 mg every three weeks (Q3W). With these approvals, KEYTRUDA has 13 indications across seven tumor types plus MSI-H tumors in Japan.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Medical Device Innovation Consortium Releases Real-World Evidence Framework for In Vitro Diagnostics. The Medical Device Innovation Consortium (MDIC) has announced the release of its Real-World Evidence Framework for regulatory decision-making for in vitro diagnostics (IVDs). Created through a collaborative process between MDIC, FDA CDRH, and industry partners, the framework aims to help industry and FDA consider when and how real-world data might be incorporated into product development and regulatory decision-making in support of clearance or approvals of IVDs. It also outlines considerations for appropriate designs and statistical methods for generating real-world evidence (RWE) for regulatory submissions.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"2020 Global Market Study on External Pain Pumps - Players Include Medical Flow Systems, Smiths Medical & Teleflex Among Others - ResearchAndMarkets.com. The \"Global External Pain Pumps Market\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"NTT Research Hosts UPGRADE 2020, Virtual Global Research Summit. Four-day event highlights basic research in cryptography, quantum information systems and healthcare technology. NTT Research, Inc. , a division of NTT (TYO:9432), today announced plans to hold UPGRADE 2020 NTT Global Research Summit as a virtual event on September 28 - October 1. The online event, to be held 1:30-4:30 pm PST on each of these four days, will feature talks involving cryptography and blockchain, quantum information systems, and healthcare AI and biosensors. NTT Group President and CEO, Jun Sawada, and NTT Executive Vice President and Head of Research and Development Planning, Katsuhiko Kawazoe, will deliver opening remarks on Day 1, which will center on the theme of \u201cFundamental Research: A Foundation of a Better Future.\u201d The subsequent three days will consist of breakout sessions featuring scientists from the three NTT Research Labs and various research partners.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Cementless Total Knee Arthroplasty Market (2020 to 2024) - The Rise in the Number of Sports Injuries is Driving Growth - ResearchAndMarkets.com. The \"Global Cementless Total Knee Arthroplasty (TKA) Market 2020-2024\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273). European Commission would have the option to purchase an additional 80 million doses for a total of up to 160 million doses. Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Company has concluded advanced exploratory talks with the European Commission to supply 80 million doses of mRNA-1273, Moderna\u2019s vaccine candidate against COVID-19, as part of the European Commission\u2019s goal to secure early access to safe and effective COVID-19 vaccines for Europe.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Cureatr Welcomes Rose Abraham, PharmD, as Director of Clinical Pharmacy Operations. Cureatr , Inc., a comprehensive medication management (CMM) technology and services company, announces that Rose Abraham, PharmD, has joined the company as Director of Clinical Pharmacy Operations.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Forbes Names PPD One of North Carolina\u2019s Best Employers. PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has been named to Forbes magazine\u2019s 2020 list of America\u2019s Best-in-State Employers for North Carolina . The recognition follows PPD\u2019s inclusion on Forbes\u2019 lists of America\u2019s Best Large Employers the past two years and America\u2019s Best Employers for Diversity.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Drug Delivery Devices Market to 2024 - Featuring Ace Medical, Ambu & Avanos Among Others - ResearchAndMarkets.com. The \"Global Drug Delivery Devices Market\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results. Antibe Therapeutics Inc. (\"Antibe\" or the \u201cCompany\u201d) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The Company's unaudited fiscal Q1 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Bioventus Appoints Katrina Church Chief Compliance Officer. Bioventus , a global leader in orthobiologic solutions, has appointed Katrina Church as its Chief Compliance Officer, effective August 24, 2020. Church brings more than 20 years of experience counseling public and private companies to ensure the highest compliance with industry standards, reporting and controls. She will be responsible for all ethics and compliance functions at Bioventus, joins the company\u2019s executive leadership team and will report directly to its CEO Ken Reali.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Silicon Valley Startup Exo Secures $40M in Series B+ Funding to Advance Handheld Medical Imaging. Exo (pronounced \u201cecho\u201d), a pioneering health information and devices company, closed a $40 million Series B+ funding round that will fund research and product development on a revolutionary handheld medical device and cloud-based workflow software platform.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Regions Bank Branches Now Open for Walk-in Service. Health and safety best practices introduced in all Regions facilities to help protect customers and associates amid the COVID-19 pandemic\n\n\nRegions bankers equipped to provide tailored financial advice and guidance\n\n\nContinued technology investments enable customers to bank with security and convenience in person and across digital channels. Regions Bank today announced it has reopened branch lobbies for walk-in service and implemented health and safety best practices to help reduce the spread of COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Gyroscope Therapeutics Announces FDA Clearance for Orbit Subretinal Delivery System. Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for the Orbit\u2122 Subretinal Delivery System (Orbit SDS). The Orbit SDS is indicated for microinjection into the subretinal space at the back of the eye. The microinjection procedure is designed to avoid damaging the structure of the eye by preventing the need for a vitrectomy, a procedure that involves removing the vitreous (the gel-like substance that fills the eye). The approach also eliminates the need to create a retinotomy (a hole in the retina) in order to access the subretinal space. This clearance is based on injection of Balanced Salt Solution (BSS) or BSS PLUS \u00ae .*",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah\u00ae (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma. NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for the combination of its lead drug candidate, NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), and Kymriah\u00ae (tisagenlecleucel), a CD19 CAR T-cell therapy, for the treatment of patients with relapsed/refractory large B cell lymphoma (r/r LBCL). This IND clearance allows NeoImmuneTech (NIT) to initiate a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard-of-care Kymriah CAR T-cell therapy.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD. Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for veverimer on August 21, 2020. The NDA was reviewed under the Accelerated Approval Program.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Wound Management Devices Market (2020 to 2026) - by Product, Application, End-user, Region, Industry Analysis and Forecast - ResearchAndMarkets.com. The \"Global Wound Management Devices Market By Product, By Application, By End User, By Region, Industry Analysis and Forecast, 2020 - 2026\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Avellino and Sugentech Announce Strategic Collaboration. Partnership Focused In Short Term On COVID-19 Genetic Diagnostics and Solutions, Long Term Collaboration On Partner Diagnostics and Therapeutics. Avellino is pleased to announce a strategic partnership with Sugentech (a Daejeon, Korea-based diagnostics company) to scale up the supply of tests designed to detect COVID-19 in the United States. The Sugentech testing technologies complement Avellino\u2019s current EUA authorized RT-PCR test in the US, the AvellinoCoV2 test. Under the terms of the agreement, Avellino will distribute Sugentech\u2019s COVID-19 rapid diagnostic serology test. Avellino will also commercialize Sugentech\u2019s quantitative viral neutralization, enzyme-linked immunosorbent assay (ELISA) to determine the presence of protective antibodies against COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Lineage Cell Therapeutics to Present at LD Micro 500 Investor Conference and Solebury Trout Zoomside Chat on September 1, 2020. Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the LD Micro 500 Virtual Investor Conference on September 1, 2020 at 9:40 am Eastern Time / 6:40 am Pacific Time.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Illumina Welcomes Kathryne Reeves as Chief Marketing Officer. Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general management experience in roles across the healthcare, technology, and consumer products industries. Reeves will report to Chief Executive Officer, Francis deSouza.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"European Mass Spectrometer Market Analysis 2020: Innovation Fuels New Deal Flow and Growth Pipelines - ResearchAndMarkets.com. The \"European Mass Spectrometer Market, 2020\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"ADDING MULTIMEDIA SAFE Certification Launches Compliance Solution to Help Entities Combat Spread of Viruses, Infectious Diseases and Bacteria. New Tool Aids Broad Range of Businesses, Facilities and Establishments as they Strive to Ensure COVID-19 Public Health, Safety and Compliance; Creates Levels of Accountability and Protection. SAFE Certification , creator of the first and only accountability and compliance tool used by businesses, facilities and establishments to help keep employees, guests and the public as safe as possible, announced today the introduction of its new SAFE Certified solution.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting. Post hoc analyses showed substantial reduction (62%) in mean annualized new heterotopic ossification volume in patients with FOP who were treated with oral investigational therapy palovarotene1\n\n\nResults from the third interim analysis of the MOVE trial, the first and only multicenter Phase III study of its kind, comprising the largest interventional study in FOP to date with 107 participants, suggest that palovarotene may be an important therapeutic option in FOP1. Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during an oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2020 annual meeting (Saturday, 12 September, 11:00am - 12:30pm ET). Dosing of palovarotene in the MOVE clinical trial was paused when futility criteria were met at a pre-specified interim analysis. However, subsequent post hoc analyses showed the RARy agonist oral investigational therapy palovarotene reduced mean annualized new heterotopic ossification (HO) volume in pediatric and adult participants with FOP. This was compared with untreated patients from a natural history study over 24 months. 1",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference. ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, announced that the company will present at the virtual Morgan Stanley 18 th Annual Global Healthcare Conference on September 16, 2020 at 5:00 p.m. ET.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod. Exicure, Inc. (NASDAQ: XCUR) , the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) technology, announced that it will host a virtual KOL meeting on Wednesday, September 16 th , 2020 from 10:30 am-12 pm ET to discuss the preliminary Phase 1b efficacy and safety data for cavrotolimod, Exicure\u2019s SNA-enabled TLR9 agonist for solid tumors.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Global Community Acquired Pneumonia Pipeline Review, H2 2020 - ResearchAndMarkets.com. The \"Community Acquired Pneumonia - Pipeline Review, H2 2020\" drug pipelines has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress\u2122 2020. -- Data Reinforce Effectiveness of Epclusa\u00ae for Hepatitis C in Key Underserved Populations -- \n\n\n-- Hepatitis B Data Demonstrate Durable Renal and Bone Safety Benefit of Vemlidy\u00ae and Support Further Evaluation of Selgantolimod as Part of Combination Approach to Functional Cure -- \n\n\n-- Full Results From Phase 2 ATLAS Study Support Potential for Combination Approaches for the Treatment of Patients With Advanced Fibrosis Due to NASH --. Gilead Sciences, Inc. (Nasdaq: GILD) announced the presentation of more than 40 abstracts reflecting the breadth of research from the company\u2019s programs addressing significant challenges in viral hepatitis, nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) at The Digital International Liver Congress\u2122 2020 (ILC) from August 27-29.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY\u00ae. Knight Therapeutics Inc. (TSX: GUD) (\u201cKnight\u201d) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (\u201cTherapeuticsMD\u201d) announced today the approval of IMVEXXY \u00ae by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas 1-4 . IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal women who experience pain before, during or after sex. IMVEXXY (estradiol vaginal inserts) is marketed by TherapeuticsMD in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of VVA, due to menopause.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the appointment of Corsee Sanders, Ph.D. to its Board of Directors and to the Audit and Scientific Advisory Committees of the Board.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Kubota Vision Completes POC Clinical Study Using Wearable Myopia Control Device Based on Kubota Glasses Technology. Kubota Vision Inc. (\u201cKubota Vision\u201d), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the successful completion of a proof-of-concept (POC) clinical study using a wearable myopia control device based on Kubota Glasses technology. This study confirmed that the changes in axial length from baseline in the test eye vs. control eye, previously seen utilizing a bench top device that projected defocused images on the peripheral retina, can be replicated with a wearable device.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"ScaleOut Software Releases COVID-19 Corporate Contact Tracing Demonstration Application. Application Harnesses the ScaleOut Digital Twin Streaming Service\u2122 to Track Real-Time Data and Help Companies Safely Return to the Office. ScaleOut Software today released a corporate contact tracing demonstration application to help companies safely return to the office during the COVID-19 pandemic. The application uses the ScaleOut Digital Twin Streaming Service\u2122 and an associated mobile app to help businesses track thousands of daily interactions among employees and promptly notify them when a possible exposure to COVID-19 occurs.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"BioMed Realty Relocates Headquarters to University Towne Centre. BioMed Realty, a leading provider of real estate solutions to the life science community, has relocated their headquarters to discover@UTC at University Towne Centre, a campus the company has assembled and transformed over the last several years into a premier life science park in one of the top biotech markets in the country.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Modern Healthcare Names VirtualHealth a 2020 Best Place to Work in Healthcare. Making the list for the second time, VirtualHealth is recognized for its mission-oriented culture, diversity, and workforce programs. VirtualHealth , provider of HELIOS , the leading SaaS care management platform, has been named as one of 2020\u2019s \u201dBest Places to Work in Healthcare\u201d by Modern Healthcare. This is the second time that VirtualHealth has been named among the nation\u2019s most outstanding employers in healthcare. The complete list of this year\u2019s winners, in alphabetical order, is available here . Modern Healthcare will also publish a special supplement to its October 12 issue that will feature a ranked list of the winners.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA\u00ae Collection of Dermal Fillers. - Revance is positioned to introduce its innovative aesthetics portfolio, starting with the launch of the RHA\u00ae Collection, the first and only FDA-approved dermal fillers for correction of dynamic facial wrinkles and folds -\n\n\n- Clinical study results support the efficacy and safety of these globally established and innovative hyaluronic acid (HA) gels that represent the latest HA filler technology -\n\n\n- 100+ field force in place and trained for launch of the RHA\u00ae Collection, and roll out of the recently acquired fintech platform, HintMD -. Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company\u2019s field force is established and will begin introducing its prestige aesthetics portfolio, including the RHA\u00ae Collection of dermal fillers, resilient hyaluronic acid, and the HintMD financial technology (fintech) platform, in the United States (U.S.) in September. 1",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Medallia Contactless Messaging Now HIPAA Compliant for Healthcare Payers, Providers and Pharmaceutical, Medical Device Companies. Patients and members benefit from contactless, mobile-messaging engagement as telehealth booms. Medallia, Inc. (NYSE: MDLA), the global leader in experience management, today announced that Medallia Zingle has achieved HIPAA compliance for the healthcare and life sciences industries. With Zingle\u2019s mobile-messaging platform, pharmaceutical and medical device companies and healthcare payers and providers can engage in live-time, patient, member and employee experiences allowing them to minimize patient friction, simplify staff workflows and create a scalable approach to personalized patient communication.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation. Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSinovac\u201d or the \u201cCompany\u201d), a leading provider of biopharmaceutical products in China, today announced it has signed two agreements in Hainan, China with PT Bio Farma, a leading biopharmaceutical company in Indonesia, for the supply, local production and technology licensing in respect of the CoronaVac, Sinovac\u2019s inactivated vaccine candidate against COVID-19. The Minister of Foreign Affairs of Indonesia, H.E. Retno LP Marsudi and Minister of State Owned-Companies of Indonesia, H.E. Erick Thohir witnessed the signing of the two agreements.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Ischemia Reperfusion Injury Therapeutics Market to Surpass US$ 2,290.1 Million by 2027, Says Coherent Market Insights (CMI). According to Coherent Market Insights, the global ischemia reperfusion injury therapeutics market is estimated to be valued at US$ 1,582.3 million by end of 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Neurovascular Devices for Hemorrhagic Stroke Market 2019-2024 - ResearchAndMarkets.com. The \"Global Neurovascular Devices for Hemorrhagic Stroke Market\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Prelude Therapeutics Announces Closing of $50M Series C Financing. - Expands Board of Directors with Two New Appointments -. Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, today announced that it has completed a $50 million Series C financing round led by Prelude\u2019s two existing institutional investors, including OrbiMed Advisors LLC, and a new investor, Fidelity Management & Research Company LLC.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Global Urinary Tract Stents (General Surgery) Market to 2030 - COVID-19 Impact Analysis - ResearchAndMarkets.com. The \"Urinary Tract Stents (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models. Data Demonstrate Overexpression of BTN3A1 is Associated with a Poor Prognosis in Ovarian Cancer and the Ability of CTX-2026 to Engage both Gamma Delta and Alpha Beta T Cells to Overcome the Immunosuppressive Tumor Microenvironment. Compass Therapeutics , Inc. a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced the publication in the journal Science of preclinical data supporting CTX-2026, the Company\u2019s novel anti-CD277 antibody product candidate. The paper describes the discovery and preclinical characterization of CTX-2026, a fully human antibody that binds to the CD277 antigen expressed on members of the butyrophilin family, including BTN3A1, and has been shown to engage two T cell subsets, gamma delta and alpha beta, to overcome the immunosuppressive tumor microenvironment associated with ovarian cancer.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Indee Labs Awarded Grant from the National Institute of Allergy and Infectious Diseases. Indee Labs announces a grant award from the National Institute of Allergy and Infectious Diseases to develop the \u00b5VS Delivery SystemTM for modified regulatory T cells. Indee Labs is a biotechnology company developing the \u00b5VS Delivery System TM for non-viral intracellular or gene delivery. The team at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop the \u00b5VS Delivery System TM for modified regulatory T cells.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Neuromodulation Devices Market to 2024 - Featuring Abbott, Advanced Bionics and B Braun Among Others - ResearchAndMarkets.com. The \"Global Neuromodulation Devices Market\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Kohlberg and Mubadala Sign a Definitive Agreement to Acquire Majority Stake in PCI Pharma Services. PCI Pharma Services (\u201cPCI\u201d or \u201cthe Company\u201d), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, and portfolio company of Partners Group, announced today the signing of a definitive agreement for the acquisition of a majority stake in the company by Kohlberg & Company, LLC (\u201cKohlberg\u201d).",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"College 101: Health and Nutrition Advice from Dr. Nicole Avena Every College Student Should Know. Going Back to College During a Pandemic? Here Are Some Wellness and Lifestyle Tips Students Should Learn in a New Era. \u201cFor many students, college is the first time they\u2019re away from home and independent and a routine is important for helping balance your work and health,\u201d says Dr. Nicole Avena \u201cHowever, this year, there are some essential additions to your campus routine that will prioritize health and safety and help you make the most of college accomplish your goals,\u201d says Dr. Nicole Avena.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Life Science Industry in Washington Continuing to Grow and Hire Amid COVID-19. \u201cFind Your Best Life in Washington\u201d Campaign Launches to Encourage Talent from Across the Country to Join the Nation\u2019s Top Emerging Life Science Cluster. Life Science Washington announced today the launch of \u201cFind Your Best Life in Washington,\u201d a campaign to encourage top talent nationwide to learn more about the abundant job opportunities across the more than 1,100 life science companies in Washington state. The campaign kicks off with a new jobs site designed specifically to raise awareness and educate jobseekers about the region\u2019s pioneering spirit and rich history of biomedical innovation, while showcasing Life Science Washington member companies hiring across a variety of life science sectors and local employees sharing why they chose to move to Washington.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome. \u2212 Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo (p=0.0007) in the combined Dravet syndrome and Lennox-Gastaut syndrome study population \n\n\n\u2212 Statistically significant reduction in seizure frequency from baseline in Dravet syndrome cohort compared to placebo (p=0.0007); based on strong efficacy results, Takeda and Ovid plan to initiate a Phase 3 registrational program of soticlestat in Dravet syndrome\n\n\n\u2212 Data from Lennox-Gastaut syndrome cohort demonstrated numeric reductions in seizure frequency compared to placebo but did not achieve statistical significance (p=0.1279); data analysis ongoing for the Lennox-Gastaut syndrome patients\n\n\n\u2212 Soticlestat was well-tolerated and demonstrated a safety profile consistent with the findings of previous studies with no new safety signals identified\n\n\n\u2212 Ovid to host conference call and webcast today at 8:00 a.m. EDT. Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (\u201cTakeda\u201d) and Ovid Therapeutics Inc. (NASDAQ: OVID) (\u201cOvid\u201d), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced positive topline results from the randomized Phase 2 ELEKTRA study of soticlestat in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS). Soticlestat is a potent, highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). It is being investigated by Ovid and Takeda for the treatment of rare developmental and epileptic encephalopathies (DEEs), a group of highly refractory epilepsy syndromes including DS and LGS.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Pop Icon Belinda Carlisle To Perform At Unite For Safe Care Virtual Event on September 17. Patient Safety Movement Foundation Hosts Global Virtual Event On World Patient Safety Day To Mandate Patient Safety Innovation During Pandemic. Today, the Patient Safety Movement Foundation announced Grammy-nominated global pop icon and Go-Gos frontwoman Belinda Carlisle will perform at the Foundation\u2019s Unite For Safe Care Virtual Event. The event will be hosted online, available globally, September 17th at 5pm Eastern Daylight Time.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"WaveFront Dynamics Inc. Initiates $3mm Series A Round to Fund Continued Development of Dynamic Wavefront Measurement System for Vision Correction. WaveFront Dynamics Inc. (WaveDyn\u2122), an early stage ophthalmic medical device company, today announced the first close of a $3 million Series A financing round. The round was led by new investor Tramway Venture Partners LP and included investments from a Phoenix Venture Partners LP affiliate and an additional angel investor. In connection with the financing, Waneta Tuttle of Tramway Venture Partners and Frank Levinson of Phoenix Venture Partners will join WaveDyn\u2019s Board of Directors. The funds will support continued development of its ophthalmic measurement device with dynamic wavefront technology and subsequent clinical studies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"SCIEX Announces Establishment of UK Centre of Innovation. SCIEX to establish UK Centre of Innovation at Alderley Park Bio Hub to enhance customer support and application development capabilities. SCIEX , a global leader in life science analytical technologies, announces that it will establish a Centre of Innovation at the Alderley Park Bio Hub, UK. SCIEX UK will relocate from its existing premises in Warrington to the new centre. The move will be completed in October 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Starpharma SPL7013 Nasal Spray for COVID-19 \u2013 Development Update. Product development activities for SPL7013, repurposed as an antiviral nasal spray, are now well advanced with formulations developed, a manufacturer selected and pilot manufacture undertaken\n\n\nAdditional antiviral testing of SPL7013 has been completed, confirming potent antiviral activity against SARS-CoV-2 and providing supporting data on mechanism of action indicating that SPL7013 acts early in the viral replication cycle\n\n\n\n\nPotent activity of SPL7013 against SARS-CoV-2 was evident when used either before or after exposure to the virus\n\n\nCompiled regulatory documentation in preparation for submission; an expedited regulatory pathway has been confirmed for a number of important markets including Europe \n\n\nA publication of the antiviral data has been submitted to peer reviewed scientific journal and is now available on bioR\u03c7iv1. Starpharma (ASX: SPL, OTCQX: SPHRY) today announced progress with development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company\u2019s proprietary antiviral dendrimer, SPL7013.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Los Tigres del Norte Lead Singer Shares COVID-19 Guidance for Essential Workers & Migrant Community. Jorge Hernandez talks with San Bernardino healthcare promotora in latest Spanish-language web episode of InformaGente public service video series & social media campaign. Joining the urgent battle to slow the spread of COVID-19 in California\u2019s immigrant communities, which becomes even more urgent during this historic heatwave and wildfire season, a new Spanish-language episode of InformaGente features Jorge Hernandez, lead singer of the international music sensation Los Tigres del Norte, and Rosaicela Estrada, a healthcare \"promotora\" with Listos California partner El Sol Neighborhood Education Center.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"COVID-19 Pandemic Impact on Global Cell Culture Market 2020-2024 |Technavio. Increase in Infectious Diseases will drive the market growth during the forecast period. The cell culture market is expected to register a CAGR of almost 13% during 2020-2024, as per the latest research report by Technavio. The report offers detailed analysis about the impact of COVID-19 pandemic on the market in optimistic, probable, and pessimistic forecast scenarios.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Webinar Discussing How Lyme Disease Affects Children to Be Held Aug. 27 and Hosted by Quidel Corporation. Summer is Lyme disease season; and while no age group is immune from potential infection, the disproportionate incidents in children is a stark reality that needs addressing. In response to this troubling fact, an important webinar focused on how Lyme disease affects the pediatric patient population will be held on Thursday, Aug. 27.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Calyxt to Present at Upcoming September Investor Conferences. Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will participate in the following investor conferences during the month of September 2020: the LD 500 Virtual Investor Conference on September 1-4, 2020, and the H.C. Wainwright 22 nd Annual Global Investment Conference on September 14-16, 2020.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Otsuka America Pharmaceutical, Inc., Purchases the Assets of Proteus Digital Health, Inc. . Otsuka America Pharmaceutical, Inc., (Otsuka) today announces that it has purchased the assets of Proteus Digital Health, Inc. (Proteus), including assets and intellectual property for its ingestible and wearable sensor technology.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Smartphone Production Registers Largest YoY Drop on Record with 16.7% Decline in 2Q20, Although Rebound in 2H20 Appears Likely, Says TrendForce. The COVID-19 pandemic has compelled governments worldwide to impose border closures and regional lockdowns, which led to significant declines in various countries\u2019 GDPs this year. As economic and social activities around the world have stagnated, the performance of the smartphone industry was severely damaged in 2Q20. According to TrendForce \u2019s latest investigations, total smartphone production reached 286 million units in 2Q20, a slight QoQ rebound of 2.2%, but a 16.7% decrease YoY, which is the largest quarterly YoY drop in history.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH. Marks\u00a0 Can-Fite\u2019s 3rd major patent for treatment of NASH; patents have also been received in the U.S. and Korea\n\n\nRecently completed Phase II study in NAFLD/NASH achieved primary and secondary endpoints. Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the European Patent Office has notified the Company of its intent to grant a patent for the invention titled \u201cAn A3 Adenosine Receptor For Use In Treating Ectopic Fat Acculturation\u201d. Patent claims include use of the A3 adenosine receptor (A3AR), the target of Can-Fite\u2019s platform technology, in reducing ectopic fat accumulation particularly in fatty liver as manifested in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"PCT LTD Announces New Distributor, Large Purchase Order for Annihilyzer\u00ae Systems. PCT LTD (OTC Pink: PCTL) is happy to announce the receipt of a purchase order for the installation of five new Annihilyzer\u00ae Infection Control systems as well as an additional distributorship to the company\u2019s growing network.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Omnigo Software Introduces Sheldon, a Comprehensive Intelligence Solution to Ensure Safety at Work. Integrated thermal scanning and facial recognition solution helps organizations manage risk and safeguard health and security in their facilities. Omnigo Software , a leading provider of safety management solutions designed to protect, prevent and preserve, today announced the launch of Sheldon its newest solution for thermal scanning and facial recognition. Sheldon provides an end-to-end solution to monitor, track, and report each person that enters a facility. Sheldon can be deployed to hospitals, campuses, public venues, corporate buildings, casinos, and correctional facilities, providing security teams with real-time visibility into the safety and wellbeing of employees, visitors, students, and guests.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Healthvana Delivers Over One Million COVID-19 Test Results in Three Months. Expert in communicating anxiety-provoking patient health information becomes largest delivery network for COVID-19 test results in the U.S. Healthvana, Inc. , the U.S. leader in delivery and management of sensitive patient test results, today announced it has delivered more than one million COVID-19 test results to patients in the past three months. Results are sent directly to patients and are tailored specifically to reduce anxiety and support informed action. This approach leads to faster and healthier outcomes for patients, health officials, labs and employers.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"AscellaHealth Partners with Summit Reinsurance Services, Provides Innovative Specialty Drug Programs, Addresses Pharmacy Claims Challenges. AscellaHealth , a national specialty pharmacy benefit manager (SPBM TM ) serving commercial, Medicare and Medicaid segments, announces today its strategic collaboration with Summit Reinsurance Services, Inc. (Summit Re), a managing general underwriter and reinsurance advisor, to provide innovative specialty drug programs to address the high costs of specialty pharmacy claims. AscellaHealth will give Summit Re clients access to its high-touch service model offering competitive pricing, improved access to limited distribution drugs, clinical programs for complex conditions and copay assistance programs.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Benign Prostatic Hypertrophy Implants Market 2019-2024: Market Size, Unit Volumes, ASPs, Sales, Competitor Sales & Market Shares - ResearchAndMarkets.com. The \"Global Benign Prostatic Hypertrophy Implants Market\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Global Neurovascular Devices for Ischemic Stroke Market 2019-2024 - ResearchAndMarkets.com. The \"Global Neurovascular Devices for Ischemic Stroke Market\" report has been added to ResearchAndMarkets.com's offering.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Biocom Institute, Illumina and Illumina Foundation Partner to Bring Genomics Education to the Classroom. Illumina Genomic Discoveries Educator Program designed to educate students on real-world genomic experiences. Biocom Institute, a 501(c)(3) non-profit that supports life science innovation by strengthening the workforce and leaders of tomorrow, today announced a partnership with Illumina and the Illumina Foundation to advance the Illumina Genomic Discoveries Educator Program & Curriculum. Using Illumina\u2019s latest technologies, this comprehensive program will allow teachers and students the opportunity to learn and connect with the world of genomics.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"BioConnect\u2019s Mobile Wellness Declaration Selected as a Strategic Solution by Canada\u2019s Digital Technology Supercluster COVID-19 Program. BioConnect is proud to announce its membership in the Digital Technology Supercluster, a growing cross-industry community of more than 680 private and public sector organizations working to accelerate Canada\u2019s economic renewal through the collaborative development, deployment, and scaling of Canadian-made digital technologies. BioConnect\u2019s initial involvement will focus the Supercluster\u2019s COVID-19 Program. Launched earlier in the year, this initiative is focused on unlocking digital solutions for protecting the health and safety of all Canadians, and fostering economic recovery and renewal.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG. SYDNEY , Aug. 23, 2020 /PRNewswire/ --\u00a0Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant glioma, which includes Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive childhood brain cancer.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"AcelRx Announces an Investigator-Initiated Study of DSUVIA\u00ae in Orthopedic Patients in the Perioperative Setting. ",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA\u00ae (pembrolizumab) for Advanced Solid Tumors. NORTH BRUNSWICK, N.J. , Aug. 24, 2020 /PRNewswire/ -- Adlai Nortye Ltd. (\"Adlai Nortye\"), a global clinical-stage biopharmaceutical company today announced that the first patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially first in class oral EP4 antagonist, in combination with Merck's KEYTRUDA\u00ae (pembrolizumab) in patients with locally advanced/metastatic solid tumors.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"ReiThera's COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study with First Healthy Volunteer Dosed in Italy. -  GRAd-COV2 encodes the full-length spike protein of the SARS-CoV-2 coronavirus. -  90 healthy volunteers in two age cohorts (18-55 and 65-85 years) to be enrolled in two clinical sites in Italy. -  The Phase 1 trial is being conducted by the Lazzaro Spallanzani National Institute for Infectious Diseases under the sponsorship of ReiThera. -  The Phase 1 trial and the manufacture of clinical material needed for the study is funded by the Italian Ministry of Scientific Research and the Lazio Region (Rome). -  International Phase 2/3 trial in countries with high rates of coronavirus infection planned to start late 2020, pending initial Phase 1 outcome. ROME , Aug. 24, 2020 /PRNewswire/ -- ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies, today announces that the first healthy volunteer has been dosed in a Phase 1 study of the Company's vaccine candidate (GRAd-COV2) against the novel coronavirus (SARS-CoV-2). The Phase 1 study is being conducted in Italy at the Lazzaro Spallanzani National Institute for Infectious Diseases (INMI) in Rome and at the GB Rossi University Hospital in Verona.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"VAPORESSO's first-round PMTA applications were accepted by FDA. SHENZHEN, China , Aug. 24,\u00a02020 /CNW/ -- On August 20, 2020 , VAPORESSO received the acceptance letter for the first round of its PMTA applications from the FDA - only three days after submission. According to its U.S. scientific CRO agent, the application received positive comments from FDA on its overall preparation.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Mitsubishi Tanabe Pharma America Announces Enrollment Has Resumed For The Global Phase 3 Study Of Oral Edaravone For ALS. JERSEY CITY, N.J. , Aug. 24, 2020 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the global Phase 3 study to evaluate the long-term safety and tolerability of an investigational oral suspension formulation of edaravone (MT-1186) in patients with amyotrophic lateral sclerosis (ALS) has resumed screening and enrollment. The trial, sponsored by Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), was initiated in November 2019 and some clinical trial operations were temporarily paused in March 2020 due to the COVID-19 pandemic.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Continue Their Collaboration to Develop a New Anti-COVID Plasma-Based Treatment. CASTELVECCHIO PASCOLI,\u00a0Italy, Aug. 25, 2020 /PRNewswire/ -- Two innovative bio-pharma companies specialized in plasma-derived therapeutics - Kedrion Biopharma of\u00a0Italy\u00a0and Kamada Ltd. of\u00a0Israel\u00a0- are continuing their work on the development, manufacturing and clinical distribution of a plasma-derived Anti-SARS-CoV-2 product.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery. -Company expects to initiate enrollment in the Phase II trial, ALTITUDE, in the second half of 2020 to evaluate the targeted, in-office suprachoroidal delivery of RGX-314. -Long-term treatment with anti-VEGF injections has been shown to reduce severity of DR and prevent vision threatening complications. ROCKVILLE, Md. , Aug. 25, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV \u00ae Technology Platform, today announced the clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR). The IND is active, and REGENXBIO plans to begin dosing patients in a Phase II trial, ALTITUDE, in the second half of 2020.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of  COVID-19 Vaccine. GAITHERSBURG, Md., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax\u2019 COVID-19 vaccine candidate. The Phase 2 clinical trial expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial\u2019s population. NVX\u2011CoV2373 is a stable, prefusion protein made using Novavax\u2019 nanoparticle technology and includes Novavax\u2019 proprietary Matrix\u2011M\u2122 adjuvant.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"UNION therapeutics A/S completes dosing of healthy volunteers with UNI911 (inhaled niclosamide) for COVID-19. - UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911. - UNION has utilized many years of experience with niclosamide to develop UNI911, a proprietary salt form and formulation of niclosamide, for inhalation as a treatment candidate for COVID-19. - Delivery directly to the lung via inhalation allows UNION to address common challenges related to low bioavailability of oral niclosamide. - Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir1. - UNION is preparing to advance UNI911 into COVID-19 patient trials. HELLERUP, Denmark , Aug. 25, 2020 /PRNewswire/ -- UNION therapeutics A/S (\"UNION\"), a privately held, clinical stage pharmaceutical company, today announces the successful completion of dosing of 44 healthy volunteers with UNI911, an optimized salt form of niclosamide, as an inhalation treatment candidate for COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Visiongain publishes Pharma Clinical Trial Services Market and Industry Forecast 2020-2030 report. Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Disease. LONDON , Aug. 24, 2020 /PRNewswire/ -- The pharma clinical trials services market is expected to grow at a CAGR of 10% in the first half of the forecast period and be worth $150.15bn by 2030.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Medicure Announces AGGRASTAT\u00ae Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports. WINNIPEG, MB , Aug. 24, 2020 /CNW/ -\u00a0Medicure Inc. (\" Medicure \" or the \" Company \") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is reporting that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT \u00ae (tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19. AGGRASTAT \u00ae is not currently indicated for use in patients with COVID-19.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors. SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that it has achieved a clinical supply milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment. The candidate, M1231, was discovered using Sutro's XpressCF\u00ae and XpressCF+\u2122 drug discovery and manufacturing technologies and includes a proprietary linker-warhead also discovered by Sutro. M1231 is a MUC1-EGFR bispecific antibody drug conjugate (ADC) for the treatment of solid tumors and relies on the strand-exchange engineered domain (SEED) platform from Merck KGaA, Darmstadt, Germany to generate bispecific antibody-like molecules.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Altair Joins Avicenna Alliance to Support Simulation-based Development of Medical Breakthroughs. TROY, Mich., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Altair (Nasdaq: ALTR), a global technology company providing solutions in product development, high-performance computing (HPC), and data analytics, has joined the Avicenna Alliance , an international consortium committed to the use of simulation to enable faster and more efficient development of new medicine and healthcare solutions.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for the Treatment of Cancer. NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research institute today announced the filing of a provisional patent application with the U.S. Patent & Trademark Office (USPTO) for the differentiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs). The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array \u00ae , the premier automated robotic platform for reprogramming skin or blood into induced pluripotent stem cells (iPSCs) and differentiating them into disease-relevant cell types.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Gallbladder cancer vaccine candidates identified. FOSTER CITY, Calif. , Aug. 24, 2020 /PRNewswire/ -- In a paper published in Nature Communications , scientists from MedGenome India / USA , along with an international team of scientists from institutions in India , USA , South Korea , Chile and Australia reported sequencing and analysis of over 150 gallbladder cancer (GBC) samples.\u00a0Currently, there are no targeted therapies for treating this cancer. GBC in the US has a higher incidence among Southwestern Native Americans and Mexican Americans. It is more prevalent in South American countries that include Chile , Bolivia , and Ecuador , and in Asian countries such as Korea, India , Pakistan and Japan.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Hawkeye Systems Sanitizer Product Released by FDA for US Entry. Following completion of the FDA review process at US Customs, Kiil is released for distribution. SAVANNAH, Ga , Aug. 24, 2020 /PRNewswire/ -- Hawkeye Systems, Inc. (OTCQB: HWKE), a technology holding company focused on pandemic management products and services, announced today its sanitizer product Kiil was released from US Customs and Border Protection following a detailed review and testing by the Food and Drug Administration (FDA).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"New Treatment Developed by Children's Hospital of Philadelphia Shows Success in High-Risk Solid Tumors. -- CHOP-engineered therapy overcomes common drug resistance and has potential to elicit fewer toxicities than most cancer treatments -. PHILADELPHIA , Aug. 24, 2020 /PRNewswire/ -- Despite intensive treatment, high-risk solid tumors like neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma are challenging to cure because the disease in those high-risk patients does not respond to therapy. Conventional chemotherapy given by vein or by mouth delivers only a small amount of the drugs to the tumor, which not only renders the treatment ineffective but also leads to drug resistance and severe side effects, including diarrhea, bone marrow suppression and secondary malignancies.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Codex DNA Demonstrates Momentum Toward Mission of Building World\u2019s First Vaccine Printer and Global Vaccine Network. The Digital-to-biological converter will enable printing life-saving vaccines on a global scale using synthetic DNA to stop future pandemics. San Diego, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Codex DNA, Inc., creators of the world\u2019s first fully automated system for high-throughput writing of DNA, today announced critical advancements in its development of the Digital-to-biological converter\u2122 ( DBC ) platform . The platform will enable the direct printing and packaging of vaccines, supporting immediate distribution through a global network of vaccine printers. At the core of the\u00a0DBC\u00a0is the BioXp \u2122 3250 system , the world\u2019s only fully automated synthetic biology workstation, which already performs most of the steps required to print vaccines\u00a0and\u00a0is\u00a0paving the way for a global solution to prevent future pandemics.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020. Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease. ",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease. TAIPEI, Taiwan , Aug. 25, 2020 /PRNewswire/ --\u00a0Elixiron Immunotherapeutics Inc. today announced that it has been awarded a $1,000,000 grant from the Alzheimer's Association under the 2020 Part the Cloud-Bill Gates Partnership Grant Program to support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":1,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Stryker launches first 64-wire cobalt chromium flow diverter in the US to treat brain aneurysms. KALAMAZOO, Michigan , USA, Aug. 24, 2020 /PRNewswire/ --\u00a0Stryker announced today the launch of the Surpass Evolve Flow Diverter following approval by the U.S. Food and Drug Administration. It is the first 64-wire cobalt chromium flow diverter in the U.S. designed to re-direct blood flow and promote aneurysm healing. Surpass Evolve is Stryker's latest innovation in flow diversion and follows the launch of Surpass Streamline in late 2018.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Most Adults with Lupus or Common Types of Arthritis Have Similar Risks of Getting Admitted to Hospital as Other COVID-19 Patients. NEW YORK , Aug. 25, 2020 /PRNewswire/ --\u00a0Most adults with systemic lupus erythematosus (SLE) are not at increased risk of hospitalization from COVID-19 due to medications used to dampen their altered immune system, the cause of their disease. Nor are most people with more common types of arthritis, such as rheumatoid, psoriatic and spondyloarthritis, at greater risk of hospitalization from COVID-19, a pair of new reports shows.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"CNS Provides FDA Update on IND Filing. Berubicin Previously Received FDA Orphan Drug Designation. HOUSTON , Aug. 25, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on the\u00a0Company's plans\u00a0for its lead product candidate, Berubicin, which is being studied for the treatment of glioblastoma multiforme (GBM). The company has taken significant strides in designing Phase 2 clinical trials and anticipates submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) this year and initiating clinical trials in early 2021. In preparing for the IND submission, CNS has focused on clinical trial design and implementation, as well as establishing the necessary manufacturing capabilities.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Large International Study Pinpoints Impact of TP53 Mutations on Blood Cancer Severity. Having two mutated copies of the TP53 gene - as opposed to a single mutated copy - is associated with worse outcomes in myelodysplastic syndrome and acute myeloid leukemia. YARDVILLE, N.J. , Aug. 25, 2020 /PRNewswire/ --\u00a0The MDS Foundation announces that a large international study led by researchers at Memorial Sloan Kettering finds that having two mutated copies of the\u00a0TP53\u00a0gene, as opposed to a single mutated copy, is associated with worse outcomes in myelodysplastic syndrome and acute myeloid leukemia. The findings have immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH). ATLANTA , Aug. 24, 2020 /PRNewswire/ -- Primary HLH is a family of devastating primary immune deficiencies with limited treatment options and no gene therapies under clinical testing. Expression Therapeutics has developed a promising and potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis (HLH) type 3 (FHL3). Untreated, FHL3 presents as a hyper-inflammatory state with multi-organ damage leading to premature death. Expression Therapeutics expects to rapidly progress candidates for other common forms of primary HLH as well.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Incysus Therapeutics Announces Name Change to IN8bio, Inc. NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on delivering innovative gamma-delta (\u03b3\u03b4) T cell immunotherapies for the treatment of cancer, today announced that it has changed its name to IN8bio, Inc. (\u201cIN8bio\u201d or the \u201cCompany\u201d). The Company\u2019s new name reflects its novel approach to cell therapy, focused on the development of gamma-delta T cells for anti-cancer therapies. These powerful immune cells possess properties of both innate and adaptive immune cells and can serve as a functional bridge between the two systems to impact tumor killing.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020. LUND, Sweden , Aug. 25, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical development plans for the clinical drug candidates mitazalimab, ATOR-1015 and ATOR-1017 on a virtual R&D Day on August 27 .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine\u00ae (rhuGM-CSF, sargramostim) in COVID-19 Patients. Study builds on extensive research showing that granulocyte-macrophage colony stimulating factor (GM-CSF) is needed for effective immune function in the lungs. iLeukPulm Phase 2 Clinical TrIal Supported by $35 Million Contract from U.S. Department of Defense. LEXINGTON, Mass. , Aug. 25, 2020 /PRNewswire/ --\u00a0Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the iLeukPulm clinical trial, a randomized phase 2 study of inhaled Leukine (sargramostim, rhu-GM-CSF) in hospitalized COVID-19 patients with acute hypoxemia [ NCT04411680 ]. This study will evaluate the safety and efficacy of sargramostim in combination with institutional standard of care on clinical outcomes in these patients. A majority of patients hospitalized for COVID-19 experience respiratory distress, also known as acute hypoxemia, that requires oxygen support.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"AbbVie Submits Regulatory Application to FDA for RINVOQ\u2122 (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis. - RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis[1]. - In a pivotal Phase 2/3 study, twice as many patients receiving RINVOQ achieved the primary endpoint of ASAS 40 response at week 14 compared to placebo (p<0.001)[1]. - A regulatory application was also submitted to the EMA for the treatment of adult patients with active ankylosing spondylitis earlier this year. - This submission represents AbbVie's ongoing commitment to bringing RINVOQ to more patients living with immune-mediated diseases. NORTH CHICAGO, Ill. , Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for RINVOQ\u2122 (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with active ankylosing spondylitis. AbbVie also submitted an application to the European Medicines Agency (EMA) for RINVOQ earlier this year for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"New Remote Learning Program to Prevent Drug Abuse. WHITE PLAINS, N.Y. , Aug. 24, 2020 /PRNewswire/ -- In the midst of the COVID-19 pandemic, opioid misuse and addiction continue to devastate communities around the US. And as many schools shift to remote learning, researchers at National Health Promotion Associates (NHPA) are testing a new online program to prevent drug abuse in high schools students.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study. Interim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020. SINGAPORE, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the resumption of patient recruitment into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Visiongain publishes Global Clinical Trial Management System Market Forecast 2020-2030 report. Type, Component, Delivery Mode, End Users, and Regions. LONDON , Aug. 24, 2020 /PRNewswire/ -- The global market for clinical trials management systems was valued to be $1,152m in 2019 and is valued to reach $4,805.6m by 2030.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb\u00ae in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19. ANN ARBOR , Mich.\u00a0and MONMOUTH JUNCTION, N.J. , Aug. 24, 2020 /PRNewswire/ -- Terumo Cardiovascular , a global leader in cardiovascular surgery technologies and subsidiary of Japan -based Terumo Corporation (TSE: 4543), and CytoSorbents Corporation (NASDAQ: CTSO), manufacturer of the CytoSorb \u00ae extracorporeal cytokine adsorber, announced an initial collaboration to exclusively sell CytoSorb to hospitals in ten U.S. COVID-19 hotspot states including Alabama,\u00a0Arizona, California , Georgia , Louisiana , Mississippi , New Mexico , Oregon , Texas , and Washington . CytoSorb previously received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for use in adult, critically-ill COVID-19 patients with imminent or confirmed respiratory failure.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":1,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO\u2122 (lemborexant) CIV, at the SLEEP 2020 Virtual Conference. Nine presentations, including a long-term efficacy and safety analysis of DAYVIGO in adults ages 65 and older and interim results from a pilot study on the transition from zolpidem to DAYVIGO, to be shared at the meeting. WOODCLIFF LAKE, N.J. , Aug. 24, 2020 /PRNewswire/ --\u00a0Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO \u2122 (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27-30, 2020 . DAYVIGO, a dual orexin receptor antagonist, was recently launched in the U.S. for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. 1",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":1,
      "OTHER":0
    }
  },
  {
    "text":"MINDACT Study Shows MammaPrint\u00ae Provides Widespread Health System Cost Savings. Analysis Published in European Journal of Cancer. Use of MammaPrint genetic assay alongside clinical assessment is cost-effective versus clinical assessment alone. IRVINE, Calif. , Aug. 25, 2020 /CNW/ -- Agendia, Inc ., a world leader in precision oncology for breast cancer, announced the publication of multi-country cost analyses from the landmark MINDACT trial in the European Journal of Cancer , which show that adjuvant chemotherapy strategies guided by MammaPrint\u00ae deliver healthcare cost savings in five of the six countries evaluated. The 70-gene risk of recurrence assay was shown to be cost-effective in all six.",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":1
    }
  },
  {
    "text":"Sirnaomics Publishes Preclinical Study of Novel siRNA-Gemcitabine Conjugate for Advancing RNAi Therapeutics to Treat Multiple Types of Cancers. GAITHERSBURG, Md. , Aug. 25, 2020 /PRNewswire/ -- Sirnaomics, Inc. , a leading biopharmaceutical company in discovery and development of RNAi therapeutics for treatment of cancer and fibrotic diseases, announced today that it has published data from a preclinical discovery effort using a novel siRNA-gemcitabine conjugate construct to enhance therapeutic efficacy of the active pharmaceutical ingredient potentially for treatment of multiple types of cancer. The findings appeared in a manuscript entitled \"A novel siRNA\u2013gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer\" in the journal Nucleic Acid Research, Cancer.\u00a02020, Vol. 2, No. 3 1 .",
    "labels":{
      "REGULATORY":0,
      "CLINICAL_TRIAL":1,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome. NEW YORK , Aug. 25, 2020 /PRNewswire/ --\u00a0Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Orphan Drug Designation (ODD) for SLS-005 in mucopolysaccharidosis type III (MPS III), Sanfilippo syndrome, from the European Medicines Agency (EMA).",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  },
  {
    "text":"U.S. FDA Approves CYSTADROPS\u00ae (Cysteamine Ophthalmic Solution) 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystinosis. LEBANON, N.J. , Aug. 25, 2020 /PRNewswire/ -- Recordati Rare Diseases Inc., today announced the U.S. Food and Drug Administration (FDA) has approved CYSTADROPS \u00ae (cysteamine ophthalmic solution) 0.37%. CYSTADROPS is a new, viscous eye drop solution that depletes corneal cystine crystal deposits in people living with cystinosis. CYSTADROPS demonstrated a significant reduction in cystine crystal deposits in the cornea of the eye and is the first and only FDA-approved cysteamine drop formulation with four times a day dosing. Cystinosis is a rare genetic condition present from birth that leads to the build-up of cystine crystals throughout the body, causing widespread tissue and organ damage and significant impact on the eyes.",
    "labels":{
      "REGULATORY":1,
      "CLINICAL_TRIAL":0,
      "COLLAB":0,
      "FINANCING":0,
      "PRESENTATION":0,
      "OTHER":0
    }
  }
]